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CHAPTER 1 
Introduction 
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Cardiovascular disease: still a challenge despite therapeutic revolutions 
Cardiovascular diseases are the leading cause of death both in the Western world and 
developing countries, and in men and women alike. In 2005, the main cause of death in 
the USA due to disease of the heart alone was more than of all neoplastic disease com-
bined (1). It is expected that these numbers will continue to increase in upcoming dec-
ades due to rising percentages of obesity, hypertension, hyperlipidemia and diabetes as 
well as population ageing (2). There is, therefore, increased emphasis on preventing 
atherosclerosis by modifying risk factors, such as healthy nutrition, exercise, and avoid-
ance of smoking tobacco. 
 
Myocardial infarction (MI) is the irreversible necrosis of heart muscle secondary to pro-
longed ischemia. Each year, more than a million cases of MI occur and >400.000 people 
die of coronary artery disease (3). Over the past three decades therapeutic advances 
such as thrombolytic treatment, angioplasty, coronary bypass surgery, and the use of 
aspirin, beta-blockers and angiotensin-converting-enzyme (ACE) inhibitors have contrib-
uted to reduce mortality after MI (4). These improvements were based on 3 important 
observations. First, it was noticed that the mortality of patients with MI is closely linked 
to infarct size and degree of pump function impairment (5,6). Second, studies done on 
the delay between the onset of symptoms and start of reperfusion therapy consistently 
found that the time between the onset of coronary occlusion and the benefit of reperfu-
sion therapy is limited to three to four hours (7-9). A third important observation was 
that following the acute phase of a first infarction, a substantial fraction of patients re-
main at relatively high risk of subsequent coronary events (10-12). Early angiographic 
studies in MI patients showed that in about 80% of patients an obstructive coronary 
thrombus was the main cause for the acute coronary syndrome (13). This finding has 
generated an era in which patients received thrombolytic therapy, for instance strepto-
kinase or tissue plasminogen activator (tPA) in the acute phase of myocardial infarction 
(14). However, in the early 1990’s it became clear that acute percutaneous intervention 
(PCI) provided substantial benefit both in terms of cardiac function as well as mortality, 
even in the long run (15,16). Therefore, current guidelines recommend early PCI as the 
preferred treatment option unless there is no PCI centre available nearby (17,18). 
 These improvements apart from better survival, resulted in a decrease in acute 
complications following MI such as acute Congestive Heart Failure (CHF), myocardial 
rupture and/or arrhythmias (4). In contrast, with more patients surviving the initial stage 
of MI, the development of late complications has become a more relevant health care 
problem (19,20). The development of left ventricular dilatation and loss of pump func-
tion in the years following the acute myocardial injury, induced by the formation of the 
scar, and the impact of the local loss of function on pressure and tensile forces in the 
rest of the heart, are the subject of intense research. 
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Many trials in this area have convincingly shown that inhibition of the renin-angiotensin 
system, through either ACE inhibitors and/or angiotensin receptor 1 blockers preserve 
cardiac function and decrease mortality post MI (21-25). In addition, intervention in 
mineralo-corticoid signaling has proven to preserve cardiac function and decrease mor-
tality significantly (26,27). Despite these advances, still a substantial fraction, about one-
third of MI patients, develop CHF in the long run (20,28,29). 
 Therefore, there is still a lot to be learned and to be gained from research in cardiac 
infarct healing and adverse left ventricular remodeling. 
Phases of infarct healing, inflammatory cell influx 
In non-injured and normal functioning human heart most of the volume is occupied by 
cardiomyocytes. The main function of cardiomyocytes is to provide coordinated contrac-
tile forces to pump out blood. For this purpose, cardiomyocytes contain specific contrac-
tile proteins, such as troponin T (TNT) and troponin I (TNI). 
 The structure of the heart is provided by the extracellular matrix (ECM), which 
serves as a scaffold for the contractile cells (30). The extracellular matrix consists of 
various types of collagen, which, in a normal heart, take up 1-2% of the total heart vol-
ume. These collagens are produced by fibroblasts and in pathologic settings myofibro-
blasts, which are also found in the cardiac interstitium (31). 
 Changes in loading conditions have an almost immediate effect on the different 
cellular and structural components of the hearts. For instance, it is known that cardio-
myocytes start to increase their protein synthesis within hours after the onset of in-
creased loading (32). Due to long-standing elevated pressure, cardiomyocytes will start 
to increase in size, resulting in hypertrophy of the heart (33). 
 In many ways, wound healing in the heart mimics wound healing in other tissue 
types, such as skin wound healing (34). However, a set of distinctive characteristics re-
sult in marked differences in the final result of cardiac wound healing. First, cardiomyo-
cytes are terminally, or almost terminally differentiated cells, which allows for only lim-
ited regenerative capacity. 
 In general, 4 distinctive phase in cardiac wound healing can be recognized (34,35). In 
the first phase, which lasts 1-2 days, cardiomyocyte cell death occurs, either trough 
apoptotic or necrotic cell death, resulting in substantial cell debris. The second phase is 
the acute inflammation phase, and overlaps quite extensively with the first phase, since 
it starts already after 6 hours, and continues to up to 5-6 days. In early phase 2, degrada-
tion of extracellular matrix occurs, which enable migration of invading Polymorphonu-
clear Leukocytes (PMN’s), and later on, monocytes/macrophages. Depletion of macro-
phages in models of myocardial infarction, as opposed to depletion of PMNs, results in 
prolonged presence of cell debris in the cardiac wound, indicating that these are the 
main phagocytic cells (36). The third phase of cardiac wound healing is characterized by 
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the deposition of novel matrix proteins, including fibrin, and collagen type III, and later 
collagen type I (31). It is thought that most of the new ECM production is due to the 
activity of myofibroblasts (31). In this phase the scar is still a cell rich tissue, which re-
sembles granulation tissue as found in outer tissue wounds, such as the skin. Another 
essential process that occurs in the third phase is the formation of novel vessels, also 
called angiogenesis. This process has generated a lot of attention in recent years, since it 
is thought that increased blood supply to the cardiac wound may help to preserve cardi-
ac function, and to limit the final injury (37). 
 In the fourth phase of cardiac wound healing, most cell types, such as the macro-
phages, start to disappear from the wound. Most likely, this is the consequence of apop-
totic cell death of these phagocytic cells (38). By contrast, a large part of the myofibro-
blasts remains present in the scar area (39). Another essential process is the cross-
linking of collagen, which is required to provide sufficient strength to withstand the 
pressure and tensile forces to which the scar is continuously being exposed to (40). 
Adverse remodeling 
The repair mechanisms described above are essential for maintaining the functional and 
structural integrity of the heart. In addition, several compensatory processes are initiat-
ed in the non-infarcted area. Although potentially beneficial, exaggerated occurrence of 
these processes can lead to morphological and functional changes to the heart which 
eventually lead to declining pumping capacity and the development of heart failure. The 
complex of these changes is known as adverse remodeling. 
 
The presence of an infarcted area in the heart and the resulting changes in loading con-
ditions trigger changes in the extra cellular matrix in the remote myocardium. In the 
normal heart, collagens in the ECM account for 1-2% of the entire cardiac volume. How-
ever, following acute myocardial infarction, this percentage can easily double. The pat-
tern of enhanced collagen deposition in the remote parts of the heart is to a large extent 
similar to that of the infarct itself (31). First, collagen type III is deposited in the ECM, 
followed by collagen type I. The effect of the increased deposition in the remote areas is 
probably to provide enhanced strength and to prevent dilatation. However, the down-
side of the increase in ECM content is enhanced stiffness, which may result in resistance 
to diastolic filling and eventually diastolic failure (41). 
 Another change in the non-infarcted myocardium is cardiomyocyte hypertrophy 
(42), which is triggered to compensate for the loss of cardiac muscle. However, exagger-
ated hypertrophy has several unfavorable effects. It may reduce the ventricular cavity 
volume, thereby reduce myocardial filling and contribute to development of diastolic 
heart failure (43). Moreover, cardiomyocyte hypertrophy decreases the capillary to my-
ocyte-fiber ratio, since endothelial cell proliferation cannot fully compensate for the 
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growth of the cardiomyocyte. The consequence is an increase in oxygen diffusion dis-
tance and, in the end a relative oxygen deficit (44). 
 One of the key regulators of fibrosis and cardiomyocyte hypertrophy is the renin-
angiotensin-aldosterone system (RAAS)(45,46); inhibition of the RAS-pathway has shown 
to effectively reduce adverse remodeling through inhibition of cellular hypertrophy and 
fibrosis (21-25,27). It is well established that myocardial neurohumoral upregulation 
more so than the systemic upregulation contributes to ventricular remodeling and de-
velopment of post-MI-CHF (47). In particular, angiotensin II type 1 receptor expression 
within the myocardium is associated with interstitial fibrosis and ventricular dysfunction 
(48). Transgenic mice lacking angiotensin II type 1 receptor expression exhibit minimal 
geometric and structural remodeling following MI, and lower upregulation of so-called 
fetal genes, such as TGF-β1, and collagen deposition in comparison to the wild-type 
animals (49). 
 Angiogenesis represents the formation of new capillaries by cellular outgrowth from 
existing microvessels and occurs as part of the natural healing process following injury. 
The physiological importance of controlling neo-angiogenesis on remodeling following 
MI is less clear. Experimental studies aimed to induce angiogenesis following MI have 
shown beneficial effects on LV function; however, this has not been proven in clinical 
studies so far (50).  
 Another phenomenon involved of cardiac remodeling resulting in congestive heart 
failure in late stages following MI, is the development of progressive left ventricular 
dilatation, leading to loss of pump function of the heart (42). The loss of cardiomyocytes 
through apoptosis may contribute to this phenomenon. Several preclinical and clinical 
studies have clearly demonstrated that apoptosis occurs in the remote areas of the left 
ventricular wall (51-53). Although the rate of apoptosis is small, the idea is that this slow 
but gradual loss of cells eventually contributes to decrease in cardiac performance. The 
renin-angiotensin-system is also involved in this process (54,55). Indeed, inhibition of AT-
1 receptor activity has shown to be beneficial in the prevention of cell loss through 
apoptosis (48,56,57). 
Possible role of the macrophage in infarct healing and fibrosis 
As mentioned before, the macrophage is the principal phagocyte in the myocardial scar 
following infarction. Depletion of macrophages has shown to result in decreased clear-
ance of dead cells and persistence of cell debris up to 3-4 weeks (58,59). In skin wound 
healing, injection of macrophages accelerates wound healing, including the clearance of 
cell debris, and the formation of collagen. Given the essential difference between cardi-
ac wound healing and skin wound healing, being the lack of significant regenerative 
capacity in the heart and the exposure of the cardiac scar to repetitive pressure and 
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tensile forces, it is not altogether clear whether enhanced presences of macrophages 
will be beneficial or detrimental (59,60). 
 In a recent study, performed in a cryo-injury model in the mouse, it was shown that 
depletion of macrophages through the administration of clodronate resulted in de-
creased wound healing, as evidenced by persistence of cell debris, formation of a scar 
with low collagen content, a decrease in the presence of myofibroblasts and less angio-
genesis (61). Furthermore, this study observed that cardiac cryo-injury in the absence of 
macrophages resulted in an increase in left ventricular size as compared to controls. 
From these data, it was concluded that macrophage depletion impairs wound healing 
and increases let ventricular remodeling. However, from the study data it is apparent 
that in the control cryo-injury group no remodeling of the left ventricle occurred during 
the course of the study, which is in contrast to observations in MI models, which con-
sistently show substantial dilatation and adverse remodeling. Therefore, the cryo-injury 
model does not necessarily reflect the events during myocardial wound healing during 
myocardial infarction. In addition, the cryo-injury study did not provide functional data 
on the effect of macrophage depletion on pump function of the left ventricle. 
 Other studies have attempted to enhance the presence of macrophages in a rat 
model MI through the administration of macrophage colony stimulating factor (M-
CSF)(62). The administration of M-CSF resulted in an increase in macrophage presence, 
and enhanced deposition of collagen type I and III. In addition, left ventricular function 
was increased in the MI group treated with Macrophage Colony Stimulating Factor (M-
CSF) compared to MI control, although these changes were not significant. This finding is 
in contrast to other preclinical studies, which have attempted to suppress collagen dep-
osition. For example, in the before mentioned study performed in AT-1 receptor KO 
mice it was shown that prevention of collagen deposition and was associated with 
preservation of cardiac function, and prevention of cardiac remodeling (49). Similarly, 
prevention of cardiac fibrosis through interference in mineralcorticoid signaling has 
shown to prevent fibrosis and preserve cardiac function (27,63). Therefore, the im-
proved function in the treated animals most likely has other causes than accelerated 
wound healing and enhanced deposition of collagen. Another argument that speaks in 
favor of inhibition of fibrosis rather than its promotion is the fact that cardiac regenera-
tion therapy is probably easier to achieve in an area devoid of a dense and fibrotic scar. 
The association between macrophages and cardiac fibrosis is suggested further by ob-
servation in mouse embryo’s, which only then shows fibrosis in wounds when macro-
phages are recruited to the wound area (64). Given the studies in the macrophage de-
pletion model and the M-CSF stimulation studies, it is likely that macrophages are im-
portant mediators in the fibrotic process. The role of the macrophage in cardiac wound 
healing may in large part depend on the balance between certain signaling molecules 
secreted by macrophages (36,65-67). In a macrophage specific overexpression of uroki-
nase plasminogen activator in a mouse model it was noted that enhanced cardiac fibro-
sis took place, even in the absence of significant epicardial disease. This same study 
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showed that the enhanced fibrosis was specific for the heart, since other organs seemed 
resistant to macrophage infiltration, and subsequent fibrosis. 
Aim of the thesis 
The aims of the thesis are twofold. In the first part, we investigated the role of the mac-
rophage in ventricular remodeling following acute myocardial infarction, to better un-
derstand the critical influence of this cell type in infarct healing post myocardial infarc-
tion. In the second part, we have used molecular imaging techniques to better under-
stand the different phases of myocardial infarct injury following ischemia. The aims are 
described in details below. 
(1): To investigate the role of macrophages in MI and other experimental models 
As suggested from the literature discussed above, macrophages potentially play an im-
portant role in cardiac fibrosis. However, a number of questions remain unanswered. 
The main difficulty with the macrophage depletion study in a cryo-injury model (61) in 
the heart is the absence of ventricular remodeling in the presence of macrophages. In 
addition, functional analysis was not performed in that study. Therefore, the question 
remains to which extent macrophage depletion would affect cardiac function and struc-
ture in models that resemble acute myocardial injury in the setting of severe ischemia 
better. In addition, it remains to be seen whether macrophage depletion affects cardiac 
function and ECM structure in other models of cardiac failure, such as hypertension 
heart disease. 
 Based on these questions we set out to perform macrophage depletion experiments 
in different models of cardiac disease. In addition, we studied the effect of inhibition of 
macrophage migration in CCR2 KO mice, subjected to myocardial infarction. Further-
more, we aimed to investigate the impact of short ischemia episodes on cardiomyocyte 
recovery, and micro repair in its direct environment. 
(2): To use Biomarkers and Molecular Imaging Probes for Cell Death Assessment 
Cell death is an essential biological process that plays a vital physiological and pathologi-
cal role within an organism. Programmed cell death is critical for the correct formation 
of organs and tissues during development and also functions to rid the body of cells that 
have been infected or damaged by pathogens (68,69). 
 There are several currently validated cell death biomarkers for molecular imaging. 
Most cell death imaging studies employ one of three modalities: optical, 
radionuclear, or magnetic resonance imaging. These modalities have complementary 
properties that make them suitable for different types of in vivo imaging applications 
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(70-73). In comparison to the other methods, radionuclear imaging methods such as 
Positron Emission Tomography (PET) and Single Photon Emission Computed Tomogra-
phy (SPECT) provide much deeper tissue penetration and greatly reduced scattering of 
the emitted signal, and thus, are more attractive for many types of clinical applications. 
In MI and heart failure three biological features represents attractive targets for molecu-
lar imaging: 1) apoptosis 2) the renin-angiotensin pathway and 3) the biological process-
es of angiogenesis and fibrogenesis. 
 First, we employed labeled annexin-A5 (AA5) for radionuclide imaging to demon-
strate the reversible phosphatidylserine externalization in cardiomyocyte apoptosis. In 
addition, We exploited the capacity of a radiolabeled trivalent arsenical peptide, 4-(N-(S-
glutathionylacetyl)amino) phenylarsonous acid (GSAO) to target intracellular dithiol 
molecules like Heat shock protein 90 (HSP90) to identify cell death. Finally, using mo-
lecular imaging techniques, we examined interstitial alterations during Post-MI remodel-
ing and assessed the efficacy of antiangiotensin and antimineralocorticoid intervention, 
alone and in combination employing radionuclide imaging with a novel arginine-
glutamate-aspartate (RGD) peptide, technetium-99m-labeled Cy5.5-RGD-imaging pep-
tide (CRIP). 
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Introduction 
Cardiovascular diseases remain the number one cause of morbidity and mortality, both 
in the Western world and developing countries and in men and women alike.1 In 2005, 
the main cause of death in the USA due to disease of the heart alone was more than of 
all neoplastic disease combined. It is expected that these numbers will continue to in-
crease in the coming decades due to escalating proportions of obesity and the aging 
population. In addition to cardiac disease, cerebrovascular disease, diabetes, and hyper-
tension result in substantial morbidity and mortality. Therefore, cardiovascular diseases 
as a whole are killer number one in the Western world, and will most likely remain to be 
so due to adverse lifestyle changes, including unhealthy diets and lack of exercise. 
 Myocardial infarction (MI) is the number one cardiac disease and often strikes the 
individual unexpectedly; in 50% of cases MI is the first symptom of coronary atheroscle-
rosis. Atherosclerosis is characterized by a chronic inflammatory response resulting in 
the formation of multiple plaques in the lumen of the artery. This can happen gradually 
as a result of progressive plaque growth or suddenly as a result of plaque rupture and, 
subsequently, thrombosis causing acute MI (AMI). 
 The improvements in treatment of AMI have resulted in better survival and a de-
crease in the acute complications of MI, such as acute congestive heart failure (CHF), 
myocardial rupture, arrhythmias, and conduction system disorders. However, with more 
patients surviving the initial stage of AMI, the development of late complications of AMI 
become a more prominent health care problem. 
 The development of left ventricular dilatation and loss of pump function in the years 
following the acute myocardial injury, induced by the formation of the scar, and the 
impact of the local loss of function on pressure and tensile forces in the noninfarcted left 
ventricle, are the subject of intense research. Many trials in this area have convincingly 
shown that inhibition of the renin–angiotensin system, through either ACE inhibitors 
and/or angiotensin receptor 1 blockers, preserve cardiac function and decrease mortali-
ty post MI.2 In addition, intervention in mineralocorticoid signaling has proven to pre-
serve cardiac function and decrease mortality significantly.3,4 Despite these advances, 
still a substantial fraction, about one-third of AMI patients, will develop pump function 
disorders of the left ventricle in the long run. The outcome of a relatively recent bi-
omarker known as NT-pro Brain Natriuretic Peptide (NT pro-BNP), which is released by 
cardiomyocytes after the occurrence of ventricular malfunction, has proven its useful-
ness in diagnosing heart failure.5 Nevertheless, it is hard to predict in which individual 
patient CHF will occur. Therefore, there is still a lot to be learned and to be gained from 
research in cardiac infarct healing and adverse left ventricular remodeling. 
 An upcoming diagnostic tool in analyzing the risk of cardiovascular disease in pa-
tients is cardiac imaging.6 The capability to visualize macroscopic cardiovascular struc-
tures and the anatomical and functional consequences of cardiac diseases in patients 
has made a remarkable progression in the last decades. The development of coronary 
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angiography (CAG), echocardiography, magnetic resonance imaging (MRI), and multi-
detector CT (MDCT) has improved our approach in diagnosing cardiovascular disease 
such as atherosclerosis or left ventricular function. However, most of these imaging 
technologies are able to diagnose the end stage of the disease, rather than the begin-
ning of the disease or even pre-disease states. The next frontier in imaging will be the 
development of the capability to image fundamental biological or molecular changes 
which cause cardiovascular disease and are able to predict disease outcome at an early 
stage. For this purpose, imaging tools other than those mentioned above have to be 
developed.7 
 Imaging techniques, which visualize the fundamental biological characteristics re-
sulting in cardiovascular disease, may provide the potential to predict cardiovascular 
catastrophe as an early diagnostic tool.8 With the introduction of molecular imaging, the 
opportunities to detect changes in biology of infarcted hearts and, therefore, cardiac 
remodeling in vivo have increased significantly in the past decade. 
 It can be hypothesized that the ability to visualize interstitial processes on a molecu-
lar level, which precede the geometric and functional deterioration of the left ventricle, 
should help to better predict the likelihood and rate of remodeling and development of 
HF.9 Several key biological features provide attractive targets for molecular imaging in 
heart failure. First, the development of imaging techniques visualizing the biological 
events of angiogenesis and fibrogenesis, which are considered key processes in myocar-
dial scar formation and left ventricular remodeling, may provide attractive targets for 
the identification of patients at risk to develop a failing heart. The use of agents targeted 
to the integrin alpha v beta 3 (avB3) may offer diagnostic means to achieve this goal. 
 Second, apoptosis, a form of programmed cell death (PCD), has shown to play a key 
role in the process of gradual loss of pump function in animal models of heart failure, 
caused by different triggers. Therefore, imaging apoptosis may provide a means to iden-
tify hearts that are in the process of substantial cardiomyocyte loss and subsequent loss 
of pump function. The use of radiolabeled annexin-A5, which shows strong affinity to 
apoptotic cells which have externalized phosphatidyl serine, may provide an opportunity 
to develop such a heart failure imaging diagnostic test. 
 Finally, it is well known that the activation of the renin–angiotensin axis plays a piv-
otal role in the development of heart failure post AMI. Therefore, imaging of the differ-
ent components of renin–angiotensin neurohumoral axis may give an additional diag-
nostic tool for better identification of patients prone to develop heart failure. This brief 
review will discuss the recent progresses made in molecular cardiac imaging, focusing 
mainly on the achievements made in avB3 imaging, apoptosis imaging, and imaging of 
the activation of the renin–angiotensin system. 
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avB3 imaging as a tool to identify post MI remodeling 
As described above, early diagnosis of the impact of the infarct on adverse left ventricu-
lar remodeling in the individual patient could prevent worsening of left ventricular pump 
function by adapting treatment to the individual needs and risks. Two main events that 
occur in the infarcted area are angiogenesis and collagen deposition. The formation of 
new blood vessels is crucial for infarct healing, and is induced by several factors, such as 
basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF).10 
Among other regulators of angiogenesis, the avB3 integrin has been identified as a criti-
cal angiogenic modulator. Angiogenic vessels display increased expression of this critical 
integrin.11 This discovery led to the development of imaging tools to detect tumor angio-
genesis with the use of avB3 integrin targeting agents.12,13 
 In addition, imaging of avB3 integrin has been used to noninvasively visualize angio-
genesis in infarcted hearts. Meoli et al used indium-111-RP748 (111In-RP748), a radio-
labeled avB3 targeted compound, to image angiogenesis in infarcted canine hearts with 
SPECT imaging.14 111In-RP748 uptake peaked at 1 week after reperfusion and was associ-
ated with avB3 integrin expression on endothelial and vascular smooth muscle cells. In 
addition, they used the same targeting agent in infarcted dog hearts which showed up-
take of 111In-RP748 at the side of the perfusion defect using SPECT imaging (Figure 1). 
 
 
Figure 1. Short axis imaging data 3 weeks after induction of LAD infarction in a dog model. At the site of the 
perfusion defect (left panel), uptake of the indium-labeled avB3 RP 748 targeting tracer was observed (middle 
panel). Right panel shows the fusion data. 
 
Recently, 18F-Galacto-RGD, a PET tracer targeting specifically avB3 integrin expression, 
has been introduced.15 Higuchi et al used this tracer to monitor avB3 integrin expression 
in rat hearts after ischemia/reperfusion, and reported results comparable with 111In-
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RP748 imaging.16 Clinical use of the 18F-Galacto-RGD PET tracer in a patient with MI was 
reported shortly.17 
 Apart from its crucial involvement in angiogenesis, avB3 integrin also has been 
linked to the development of fibrosis,18,19 which led our group to evaluate whether avB3 
integrin imaging could be used to visualize fibrogenesis in the infarcted heart.20 MI was 
induced in mice, which received a 99mTc-labeled Cy5.5-RGD imaging peptide (CRIP) intra-
venously for microSPECT imaging of integrin at 2, 4, and 12 weeks after MI (Figure 2). 
 
 
Figure 2. A, Nuclear imaging showed that no uptake was seen of the avB3 targeted tracer was seen in normal 
controls and in mice with infarcted hearts injected with a scrambled variant of the targeting peptide. Uptake of 
the tracer peaked at 2 weeks post MI, and decreased gradually at 4 weeks and 12 weeks, respectively. 
B, The in vivo imaging data are confirmed by quantitative measurement (% injected dose per gram) in the 
infarct zone (left panel). In the mid sections and base sections no significant uptake of the tracer was observed 
 
The uptake of CRIP was most pronounced in the infarcted area, and peaked at 2 weeks 
after MI. Immunological analysis linked CRIP uptake to myofibroblasts, and CRIP uptake 
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paralleled with the production of newly formed collagen, with a yellow/green birefrin-
gence. In addition, several mice were treated with antagonists of the renin–angiotensin 
system, which is known to be involved in pathological myocardial remodeling. Interest-
ingly, mice treated with captopril or with captopril and losartan displayed significantly 
reduced uptake of the CRIP (Figure 3). Thus, apart from the potential value of radio-
labeled CRIP in visualizing collagen formation, it may also fulfill the need for a surrogate 
endpoint marker for therapeutic interventions. 
 
 
Figure 3. A, The effect of treatment with captopril and/or losartan post MI. In the treated groups, less uptake of 
the avB3 targeting tracer was observed using captopril and an even more extensive reduction when the treat-
ment of captopril was combined with losartan.  
B, The imaging data were confirmed by quantitative measurement (% injected dose per gram) 
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In conclusion, imaging of avB3 integrin has the potential to identify HF-prone patients 
early after MI, and thereby will help to optimize medical treatment. However, prospec-
tive clinical trials are needed to investigate whether the potential of integrin imaging 
translate into clinically useful diagnostic tests. 
Apoptosis as a target for molecular imaging in CHF 
Apoptosis plays a key role in the process of degradation of cardiomyocytes resulting in 
ventricular dysfunction.21-24 Research in animal models of CHF has demonstrated that 
interference in apoptosis pathways delays the ongoing process of pump function disor-
ders resulting in heart failure.25 
 One of the main biochemical characteristics of apoptosis is caspase 3 activation. The 
process of activation of caspase 3, an apoptosis-related cysteine protease, begins with 
the release of cytochrome C into the cytoplasmic area, mainly caused by oxidative stress 
and cytokinemia. Caspases have numerous substrates, including contractile proteins, 
such as troponin-T. In addition, in most cells, caspase activation results in activation of 
DNA fragmentation enzymes. However, it is thought that the activation of DNA fragmen-
tation enzymes in heart muscle cells is compensated for by different antiapoptotic 
pathways. The consequence of apoptosis activation in cardiomyocytes is that these cells 
become dysfunctional, but still survive due to the preservation of DNA. This means that 
restoration of a healthy environment could potentially restore individual cardiomyocyte 
function. Another consequence of caspase 3 activation is that it results in alterations in 
phospholipid distribution in the sarcolemmal lipid bilayer, causing revelation of phospha-
tidyl serine (PS) to the surface of the cell membrane.26,27 Theoretically, the extent of PS 
externalization reveals an indication of the degree of apoptosis in the heart. Accordingly, 
it is plausible that PS can be a used as a target to detect activated cell death in heart 
failure. The detection of PS exposure has been proven extensively by radionuclide imag-
ing using 99mTc-labeled annexin-A5.28,29 
 Kietselaer et al recently demonstrated the feasibility of annexin-A5 imaging to reveal 
PCD in a small group of patients with recently diagnosed advanced heart failure. Imaging 
of 99mTc-labeled annexin-A5 was performed using a SPECT in nine CHF patients with 
advanced nonischemic cardiomyopathy (hypertrophic, N = 1, dilated, N = 8). To include a 
similar genetic background as the hypertrophic cardiomyopathy patient, the same imag-
ing procedure was performed on two relatives who did not suffer from CHF. Left ven-
tricular uptake of annexin-A5 was demonstrated focal, multifocal, or diffuse in a total of 
five patients.30 All patients in whom99mTc-labeled annexin-A5 uptake was present in the 
left ventricle were diagnosed with a significant decrease of left ventricular function as 
demonstrated by follow-up echocardiography 1 year later (Figure 4). 
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Figure 4. Uptake of 99mTc-labeled annexin-A5 in advanced cardiomyopathy. A, Patient with dilated cardiomyo-
pathy (DCMP) and reduced left ventricular function showing focal uptake in the anterolateral region of the 
heart. B, Patient with DCMP in acute heart failure showing global uptake. C, DCMP in a patient with no symp-
toms of heart failure, notice no uptake is present. In D, relative of DCMP patient, absence of uptake of 99mTc-
labeled annexin-A5 (adapted from Kietselaer et al30) 
 
The five patients who demonstrated no uptake of annexin-A5 remained in a stable clini-
cal state or even showed improvement of left ventricular function (Figure 5). In line with 
the data in animal models of CHF, these data suggest that annexin-A5 uptake is related 
to dysfunction of the left ventricle. Annexin-A5 may provide the potential to become a 
useful imaging tool to identify patients with active apoptosis in the myocardium, which 
most likely indicates a transition to overt heart failure. The question remains what an-
nexin-A5 binding into the myocardium indicates, since it was suggested that cardiomyo-
cytes activate caspases during apoptosis, but that DNAses are not activated, resulting in 
the concept of apoptosis interruptus. 
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Figure 5. Differences in left ventricular ejection 
fraction after 1 year follow-up in CDMP patients 
with uptake of annexin-A5 and no uptake of 
annexin-A5 on SPECT (adapted from Kietselaer et 
al30 
 
 
Figure 6. The concept of PS externalization in heart failure. Cytokine and oxidative 
stress (reactive oxygen species) inducing release of cytochrome c out of the mito-
chondria lead to caspase 3 activation. This results in cytoplasmic proteolysis and 
DNA fragmentation, ultimately leading to apoptosis. The increase of BC12- and XIAP 
proteins and the loss of DNAses prevent the so-called apoptosis interruptus and 
activate caspase 3 
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Figure 6 shows a possible explanation for uptake of 99mTc-labeled annexin-A5 after apop-
tosis is stimulated. The revelation of PS is a response of caspase 3 activation. As men-
tioned above, different antiapoptotic pathways, preventing the degradation of DNA, 
compensate for the activation of DNA fragmentation enzymes in heart muscle cells. It is 
assumed that the quantity of PS, which manifests externally, is an indication of the 
amount of activated of caspase 3. Therefore, it is believed that annexin-A5 uptake not 
necessarily indicates loss of cardiomyocytes, but is a reflection of the activation level of 
caspase-3. 
The AT-1 receptor as a target for molecular imaging in CHF 
The essential role of the renin–angiotensin system in ventricular remodeling following 
AMI has been established in many experimental and clinical studies. Rather than circu-
lating renin–angiotensin levels, it believed that myocardial upregulation of angiotensin 
converting enzyme, angiotensin II, and its receptors determine the likelihood of ventricu-
lar remodeling.31,32 In an experimental study in mice, it was shown that transgenic mice 
with deficient angiotensin II type 1 receptor expression revealed negligible remodeling 
post MI. Moreover, a lower expression of fibrosis and transforming growth factor (TGF-
B1) was demonstrated.31These insights from experimental models have been translated 
to clinical studies showing that patients with CHF patients using angiotensin receptor 
blockers33,34 and/or ACE-inhibitors35-37 have substantially improved survival. It has been 
suggested that maximization of antiangiotensin therapy, including increase in ACE-
inhibitor dose or addition of ARB over ACE-inhibitor therapy, could further reduce mor-
bidity33,38 and mortality39 in HF. It is, therefore, imaginable that accurate assessment of 
myocardial angiotensin receptor expression could potentially guide optimization of anti-
angiotensin therapy. Nowadays, diagnostic imaging of HF is focused on geometric and 
structural cardiac imaging.40,41 
 As mentioned above, it is well known that inhibition of the renin–angiotensin sys-
tem, through either ACE inhibitors and/or angiotensin receptor 1 blockers, preserve 
cardiac function and decrease mortality post MI.2Verjans et al investigated the potential 
of angiotensin receptor II type 1 imaging in an animal model of post MI left ventricular 
remodeling.42 A fluorescent label was marked to an angiotensin peptide analogue (APA), 
which traced angiotensin type 1 and 2 receptors for imaging purposes. The data from 
the study showed distinct uptake of the fluorescent tracer in the infarct and border zone 
of the mouse hearts between 1 and 6 weeks post MI (Figure 7). 
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Figure 7. A, Imaging data show the uptake of the fluorescent AT1 receptor-targeted tracer at different time 
points after MI. The uptake peaks at 1 week post AMI, and then gradually decreases over time. In B, the con-
comitant echocardiographic data are shown, indicating a clear increase in LV end diastolic diameter 
At time point of 12 weeks, the uptake was markedly reduced. Immunohistochemical 
analysis and 2-photon microscopy showed co-localization of the tracer with both myofi-
broblasts and collagen. No uptake of the fluorescent tracer was observed in cardiomyo-
cytes. Upregulation of the AT1 receptor on myofibroblasts allows for growth factor (such 
as angiotensin-II)-induced proliferation and collagen production, which is believed to 
contribute to healing and the remodeling process following MI.43,44 
 The same research group created a radiolabeled imaging tracer of a well-known 
angiotensin II antagonist named Losartan. With the use of this analogue, SPECT-CT imag-
ing was performed after left ventricular function was evaluated by echocardiography. 
These imaging studies showed that uptake of the radiolabeled Losartan product co-
localized to the infarct area on SPECT-CT imaging, and that the uptake of the radio-
labeled product in the infarct area was 2.4-fold higher as compared to control hearts 
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(Figure 8). Together, these data demonstrate the feasibility of in vivo imaging through 
targeting of angiotensin receptors in an experimental HF model. 
 
 
Figure 8. In A, the control mouse does not show uptake of the technetium-labeled losartan product on SPECT-
CT imaging. In B, in a mouse 3 week post MI clear uptake of the tracer can be seen on SPECT-CT imaging. In C, 
quantitative analysis (% injected dose per gram) shows a 2.4-fold uptake of the tracer in the infarct area. In the 
border zone and remote zone no significant differences were seen 
 
Furthermore, the data showed that upregulation of angiotensin receptor preceded the 
development of left ventricular remodeling, as detected by echocardiography. Currently, 
significant emphasis is being placed on the recognition of stage A and B HF patients as a 
strategy of prevention of more advanced HF.45 Accordingly, development of a technology 
that predicts occurrence of cardiac remodeling, such as AT-1 receptor imaging, is of 
crucial importance, especially since the clinical practice nowadays allows diagnosis of HF 
only after the left ventricle has undergone adverse remodeling. 
 This concept is further emphasized by the recent demonstration of another strategy 
for imaging renin–angiotensin axis with the use of radiolabeled benzoyl lisinopril. 
Dilsizian et al incubated short-axis myocardial slices explanted from patients undergoing 
cardiac transplantation for end-stage ischemic cardiomyopathy with F-18 fluoro-benzoyl 
lisinopril.46 There was specific binding of radiotracer to ACE; mean binding was 6.6 ± 5.2 
compared with 3.4 ± 2.5 luminescence/mm2 in segments pre-incubated with cold lis-
inopril (P < 0.0001). Furthermore, mean radiotracer binding was 6.3 ± 4.5 in infarcted, 
7.6 ± 4.7 in peri-infarcted, and 5.0 ± 1.0 luminescence/mm2 remote noninfarcted (P < 
0.02) segments. Together, these imaging studies demonstrate that activation of the 
renin–angiotensin system can be visualized using molecular imaging technology. Both 
studies also showed that the components of the tissue renin–angiotensin cascade are 
upregulated only about 2- to 3-fold. It remains unclear whether such relatively small 
difference between remodeling cardiac tissue and control hearts could provide a clinical-
ly robust diagnostic strategy for imaging targeted to ATR and/or ACE. 
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Outlook 
Based on the preclinical and clinical data obtained in molecular imaging of adverse left 
ventricular remodeling, the current outlook for the development of such an imaging 
technology is promising. For both the imaging of avB3 integrin and imaging of phospha-
tidyl serine expression as a reflection of caspase 3 activation, the preliminary data pro-
vide a sufficient basis for the design and execution of novel studies. For imaging of the 
components of the renin–angiotensin system, the extent of uptake may be insufficient 
to form a basis for clinical applications. However, before one of these technologies could 
be adopted as diagnostic tests for routine clinical use, large clinical studies need to be 
conducted to address key questions. For instance, it is still unknown whether the uptake 
of avB3 targeting tracers is robust enough to uncover patients that are at the brink of 
developing adverse remodeling post MI. In addition, it remains to be seen whether the 
extent of the uptake of the tracer can be modulated by treatment with different regimes 
of CHF treating compounds. Studies focused on addressing these questions are under 
way. 
 For imaging phosphatidyl serine exposure in the heart using annexin-A5, as a reflec-
tion of caspase-3 activation, the outlook depends largely on the availability of clinically 
graded annexin-A5 imaging diagnostic kits. With the availability of clinical annexin-A5 
imaging kits, studies could be designed to further explore the predictive value of annex-
in-A5 in patients with failing hearts and to study the effect of therapeutic interventions. 
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Abstract 
Inflammation contributes to the process of ventricular remodeling after acute myocardi-
al injury. To investigate the role of macrophages in the chronic process of cardiac re-
modeling, they were selectively depleted by intravenous administration of liposomal 
clodronate in heart failure–prone hypertensive Ren-2 rats from the age of 7 until 13 
weeks. Plain liposomes were used for comparison. Liposomal clodronate treatment 
reduced the number of blood monocytes and decreased the number of macrophages in 
the myocardium. Compared to plain liposomes, liposomal clodronate treatment rapidly 
worsened left ventricular ejection function in hypertensive rats. Liposomal clodronate– 
treated Ren-2 rat hearts showed areas of myocyte loss with abundant inflammatory cell 
infiltration, predominantly comprising CD4 positive T lymphocytes. The current study 
showed that lack of macrophages was associated with earlier development of myocardi-
al dysfunction in hypertensive rats. Modulation of macrophage function may be of value 
in the evolution of cardiomyopathy. 
 
Keywords: hypertension; inflammation; ventricular remodeling; heart failure 
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Introduction 
Although inflammatory myocardial diseases are well known to induce chronic cardiomy-
opathic state, sparse inflammatory cell infiltration is commonly observed in noninflam-
matory heart muscle disease.1,2 It is believed that inflammatory mechanisms contribute 
to chronic cardiomyopathy by slow and progressive tissue damage and alteration of 
myocardial architecture or induction of autoimmunity.3,4 
 Macrophages may also contribute to myocardial dysfunction by producing inflam-
matory and profibrotic mediators.5 Accumulating evidence on the patho- physiological 
consequences of sustained expression of macrophage-based proinflammatory mediators 
in preclinical and clinical heart failure (HF) models has led to several clinical trials that 
have used targeted approaches to neutralize tumor necrosis factor (TNF) in patients with 
moderate to advanced HF.6,7 However, these targeted approaches have not yielded the 
anticipated results. In the current study, we investigated the role of macrophages in 
evolution of ventricular dysfunction in hypertensive homozygous Ren-2 rats. These ani-
mals are known to demonstrate rapid progression from hypertension to compensated 
left ventricular hypertrophy and HF. Male homozygous transgenic rats carrying 2 copies 
of mouse renin-2 genes (Ren-2 rats) exhibit moderate hypertension, myocardial hyper-
trophy, and excessive fibrosis associated with overproduction of angiotensin-II (Ang-II). 
These pathological changes can begin as early as 6 weeks of age and 50% of these rats 
progress to HF by 12 to 14 weeks, while the other half remain compensated at least till 
17 weeks. The failing Ren-2 rat hearts reveal abundant macrophage infiltration. We 
hypothesized that antagonizing macrophage influence in the heart by a depletion strate-
gy would result in a delay in the development of end- stage hypertensive cardiomyopa-
thy and HF. For this purpose, we injected liposomal clodronate (LC) intravenously in 
homozygous Ren-2 rats, for selective elimination of macrophages.8,9 Liposomal clodro-
nate is phagocytosed by circulating monocytes. Free clodronate does not cross cell 
membranes and has an extremely short half-life in the circulation. Liposomal clodronate 
is removed from the circulation by the renal system and has no major adverse effects on 
cell types that do not phagocytose the liposomes.8-10 
Methods 
Experimental Design 
Male, 6-week-old homozygous Ren-2 and Sprague Dawley (SD) rats were obtained from 
M&B (Bom- holtvej, Denmark). Clodronate was a gift from Roche Diagnostics GmbH, 
Mannheim, Germany. Liposomal clodronate and plain liposomes (PL) were prepared as 
described previously.9 Under light isoflurane anesthesia, 10 male homozygous Ren-2 rats 
received LC (4 mL/gram body weight) through the tail vein, every week for 7 weeks. As a 
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control for the liposomally encapsulated clodronate, liposomes filled with phosphate 
buffer saline (PBS) were injected in 7 Ren-2 rats. In addition, 4 healthy SD rats received 
LC and 4 age-matched SD rats received PL. Rats were euthanized at 13 weeks. In all ex-
perimental groups, blood pressure was measured by tailcuff method, and echocardiog-
raphy was performed at 0, 14, 28, and 42 days of LC or PL treatment in rats sedated with 
2% isoflurane. Standard views were obtained in 2-dimensional as well as M-mode with a 
12-MHz transducer (Sonos 5500, Hewlett Packard, Netherlands) with approximately 220 
frames per recording and the data analysis was performed by a blinded observer. The 
Institutional Animal Care and Use Committee approved the procedure for care and 
treatment of animals. 
Peripheral Blood Monocytes and CD4þ and CD8þ T cells 
Peripheral blood monocytes and CD4þ and CD8þ T cells were analyzed in Ren-2 rats at 2 
and 7 days after intravenous infusion of LC or PL with specific antibodies by flow cytome-
try. In brief, anticoagulated blood (200 mL) was incubated for 30 minutes (4o C) with 
mouse anti-rat R-phycoerythrin (RPE)-conjugated anti-CD4, CD8, and CD68 antibodies 
(Serotec, Dus- seldorf, Germany) and isotype controls. All analyses were performed 
separately. Fluorescence-activated cell sorting (FACS) lysing solution (1:20 dilution) was 
added for 15 minutes. The residual cells were washed (x1500 rpm, 5 minutes, 4o C) in 
FACS medium (PBS, 1% bovine serum albumin [BSA], 0.02% sodium azide) and suspend-
ed for flow cytometry. Monocytes and lymphocytes were identified according to their 
relative size, side scattering, and fluorescence. 
Immunohistochemical localization of macrophages and T lymphocytes in 
myocardium 
Immunohistochemistry was performed on cryofixed myocardial sections. After drying 
the sections for 15 minutes, ice-cold methanol (100%) was added for 10 minutes; sec-
tions were washed 3 times with PBS and blocked with 5% horse serum for 60 minutes. 
Anti-CD3, -CD4, -CD8, and -CD68 (Serotec) and anti-annexin A5 (BioVision, Uithoorn, The 
Netherlands) antibodies (1:250 in 0.1% BSA in PBS) were applied and incubated over-
night at 4°C. Horseradish peroxidase–conjugated secondary antibodies were then used 
for 4 hours at room temperature followed by horseradish peroxidase–labeled streptavi-
din for 60 minutes. After washing 3 times for 5 minutes in PBS, 3,30-diaminobenzidine 
tetrahydrochloride reagent was applied to visualize the reaction. 
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Statistical Analyses 
Data are presented as mean + SD. The comparisons were made by unpaired t test. For 
multiple comparisons, 1-way analysis of variance (ANOVA) in combination with a Dun-
nett’s post hoc analysis was made. Analyses were performed by the use of the statistical 
package SPSS 10.0. Probability value of P < .05 was considered to be statistically signifi-
cant. 
Results 
Peripheral Blood Monocyte Count and the Interstitial Macrophage Infiltration 
Baseline peripheral blood monocyte proportion in PL-treated Ren-2 rats was 2.28% + 
0.15% (Figure 1A and B). Two days after LC injection in Ren-2 rats, the number of mono-
cytes sharply reduced to 0.81% 
+ 0.21% (Figure 1C and D), whereas CD4 and CD8 count remained unchanged (CD4: LC, 
43.6% + 3.5% vs. PL, 45 + 4.6; CD8: LC, 5% + 2.5% vs. PL, 4.8 + 1.9, P = NS; Table 1). How-
ever, the monocyte count returned to baseline levels (1.8 + 0.38) by 7 days. Presence of 
macrophages in the hearts was shown by CD68-specific monoclonal antibody. In the 
Ren-2 rats that received PL, macrophages were frequently observed (Table 2). However, 
LC-treated Ren-2 rats showed scattered cells identical to macrophage morphology; the 
macrophages also stained positively for annexin A5, suggesting LC- induced apoptotic 
changes in these cells (Figure 2A). Annexin A5 positivity was not seen in the PL-treated 
Ren-2 rats (Figure 2B) and control rats with LC (Figure 2C) and PL (Figure 2D) treatment. 
 
Table 1. Monocyte, CD4, and CD8 Count of LC- and PL-treated Rats (%)a 
 Ren-2-LC Ren-2-PL 
Monocytes 0.81 + 0.21 2.28 + 0.15 
T-helper cells (CD4)  43.6 + 3.5 45 + 4.6 
Cytotoxic T cells (CD8) 5 + 2.5 4.8 + 1.9 
Abbreviations: LC, liposomal clodronate; PBS, phosphate buffer saline; PL, PBS liposomes. 
aP = NS. 
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Table 2. Morphometric Data to Compare the Cellular Infiltration and Apoptotic Changes in the Myocardium of 
LC- or PL-treated Rats 
 Cell counts/HPF 
 Ren-2-LC  
(N = 7) 
Ren-2-PL 
(N = 7) 
SD-LC  
(N = 4) 
SD-PL  
(N = 4) 
Mononuclear cells (HE-staining) 89.3 + 26a 7 + 2.4 13.8 + 2.1 8.5 + 1 
Macrophages (CD68) 1.8 + 0.31 13.8 + 3.3b 0.66 + 0.4 2.5 + 0.7 
T-lymphocytes (CD3)  49 + 13.3a 3.3 + 0.68 4.8 + 1.1 4.3 + 0.8 
T-helper cells (CD4) 33.8 + 13.7a   3.1 + 0.8 
Cytotoxic T-cells (CD8) 2.8 + 0.4 2.3 + 0.50 2.1 + 0.4 2.3 + 0.51 
Apoptotic cells (Annexin A5) 10.5 + 4.2a 2.1 + 0.66 3.1 + 0.7 1.1 + 0.4 
Abbreviations: HE, hematoxylin-eosin; HPF, high power field; LC, liposomal clodronate; PBS, phosphate buffer 
saline; PL, PBS liposomes; SD, Sprague Dawley. 
a P < .05 versus Ren-2-PL, SD-LC, and SD-PL; b P < .05 versus Ren-2-LC, SD-LC, and SD-PL. 
 
 
Figure 1. Flow cytometric analysis of blood monocyte population after the infusion of LC or PL in Ren-2 rats. 
We injected PL or LC in Ren-2 rats and collected the blood samples after 48 hours. Height of the histogram 
represents monocyte population. A, FACS analysis of CD68 positive cells in the blood in PL-treated Ren-2 rats. 
B, Isotype control for panel A. C, CD68 positive cells in LC-treated Ren-2 rats. D. Isotype control for panel C. 
FACS = fluorescence-activated cell sorting; LC = liposomal clodronate; PL = plain liposomes. 
 
M A C R O P H A G E  D E P L E T I O N  I N  H Y P E R T E N S I V E  R A T S  
 47 
 
Figure 2. Demonstration of apoptosis-specific changes by annexin A5 positivity. A, Anti-annexin A5 staining 
showing apoptosis of macrophages in LC-treated Ren-2 rat hearts. B-D, Anti-annexin A5 staining in PL-treated 
Ren-2 rats, LC-treated SD rats, and PL-treated SD rats, respectively. LC = liposomal clodronate; PL = plain lipo-
somes; SD = Sprague Dawley. 
Evolution of Cardiac Function in Monocyte-depleted Ren-2 Rats 
The Ren-2 rats that received LC from 7 to 13 weeks of age demonstrated significant 
deterioration of myocardial function (ejection fraction (EF) %, baseline, 65.2 + 4.1; 6 
weeks, 49 + 5.4, P < .05). However, Ren-2 rats that received PL showed only a mild and 
no decrease in cardiac performance (EF%, baseline, 67 + 3.1; 6 weeks, 62 + 5.3). The 
control rats did not show any significant alteration in cardiac perfor- mance, regardless 
of LC (EF%, baseline, 64 + 4; 6 weeks, 63 + 3.8) or PL (EF%, baseline, 65.5 + 1.9; 6 weeks, 
66.4 + 1.0) administration (Table 3). This suggests that persistent macrophage depletion 
in hypertensive hearts (and normally with abundant macrophage infiltration) accelerates 
functional dete- rioration. There was no significant difference in body weight between 
the 4 experimental groups. Ren-2 rats were hypertensive and had significantly increased 
heart weight to body weight ratio compared to controls. However, these parameters 
were not significantly different between LC- and PL-treated rats (Table 4). 
Histological Consequences of Macrophage Depletion 
The Ren-2 rats that received LC treatment for 6 weeks showed areas of cardiomyocyte 
damage (Figure 3A), which was not discernible in control groups (Figure 3B-D). Although 
there was a marked decrease in number of macrophages, abundant focal infiltrates of 
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mononuclear cells were noted in the myocardium in LC-treated Ren-2 rat hearts. Mor-
phologically, the infiltrated cells showed round nucleus with myocardial interstitial pat-
tern of dis- tribution (Figure 3A). Immunohistochemical analysis revealed that these 
round cells expressed CD3 (Figure 4) and CD4 antigen, suggesting that the macrophage-
depleted Ren-2 rat hearts harbor increased CD4þ T-helper cells in the myocardium (Ta-
ble 2). 
 
Table 3. Baseline, 2-,4-, and 6-Week Echocardiographic Parameters in LC- or PL-treated Ren-2 Rats and SD 
Controls 
LV Functional 
Parameters 
Time Point  Ren-2-LC  
(N = 10)  
Ren-2-PL  
(N = 7)  
SD-LC  
(N = 4)  
SD-PL  
(N = 4)  
EF (%) Baseline 65.2 + 4.1 67 + 3.1 64 + 4 65.5 + 1.9 
 2 weeks 64.6 + 4.9 66.9 + 3.04 63.3 + 3.4 63.7 + 2.7 
 4 weeks 57 + 6.6 64.3 + 6.4 62.6 + 2.3 64.5 + 3.9 
 6 weeks 49 + 5.4a 62 + 5.3 63 + 3.8 66.4 + 1.0 
FS (%) Baseline 32.7 + 4.2 34.8 + 4.2 31.2 + 3.8 36.7 + 0.5 
 2 weeks 30 + 4 30.2 + 4 30.2 + 1.5 35.2 + 1.2 
 4 weeks 26 + 3.2 26.5 + 3.2 28.5 + 3.7 34.2 + 2.2 
 6 weeks 22.8 + 4.8a 30.2 + 4.2 30.7 + 3.5 34.4 + 3.2 
EDV (mL) Baseline 0.41 + 0.26 0.40 + 0.17 0.44 + 0.15 0.40 + 0.07 
 2 weeks 0.55 + 0.21 0.41 + 0.16 0.41 + 0.1 0.4 + 0.05 
 4 weeks 0.81 + 0.35 0.43 + 0.09 0.41 + 0.07 0.4 + 0.06 
 6 weeks 1.1 + 0.68a 0.43 + 0.16 0.42 + 0.03 0.42 + 0.07 
Abbreviations: EF, LV ejection fraction; EDV, end diastolic volume; FS, LV fractional shortening; LC, liposomal 
clodronate; LV, left ventricular; PBS, phosphate buffer saline; PL, PBS liposome; SD, Sprague Dawley. 
a P < .05 versus Ren-2 placebo and SD rats. 
 
Table 4. Blood Pressure, Heart Weight, and Body Weight of LC- and PL-treated Rats 
 Ren-2-LC  
(N + 7) 
Ren-2-PL  
(N = 7) 
SD-LC  
(N = 4) 
SD-PL  
(N = 4) 
BP (mm Hg) 253 + 15a 259 + 10a 131 + 4.7 128 + 10 
BW (g) 314 + 18 310 + 23 314 + 13.5 308 + 8.9 
HW/BW (%) 0.47 + 0.04a 0.50 + 0.05a 0.36 + 0.03 0.35 + 0.03 
Abbreviations: BP, blood pressure; BW, body weight; HW/BW, heart weight to body weight ratio; LC, liposomal 
clodronate; PBS, phosphate buffer saline; PL, PBS liposomes; SD, Sprague Dawley. 
a P < .05 versus SD-LC and SD-PL. 
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Figure 3. Histological characterization of the myocardial changes in LC-treated Ren-2 rats and 
controls. A, Hematoxylin-eosin stained myocardial sections showed areas of cardiomyocyte 
damage with mononuclear cellular infiltration in LC-treated Ren-2 rats. These changes were not 
remarkable in PL-treated Ren-2 (panel B), LC-treated SD (panel C), and PL-treated SD (panel D) rat 
hearts. LC = liposomal clodronate; PL = plain liposomes; SD = Sprague Dawley. 
 
 
Figure 4. Demonstration of T-lymphocyte infiltration in LC-treated Ren-2 rat hearts. A, Anti-CD3 
staining showing abundance of T lymphocytes in the hearts of Ren-2-rats treated with LC. B-D, 
Anti-CD3 staining in PL-treated Ren-2, LC-treated SD, and PL-treated SD rat hearts, respectively. 
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Discussion 
In contrast to our beginning hypothesis, the results of the current study suggest that the 
depletion of macrophages, in a model of hypertensive heart disease, results in the accel-
erated development of end-stage hypertensive cardiomyopathy and HF. The macro-
phage-depleted hearts showed infiltration with CD4þ T lymphocyte and multifocal loss 
of cardiomyocytes. 
 The possible role of macrophage infiltration in cardiomyopathy can be discussed as 
follows. First, minimal fibrosis was demonstrated and neither fibroblasts nor collagen 
deposition was observed. It is known that macrophage-related cytokines are associated 
with myofibroblast proliferation and collagen production. Although development of 
interstitial fibrosis is an important component of cardiomyopathic process, it is reasona-
ble to observe that complete abolition of fibrosis should be detrimental. In a postinfarc-
tion model, macrophage depletion has been reported to be associated with acute ven-
tricular dilatation and early onset of HF.11 It has also been demonstrated that intramyo-
cardial injection of collagen prevents ventricular aneurysmal formation and HF.12 Alt-
hough these experiments highlight the importance of the collagen framework in healing 
from myocardial injury, neurohumoral antagonists (which have proven to be effective in 
prevention of remodeling and longevity) are known to reduce collagen deposition.13 It is 
therefore likely that both excessive collagen deposition as well as lack of collagen depos-
it is adversorial in myocardial remodeling. Second, cardiomyopathies are associated with 
increased circulating levels of various cytokines, including TNF-α, which are known to be 
detrimental for myocardial function.14 However, blocking of TNF-α has paradoxically 
resulted in worsening of experimental chronic Chagas disease–mediated cardiomyopa-
thy,15 which is similar to our observations. Third, macrophage-depleted hearts showed 
abundant T-lymphocyte infiltration. The mechanisms for compensatory CD4þ T-cell 
infiltration in macrophage-depleted hypertensive rats remain unclear. At least 4 distinct 
subsets of CD4þ T cells have been recognized including Th1, Th2, Treg, and Th17 cells. 
Treg appear to play a protective role16 and Th2 cells play a role in antibody-mediated 
response; as such CD4þ T cells in our study are unlikely to be Treg or Th2 cells. There-
fore, we assume that the CD4þ T-cell infiltrates may be composed of either Th1 cells, 
Th17 cells, or both. Th17 cells secrete a number of proinflammatory cytokines, including 
inter-leukin (IL)-17, and have shown to play an important role in autoimmunity and in-
flammation.17-19 It has been shown that IL-7-mediates experimental autoimmune cardi-
omyopathy in t-bet knock out mice (t-bet favors Th1 development), suggesting a role of 
IL-17 in cardiomyopathy.20 
 Taken together, sustained depletion of macrophages could contribute to the deteri-
oration of cardiac function because of the loss of the beneficial aspects of macrophage 
function and/or deleterious effects of enhanced CD4þ T-cell infiltration. 
M A C R O P H A G E  D E P L E T I O N  I N  H Y P E R T E N S I V E  R A T S  
 51 
Conclusions 
The results of the current study show a potentially important role of macrophages in 
ventricular remodeling in hypertension. Macrophage activation may be important in 
repair processes and debris clearance and hence depletion of macrophages may not 
necessarily be an effective strategy in prevention of HF. However, larger studies may be 
needed to evaluate the role of modest modulation of macrophage function. 
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Abstract 
Monocyte macrophage infiltration contributes to infarct healing by removal of necrotic 
debris and replacement fibrosis in the aftermath of myocardial infarction. The latter 
evolves secondary to myofibroblastic proliferation and collagen deposition. Expansion in 
interstitial volume in the remote regions may influence the clinical outcomes adversely. 
It is hypothesized that modulation of macrophage infiltration may influence replacement 
and interstitial fibrosis and hence outcome. We have used clodronate liposome admin-
istration to selectively deplete macrophages early and late after infarction and evaluate 
the impact on the evolution of left ventricular function. 
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The role of macrophages in wound healing in acute myocardial infarction (MI) has been 
frequently debated.1,2 It has been considered to be a double-edge sword. The macro-
phage infiltration is deemed necessary to scavenge the necrotic debris from the infarct 
site, its intimate interaction with myofibroblasts and collagen production is both benefi-
cial and deleterious. Whereas collagen laid down in the infarcted zone provides strength 
to the scar and restricts infarct expansion, gradual fibrosis in the peri-infarct and remote 
zones leads to ventricular remodeling. It is therefore important that the role of macro-
phages is clarified by selective depletion of macrophage infiltration in the infarcted myo-
cardium. 
 
For this purpose, we injected liposomal clodronate (LC) intravenously for selective elimi-
nation of macrophages.3,4 Plain liposomes (PL) were used as treatment control. Liposo-
mal clodronate is phagocytosed by circulating monocytes. Free clodronate does not 
cross cell membranes and has an extremely short half-life in the circulation. Liposomal 
clodronate is removed from the circulation by the renal system and has no major ad-
verse effects on cell types that do not phagocytose the liposomes.3-5 In our previous 
experiment we analyzed peripheral blood monocytes and CD4+ and CD8+ T cells in Ren-
2 rats at 2 and 7 days after intravenous infusion of LC or PL by flow cytometry.6 R-
phycoerythrin (RPE)-conjugated anti-CD4, CD8, and CD68 antibodies (Serotec, Dussel-
dorf, Germany) and isotype controls. Baseline peripheral blood monocyte proportion in 
PL-treated rats was 2.28%±0.15%. Two days after LC injection the number of monocytes 
sharply reduced to 0.81%±0.21% whereas CD4 and CD8 count remained unchanged 
(CD4: LC, 43.6%±3.5% vs. PL, 45%±4.6%; CD8: LC, 5%±2.5% vs. PL, 4.8%±1.9%, P = NS). 
However, the monocyte count returned to baseline levels (1.8±0.38) by 7 days. 
 
We depleted macrophages in early and late phases of infarct healing with the help of 
intravenously administered clodronate-liposomes (CL).6 The outcome of CL-related ef-
fect of macrophage depletion was evaluated by magnetic resonance imaging based left 
ventricular functional assessment; plain-liposomes (PL) were used in a treatment control 
group. 
 
Experimental MI was produced in 12 Wistar rats. Nine animals with MI received CL and 
the remaining 3 received PL. CL-treated animals were divided in 3 groups based on the 
length of CL treatment (Table 1); animals received CL throughout 3-week follow-up peri-
od, only in the first 12 days or only in the last 12 days. 0.2ml of CL or PL was adminis-
tered intravenously every other day through the tail vein. In addition to 3 treatment 
control rats, no manipulation or surgery was performed in 2 animals that were used as 
disease control animals. 
 
The myocardial healing in the presence of PL resulted in a 50% MR-verified reduction in 
LVEF at 3 weeks after MI. If macrophages were depleted all across the healing period i.e. 
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for 28 days, the LVEF improved substantially. The EF remained similarly improved if the 
macrophages were only depleted in the first 12 days after MI but were allowed to recruit 
macrophages at day 12. On the other hand only late depletion of macrophages did not 
restore LV function (Table 1). 
 
Table 1. Administration of Clodronate and Empty Liposoms During Different Time Points Post MI, Left Ventricu-
lar Ejection Fraction, Left Ventricular End Diastolic Volume, Left Ventricular End Systolic Volume  
Group CL and PL  
administration (d) N 
LVEF (%) 
(%, std error) 
LVEDV 
(std error) 
LVESV 
(std error) 
no MI 2 52.37±1.73 *#†‡¥ 0.28±0.025 0.13±0.010 
PL 0-21 3 26.68±0.85 *§ 0.37±0.170 0.27±0.123 
CL 13-21 3 25.06±1.82 *‡§ 0.42±0.032 0.32±0.021 
CL 0-10 3 34.49±2.13 *†¥ 0.29±0.038 0.19±0.032 
CL 0-21 3 34.91±1.02 *#†‡ 0.31±0.019 0.20±0.010 
Data are presented as mean±Standard error 
* p≤0.05 vs no MI, # p≤0.05 vs PL0-21, † p≤0.05 vs CL13-21 , ‡ p≤0.05 vs CL0-10, § p≤0.05 vs CL0-21, ¥ p≤0.05 
vs CL0-7 
 
In CL treatment experiments, the functional deterioration was more pronounced when 
macrophages were present in the initial 2 weeks after infarction and demonstrated im-
provement if they were depleted early. The results are intriguing, and it is reasonable to 
suggest that a reduction in macrophage infiltration early after MI may be of some bene-
fit. Although macrophages are necessary for the scavenger function2, accompanying 
cytokine activity may delay the healing process.7 Since macrophages are only partially 
obviated it is conceivable that the partial reduction in macrophage number may not 
adversely affect interaction with myofibroblasts and collagen deposition. 
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Abstract 
MRI has been proven to be an accurate method for noninvasive assessment of cardiac 
function. One of the current limitations of cardiac MRI is that it is time consuming. 
Therefore, various geometrical models are used, which can reduce scan and postpro-
cessing time. It is unclear how appropriate their use is in rodents. Left ventricular (LV) 
volumes and ejection fraction (EF) were quantified based on 7.0 Tesla cine-MRI in 12 
wild-type (WT) mice, 12 adipose triglyceride lipase knockout (ATGL−/−) mice (model of 
impaired cardiac function), and 11 rats in which we induced cardiac ischemia. The LV 
volumes and function were either assessed with parallel short-axis slices covering the full 
volume of the left ventricle (FV, gold standard) or with various geometrical models 
[modified Simpson rule (SR), biplane ellipsoid (BP), hemisphere cylinder (HC), single-
plane ellipsoid (SP), and modified Teichholz Formula (TF)]. Reproducibility of the differ-
ent models was tested and results were correlated with the gold standard (FV). All mod-
els and the FV data set provided reproducible results for the LV volumes and EF, with 
interclass correlation coefficients ≥0.87. All models significantly over- or underestimated 
EF, except for SR. Good correlation was found for all volumes and EF for the SR model 
compared with the FV data set (R2 ranged between 0.59–0.95 for all parameters). The 
HC model and BP model also predicted EF well (R2 ≥ 0.85), although proved to be less 
useful for quantitative analysis. The SP and TF models correlated poorly with the FV data 
set (R2 ≥ 0.45 for EF and R2 ≥ 0.29 for EF, respectively). For the reduction in acquisition 
and postprocessing time, only the SR model proved to be a valuable method for calculat-
ing LV volumes, stroke volume, and EF. 
 Cardiovascular diseases still are one of the main causes of death in Western coun-
tries, and the incidence and prevalence of cardiovascular diseases are still increasing 
(28,29). Therefore, many studies have focused on the prevention, treatment, and etiolo-
gy of these diseases. Rodent models of cardiac disease have played a critical role in this 
area of expertise and hence models to assess rodent cardiac function have become 
increasingly important over the last decades (12,24). MRI has been proven to be an 
accurate method for noninvasive assessment of cardiac function in rodents (22,23,25) 
and has therefore become an important tool in studies of rodent models of cardiac dis-
ease (7,14). With MRI, systolic function can be assessed by calculating the ejection frac-
tion (EF) from sequential multislice short-axis cine-MRI covering the complete volume of 
the left ventricle (25). However, this requires an acquisition of at least six to eight slices 
(depending on the size of the heart), which can be quite time consuming, especially in 
studies requiring high spatial resolution. Also manual or semiautomatic analysis of these 
slices can demand a substantial amount of time in high-throughput applications (31). 
Furthermore, it might be desirable to be able to allow quick assessment of the cardiac 
function, as a secondary parameter, without increasing scan time too much. The acquisi-
tion duration is not only demanding in terms of scan time but also prolongs the duration 
of anesthesia and hence increases stress in the animals under investigation (5, 11). In 
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specific cardiovascular compromised genotypes, such as the adipose triglyceride lipase 
knockout (ATGL−/−) mouse, which was used in our studies (10), prolonged anesthesia can 
in some cases increase mortality rate. 
 To circumvent this, several studies have implemented geometrical models for as-
sessment of cardiac function in rodents, rather than acquiring multiple parallel slices 
with multislice cine-MRI to determine the full volume of the left ventricle (4, 
8,13,15,18,26,30). These models estimate left ventricular (LV) volumes based on single 
or perpendicular biplane or even triplane slices (6) and therefore allow quick assessment 
of LV volumes and EF, as they only require acquisition of one up to three instead of six to 
eight slices for mice. For rats, due to the larger size of the left ventricle, the reduction in 
number of slices is even larger, i.e., 1–3 instead of 6–10 slices. This would substantially 
reduce total scan time with 10–30 min for mice and even 20–45 min for rats. A typical 
total examination time during which the mice and rats are kept under anesthesia for 
assessment of cardiac function is 40–45 and 45–60 min, respectively. Additionally, ac-
quisition of images required for the geometrical models instead of a full volume data set 
would reduce the number of slices to be segmented to calculate the LV volumes and EF 
with a factor of 2–3 for mice and 2–4 for rats, thereby also reducing time spent on the 
assessment of cardiac function in rodent models of cardiac disease. 
 Although these models have been compared with ultrasound (4) and have been 
validated in humans (6), to our knowledge no study has determined which of these ge-
ometrical models is most accurate in determining cardiac function compared with the 
gold standard, i.e., cine-MRI of the complete left ventricle by full volume imaging in 
rodents. Therefore, the aim of the present study was to evaluate reproducibility and 
validity of these geometrical models in mice compared with the gold standard, cine-MRI 
of the complete left ventricle. After testing the validity of these geometrical models in 
wild-type mice with anticipated normal cardiac function, we tested applicability of these 
models in mice with anticipated cardiac failure and in rats in which we induced myocar-
dial infarction. 
Methods 
Animals 
Mice and rats were housed under standard conditions at 25°C with a 14:10-h light-dark 
cycle with ad libitum access to water and standard chow diet. The Maastricht University 
Medical Centre Institutional Ethics Committee on Animal Welfare approved all experi-
ments. Twelve wild-type C57BL/6 mice with anticipated normal cardiac function were 
imaged for validation of the geometrical models. In addition, we extended the validation 
to a model of severe cardiac dysfunction by using 12 adipose triglyceride lipase knockout 
mice (ATGL−/−, age 8–12 wk). ATGL−/− mice were generated on a mixed genetic back-
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ground (50% C57BL/6 and 50% 129/Ola) as previously described (9). The targeted ATGL 
allele was then backcrossed onto the C57BL/6 background strain for >10 generations. 
Furthermore, myocardial infarction (MI) was induced in 11 male Wistar-rats (300–500 g) 
by ligation of the left anterior descending coronary artery using a 6–0 Prolene suture, as 
described previously (17,19). Subsequently, the rats were scanned between 7 and 21 
days post-MI. 
 Before MRI, mice were anesthetized using 1–2% isoflurane (Abbott Laboratories, 
Queensborough, UK) in medical air. Neonatal ECG electrodes (3M, St. Paul, MN) were 
placed on the paws of the right front leg and left hind leg and connected to an MR com-
patible small animal monitoring system (SA Instruments, Stony Brook, NY). Animals were 
placed on a warm waterbed. Respiratory rate was continuously monitored. 
MRI protocol 
MRI was performed on a 7 Tesla Bruker Biospec 70/30 USR (Bruker Biospin, Ettlingen, 
Germany) using the BGA12-S mini-imaging gradient (maximum gradient strength: 400 
mTm−1, slew rate: 5,000 Tm−1·s−1, and linear inductive rise time: 5–95% on all axis, 80 μs), 
interfaced to an AVANCE II console. First, a bright blood cine image with 10 cardiac 
phases was recorded in horizontal 4-chamber view (4CH) using a retrospectively self-
gated protocol (IntraGate, Bruker Biospin; imaging time: ≈2–4 min, for the mice: 2.56 × 
2.56 cm2 field of view, 164 × 164 matrix size; for the rats: 5.0 × 5.0 cm2 field of view, 128 
× 128 matrix size see Fig. 1, I and J). This 4CH orientation was used to plan a long axis 
view (LA) perpendicular to the 4CH view with the same self-gated protocol (see Fig. 1, A, 
B, E, and F). The orientation was defined as a sagittal plane through the mitral valve and 
the apex. Perpendicular to this LA and 4CH view and the septum, a short axis view (SA) 
was positioned (see Fig. 1, C, D, G, H, K, and L). The slice was planned at half height of 
the left ventricle, 1–2 mm below the leaflets of the mitral valve. This image was acquired 
ECG and respiratory gated, using a bright blood gradient echo sequence with the follow-
ing parameters for the mice studied: repetition time: 11.6 ms, echo time: 2.5 ms, flip 
angle: 50°, one slice, 1-mm thickness, eight signal averages, field of view: 25.6 × 25.6 
mm, and matrix-size: 164 × 164, resulting in an in-plane resolution: 0.16 × 0.16 mm2 and 
acquisition time: ≈4 min. The SA images of the rats were acquired with the following 
parameters: repetition time: 7 ms, echo time: 2.8 ms, flip angle: 50°, 1 slice, 1.263-mm 
thickness, one signal average, field of view: 50 × 50 mm, and matrix-size: 192 × 192, 
resulting in an in-plane resolution: 0.26×0.26 mm2 and acquisition: time ≈5 min. For 
image analysis of the complete LV volumes, five to nine additional slices were planned 
parallel to the short axis slice with a slice thickness of 1 mm in the mice and 1.2 mm in 
the rats, without gap between slices. The slices covered the whole left ventricle, from 
the apex to the base. The images were acquired using the same pulse sequence. The 
average time for acquiring the images needed to assess EF with a full volume data, using 
eight slices, is ≈50 min. 
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Fig. 1. Long axis (LA), 4-chamber view (4CH), and short axis (SA) images of adipose triglyceride lipase knockout 
mice (ATGL−/−) and wild-type (WT) mice and a rat model of myocardial infarction. Depicted are the LA-plane 
images of the WT mice. A: in diastole. B: in systole. E: LA-plane image in diastole of a ATGL−/− mice. F: LA-plane 
image in a ATGL−/− mice in systole. Here a plane through the mitral valve and the apex was chosen to assess left 
ventricular (LV) length and volume. I: 4CH view is depicted of a rat heart in diastole. J: 4CH view of a rat heart 
in diastole, after myocardial infarction. C and D: SA images are depicted in wild-type (WT) mice. G and H: SA 
images are depicted of a ATGL−/− mice. K and L: SA images are depicted of a rat heart after myocardial infarc-
tion in diastole and systole, respectively. SA view was positioned perpendicular to the LA plane and 4CH view 
for the quantification of LV volumes. Furthermore, in these images an impaired systolic contraction and a 
dilated and thickened ventricular wall is visible in the ATGL−/− mice (middle), as well as an infracted area in the 
left ventricle and slight dilatation of the rat heart (bottom). 
Image analysis 
All images were analyzed in OsiriX (Dicom viewer, version 3.5; Pixmeo, Geneva, Switzer-
land). The end-diastolic volumes (EDV) and end-systolic volumes (ESV) of the left ventri-
cle were considered the largest and the smallest areas, respectively, of the LV cavity in 
each slice. For the analysis of cine-MRI, the window width and level were manually ad-
justed to recognize the internal ventricular morphologic characteristics. For the meas-
urements of LV volumes, the whole LV cavity was selected with semiautomated segmen-
tation parameters in OsiriX. The papillary muscle was excluded from the LV volume dur-
ing analysis. The diameter (D) of the LV volume on the short axis was measured as the 
longest distance between the septum and the ventricular wall. Length (L) of the LV on 
the LA view was defined as the longest distance from the apex to the valves. On average, 
the time needed to analyze one slice was 3 min. 
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Data analysis 
In all animals, EDV, ESV, stroke volume (SV = EDV − ESV), and EF (EF = SV/EDV) were 
calculated from the EDV and ESV volumes based on either the multislice short axis cine-
images of the complete left ventricle (gold standard) or based on the different geomet-
rical models as described by Dulce et al. 1993 (6). The algorithms and required imaging 
slices for these models can be found in Fig. 2. 
 
 
Fig. 2. Algorithms and formula’s for calculation of LV volumes with a full volume MRI data set of the complete 
left ventricle or geometrical models based on a few MRI slices. Top: algorithms for full volume data set and the 
various geometrical models for the determination of LV volumes and ejection fraction (EF) are presented. Ai, 
cross-sectional area of LV cavity in the LA plane; Am, cross-sectional area of the LV cavity in the SA plane, ≈1–2 
mm below the mitral valve; Ap, cross-sectional area of the LV cavity in the SA plane, approximately at the base 
of the papillary muscles; D, diameter of the LV cavity in the short axis plane, ≈1–2 mm below the mitral valve; 
L, longest length of LV cavity in the LA plane; LVV, LV volumes [end-diastolic volume (EDV) and end-systolic 
volume (ESV), respectively]; S1, S2, S3, . . ., 1-mm SA slices from the apex to the base of the left ventricle. 
Statistical analysis 
Measurements of LV volumes and EF from cine MRI in both the wild type animals and 
the transgenic ATGL−/− mice are presented as mean values ± SD. The correlations of LV 
volumes and EF, as measured with the various geometric models vs. the full volume data 
set of the left ventricle (gold standard), were assessed by linear regression analysis. R2, P 
values, and 95% individual confidence intervals (also known as prediction intervals) are 
reported for all regression analysis. Differences in LV volumes and EF between the geo-
metric models and the gold standard were analyzed for statistical significance with a 
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one-way ANOVA. Also, differences in outcome measures between the different geno-
types were assessed with a one-way ANOVA for each model separately. P value <0.05 
was considered statistically significant. Reproducibility was tested by calculating the 
interclass correlation for two consecutive measurements for all geometrical models and 
the gold standard in five wild-type mice. For measuring the two consecutive measure-
ments, mice were taken out of the scanner in-between the measurements, where after 
they were repositioned and all preparatory steps (including shimming and acquisition of 
scout-images) were repeated. 
Results 
Reproducibility 
The interclass correlation coefficients for each model for the LV volumes and EF are 
summarized inTable 1. The interclass correlation coefficient was >0.85 for all parameters 
in each model indicating a good reproducibility for all models. 
 
Table 1. Interclass correlation coefficients of LV volumes and ejection fraction in wild-type animals 
 Wild-type animals–interclass correlation coefficients 
 EDV ESV SV EF  
FV 0.944 0.915 0.981 0.995 
BP 0.991 0.994 0.986 0.975 
SR 0.995 0.981 0.986 0.955 
HC 0.979 0.997 0.961 0.996 
SP 0.997 0.989 0.976 0.939 
TF 0.983 0.893 0.887 0.866 
Values were obtained with geometric models and a complete imaging set of the left ventricle (LV) acquired 
with cine-MRI. Presented are the interclass correlation coefficients of a repeated measurement in 5 mice. EDV 
and ESV, end-diastolic and end-systolic volume; SV, stroke volume; EF, ejection fraction; FV, full volume data 
set; BP, biplane ellipsoid model; SR, modified Simpson rule model; HC, hemisphere cylinder model; SP, single 
plane ellipsoid model; TF, modified Teichholz formula model. 
Validation of LV volumes and EF 
The values for LV volumes and EF in the various animal groups are summarized in Table 
2. Only the modified Simpson rule model gave statistically indifferent values for both the 
LV volumes and the EF compared with the full volume data set for all study groups. All 
models could pick up the marked differences in LV volumes and EF found between wild-
type and transgenic mice (P < 0.05, one-way ANOVA test, data not shown). 
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Table 2. LV volumes and EF 
 EDV, μl ESV, μl SV, μl EF, % 
Wild-type mice (n = 12)     
    FV 52.7 ± 3.3 14.8 ± 1.0 37.9 ± 2.8 71.5 ± 1.5 
    BP 84.8 ± 6.0* 18.0 ± 1.8 (NS) 66.8 ± 4.6* 79.0 ± 1.1* 
    SR 60.3 ± 2.7 (NS) 14.7 ± 1.4 (NS) 45.6 ± 2.1 (NS) 75.9 ± 1.8 (NS) 
    HC 71.2 ± 3.6† 14.3 ± 1.4 (NS) 56.9 ± 2.7* 80.2 ± 1.3* 
    SP 58.0 ± 5.0 (NS) 22.2 ± 2.2 (NS) 35.9 ± 3.7 (NS) 61.4 ± 2.6* 
    TF 149.5 ± 15.5* 45.4 ± 7.5* 104.1 ± 9.6* 71.1 ± 3.0 (NS) 
Transgenic mice (n = 12)     
    FV 53.4 ± 2.7 28.6 ± 3.3 20.6 ± 3.8 47.6 ± 4.2 
    BP 89.3 ± 4.9* 41.0 ± 5.8 (NS) 48.3 ± 3.3* 55.9 ± 4.9 (NS) 
    SR 55.0 ± 4.8 (NS) 27.1 ± 4.7 (NS) 27.9 ± 1.6 (NS) 53.4 ± 4.8 (NS) 
    HC 74.2 ± 5.1 (NS) 35.2 ± 4.9 (NS) 39.1 ± 2.2* 54.7 ± 4.2 (NS) 
    SP 63.8 ± 5.7 (NS) 48.0 ± 7.0 (NS) 15.8 ± 2.1 (NS) 28.6 ± 5.2* 
    TF 180.8 ± 20.3* 135 ± 18.6* 45.8 ± 9.6* 26.8 ± 4.7* 
 
 EDV, ml ESV, ml SV, ml EF, % 
Rat ischemic heart model (n = 11)     
    FV 0.36 ± 0.05 0.23 ± 0.04 0.13 ± 0.02 35.2 ± 5.7 
    BP 0.36 ± 0.07 (NS) 0.24 ± 0.06 (NS) 0.12 ± 0.04 (NS) 33.6 ± 11.9 (NS) 
    SR 0.36 ± 0.05 (NS) 0.23 ± 0.04 (NS) 0.13 ± 0.03 (NS) 36.1 ± 6.4 (NS) 
    HC 0.33 ± 0.05† 0.21 ± 0.05 (NS) 0.11 ± 0.03 (NS) 35.4 ± 7.8 (NS) 
    SP 0.24 ± 0.11* 0.17 ± 0.11* 0.07 ± 0.03* 34.7 ± 18.4 (NS) 
    TF 0.39 ± 0.29 (NS) 0.23 ± 0.17 (NS) 0.16 ± 0.16 (NS) 41.3 ± 23.6† 
Presented above are the averages and SD of the LV volumes and EF ± SD per group (wild-type mice, adipose 
triglyceride lipase knockout mice (ATGL−/−) mice, and rats with cardiac ischemia) and per geometrical model. 
Values were obtained with geometric models and the complete imaging set of the entire left ventricle acquired 
with cine-MRI. * P < 0.05; † P < 0.10; NS, not significant, when compared with the gold standard (FV). 
Linear regression analysis 
The scatter plots with individual regression lines of the EF quantified by the models vs. 
the gold standard (quantification based on full volume data set) are provided in Fig. 3. 
Pearson’s correlation coefficients (r), individual 95% confidence intervals and R2 can also 
be found in Fig. 3. As the modified Simpson rule model was the only model that provided 
the correct absolute values for EF and LV volumes, we also present the scatter plots of 
the LV volumes and SV with the full volume data set for this model in Fig. 4 (for mice and 
rats the data are presented separately). 
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Fig. 3. Scatter plots of EF. Scatter plots of EFs of the various models vs. full volume data set for A. B: biplane 
ellipsoid model. C: modified Simpson rule model. C: hemisphere cylinder model. D: single plane ellipsoid mod-
el. E: modified Teichholz Formula. In all scatter plots, the regression line is given with a 95% confidence inter-
val. R squares and Pearson correlation coefficients (with according P values) can also be found in the graph for 
each fit. 
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Fig. 4. Scatter plots of LVV for the modified Simpson rule vs. the full volume data set. Scatter plots of LVV and 
stroke volume for the modified Simpson rule model (SR) vs. full volume data set. A: scatter plot for the EDV in 
WT (○) and ATGL−/− (▴) mice. B: scatter plot for the ESV in WT and ATGL−/− mice. C: scatter plot for the stroke 
volumes in WT and ATGL−/− mice. D: scatter plot for the EDV in rats with myocardial infarction (MI) (♦). E: 
scatter plot for the ESV in rats with MI. F: scatter plot for the stroke volumes in rats with MI. In all scatter plots, 
the regression line is given with a 95% confidence interval. Dotted line in the graph represents x = y. R squares 
and Pearson correlation coefficients (with according P values) can also be found in the graph for each fit. 
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Although all correlations were significant, only the hemisphere cylinder model, the modi-
fied Simpson rule model and the biplane ellipsoid model showed a linear regression with 
a Pearson’s correlation coefficient for EF >0.85. The other two models showed a poor 
correlation with correlation coefficients <0.7 and R2 values <0.45. The 95% confidence 
interval was smallest for the modified Simpson rule model, as the R2 and r- values were 
the highest for this model (R2 = 0.937, r = 0.968, and P < 0.001). The LV volumes and SV, 
as calculated with the modified Simpson rule model, correlated with the full volume data 
set both in the mouse models as well as in the rat model. However, it should be noticed 
that the correlations were stronger for the rat model. The R2 values ranged between 
0.59–0.95 with P values <0.01 for all correlations (also see Fig. 4). 
Discussion 
In this study, we aimed to assess the validity of common geometrical models compared 
with the gold standard, a full volume data set, for quantification of LV volumes and EF 
with cine-MRI in rodents. We showed that the reproducibility of all models was good, 
with higher variations in the Teichholz formula model. When the models were compared 
with the full volume data set, only the modified Simpson rule model showed no signifi-
cant differences with the gold standard for all the calculated parameters. The values 
found for the LV volumes, SV, and EF with the modified Simpson rule model correlated 
well with the full volume data set (gold standard). Also the EF found with the hemi-
sphere cylinder and biplane ellipsoid model showed high correlation coefficients with 
the full volume data set. The two remaining models were poor predictors of EF. 
 Although these findings are new for MRI applications, previous research using other 
imaging modalities already pointed in this direction. For instance, it has been shown that 
the Teichholz formula model does not give comparable results in MRI compared with 
ultrasound (4). These results also did not correlate with values found with the modified 
Simpson rule model in this study either (4). The discrepancy in absolute values compared 
with the gold standard for all models except the modified Simpson rule points out that 
care should be taken when cardiac function is compared between studies using different 
methodology. 
 By using the modified Simpson rule, one needs to acquire and assess only three 
imaging planes, thereby reducing total examination time by 10–45 min compared with 
total examination time including positioning of the animal of 30–60 min in the present 
study. In addition, segmentation time is reduced by two to threefold (depending on the 
animal species used). The modified Simpson rule model is the only model that divides 
the heart into three different compartments, based on three imaging planes. This may 
explain why it is more accurate in estimating the LV volumes, and therefore it might also 
be more sensitive for nonsymmetrical pathologies (like myocardial infarction, for in-
stance). The other models are based on only one (modified Teichholz formula and single 
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plane ellipsoid model) or two (Hemisphere and biplane ellipsoid models) imaging planes. 
The most simplified models, using only one plane, showed indeed the weakest correla-
tions, whereas the two plane models did better. Although the EF as determined by these 
two plane models correlated well with the EF calculated from the full volume data set, 
they significantly over- or underestimated the real volumes of the left ventricle. There-
fore, only the modified Simpson rule can be applied in rodent studies of cardiac disease. 
 For high throughput studies, parallel imaging or simultaneous scanning of multiple 
animals might by used as an alternative to reduce scan time. These methods will, how-
ever, not lead to a reduction in segmentation time. Scanning multiple animals simulta-
neously is still a quite new technique, which requires specific system requirements (1–3). 
Parallel imaging leads to a reduction of the signal-to-noise ratio and therefore may not 
always be appropriate (16,20,21,27). The Simpson rule model could be a good alterna-
tive, and combining parallel imaging with the Simpson rule model will even further in-
crease the throughput. 
 One of the limitations of this study is that the mouse model of transient cardiac 
disease, namely the ATGL−/− as a model for cardiomyopathy, is quite a rare model. None-
theless, we choose to use this model as their cardiac function is severely impaired and 
the progression of their disease is rather extreme (9), which introduces variation in the 
main outcome parameters as can be found in Table 2. This variation is not due to a poor 
reproducibility in this specific group, rather it is due to variation of the disease stage as 
cardiac function drastically drops with age. A greater variation in the outcome parame-
ters gives a larger spread in the data and makes these data more suited for linear regres-
sion analysis. Therefore, this model was ideal for looking at correlations in EF. In addition 
to the ATGL−/− mice, we also included wild-type mice and rats with myocardial infarction 
in the present study, since these are more commonly used. 
 Introducing the rat model of myocardial infarction in this study not only introduced 
a more common model of cardiac disease but also increased the number of animals for 
linear regression analysis of EF. One drawback might be that we did handle two different 
kinds of species in the same analysis. Therefore, we analyzed the correlations between 
the modified Simpson rule model and full volume data set for the LV volumes and SV for 
the different animal species separately. The LV volumes seemed to correlate better in 
the rat model than in the mouse model. The differences in the correlations found are 
most likely due to the better estimation of the LV volumes in the segmentation analysis 
of the rat hearts due to relatively higher resolution of the left ventricle (as the LV is quite 
a bit bigger in rats). Also, the spread of the EDV in the rat hearts was greater, resulting in 
a better spread of the data suitable for regression analysis. 
 In conclusion, the modified Simpson rule is a good alternative to a full volume data 
set and reduces scan and postprocessing time. Comparing the absolute values as deter-
mined by different geometrical models should be done with caution as they give variable 
results. 
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Abstract 
Ischemic insult to the myocardium is associated with cardiomyocyte apoptosis. Because 
apoptotic cell death is characterized by phosphatidylserine externalization on cell mem-
brane and annexin-A5 (AA5) avidly binds to phosphatidylserine, we hypothesized that 
radiolabeled AA5 should be able to identify the regions of myocardial ischemia. 
 Methods: Models of brief myocardial ischemia by the occlusion of the coronary 
artery for 10 min (I-10) and reperfusion for 180 min (R-180) for the detection of phos-
phatidylserine exteriorization using 99mTc-labeled AA5 and γ-imaging were produced in 
rabbits. 99mTc-AA5 uptake after brief ischemia was compared with an I-40/R-180 infarct 
model. Histologic characterization of both myocardial necrosis and apoptosis was per-
formed in ischemia and infarct models. Phosphatidylserine exteriorization was also stud-
ied in a mouse model, and the dynamics and kinetics of phosphatidylserine exposure 
were assessed using unlabeled recombinant AA5 and AA5 labeled with biotin, Oregon 
Green, or Alexa 568. Appropriate controls were established. 
 Results: Phosphatidylserine exposure after ischemia in the rabbit heart could be 
detected by radionuclide imaging with 99mTc-AA5. Pathologic characterization of the 
explanted rabbit hearts did not show apoptosis or necrosis. Homogenization and ultra-
centrifugation of the ischemic myocardial tissue from rabbit hearts recovered two thirds 
of the radiolabeled AA5 from the cytoplasmic compartment. Murine experiments 
demonstrated that the cardiomyocytes expressed phosphatidylserine on their cell sur-
face after an ischemic insult of 5 min. Phosphatidylserine exposure occurred continuous-
ly for at least 6 h after solitary ischemic insult. AA5 targeted the exposed phosphatidyl-
serine on cardiomyocytes; AA5 was internalized into cytoplasmic vesicles within 10–30 
min. Twenty-four hours after ischemia, cardiomyocytes with internalized AA5 had re-
stored phosphatidylserine asymmetry of the sarcolemma, and no detectable phosphati-
dylserine remained on the cell surface. The preadministration of a pan-caspase inhibitor, 
zVAD-fmk, prevented phosphatidylserine exposure after ischemia. 
 Conclusions: After a single episode of ischemia, cardiomyocytes express phosphati-
dylserine, which is amenable to targeting by AA5, for at least 6 h. Phosphatidylserine 
exposure is transient and internalized in cytoplasmic vesicles after AA5 binding, indicat-
ing the reversibility of the apoptotic process. 
 
Keywords 
programmed cell death, radionuclide imaging, caspase, apoptosis, ischemic memory 
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Although it has been traditionally believed that most heart muscle cells during the is-
chemic insult to the myocardium are lost by necrosis, it is now being increasingly recog-
nized that apoptosis plays an important role in the cell death. Apoptosis may either oc-
cur concurrently or precede the process of necrotic cell death (1). Unlike necrosis, apop-
tosis is associated with a genetically programmed cascade of intracellular events and 
may be amenable to intervention. Spontaneous recovery from an active cell death pro-
gram has been reported in the nematode Caenorhabditis elegans, and the recovery may 
occur even after the shrinkage of the cells and activation of CED-3, a caspase-3 homolog 
(2). Although no experimental evidence is available, a similar recovery has been hypoth-
esized in mammalian cell systems (3), and the use of caspase inhibitors in myocardial 
ischemia has resulted in the substantial salvage of cardiomyocyte death. The use of 
caspase inhibitors is associated with the reduction in the extent of both apoptosis and 
necrosis and suggests that these 2 components of cell death are interrelated (4). Thus, 
the feasibility of the noninvasive detection of apoptosis should help maximize the poten-
tial of salvage. 
 Caspase-3 activation during mammalian cell apoptosis is associated with phosphati-
dylserine expression on apoptotic cells (5). Annexin-A5 (AA5), which has a nanomolar 
affinity for binding to phosphatidylserine, has been used for the in vitro (6,7) and in vivo 
(8,9) detection of apoptosis. Radiolabeled AA5 has been successfully used, both clinically 
and experimentally, for the localization of apoptosis in the myocardial infarcts. This 
study evaluated whether apoptosis was initiated in brief episodes of myocardial ische-
mia and whether AA5 would be useful for the detection of ischemia. For this purpose, 
we performed molecular imaging with 99mTc-labeled AA5 in an experimental rabbit mod-
el of brief coronary occlusion. Because myocardial ischemia is a brief event, it was im-
portant to define the time window after the initial ischemic insult for the possible detec-
tion of apoptosis by imaging. As such, for the characterization of the length and duration 
of phosphatidylserine exposure we used AA5 labeled with biotin or fluorophores in mice 
after brief occlusion of a coronary artery. 
Materials and methods 
Preparation of AA5 probes for in vivo use 
Human AA5 was produced by expression in Escherichia coli (10). The recombinant AA5 
retained its phosphatidylserine binding activity equivalent to the native AA5. In addition 
to the AA5, 2 mutants were used for the control experiments, one that had lost its phos-
phatidylserine binding capacity and another that did not internalize after surface phos-
phatidylserine binding. The cDNA of AA5 mutant M1234 (E72D, D144N, E228A, and 
D303N) (a kind gift by Dr. Françoise Russo-Marie) has 4 defective calcium binding sites 
(11). The AA5 mutant M23 was generated by subcloning the mutations D144N and 
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E228A into the AA5 cDNA. The recombinant AA5 and the mutants M23 and M1234 were 
labeled with either Oregon Green or Alexa 568–succinimidylester according to the man-
ufacturer’s protocol (Molecular Probes). The labeled proteins, with 1:1 stoichiometry, 
were purified from the mixtures by MonoQ chromatography with Acta Explorer (Amer-
sham-Pharmacia). In addition, hydrazinonicotinamide-derivatized AA5 was prepared as 
previously described, without affecting phosphatidylserine binding activity, for radio-
labeling with99mTc (12). The radiolabeled material retained specific activity, ranging from 
3,700 to 7,400 kBq (100 to 200 μCi) of protein per microgram. The AA5 tracers used in 
this study are shown in Table 1, and protocols are shown in Table 2. 
 
TABLE 1. Recombinant AA5 Tracers 
AA5 type Phosphatidylserine 
binding capability 
Internalization 
capability 
Label Dose 
AA5 + + Biotin 25 mg/kg 
AA5 + + Alexa 568 2.5 mg/kg 
AA5 + + Oregon Green 2.5 mg/kg 
AA5 M23 + — Alexa 568 2.5 mg/kg 
AA5 M1234 — — FITC 2.5 mg/kg 
AA5 Hynic + + 99mTc 30–40 μg/kg 
 
TABLE 2. Experimental Protocols and Conclusions 
Exposure 
[model] 
AA5 
and tracer 
Time of  
injection 
Ischemia  
(min) 
Reperfusion  
(min) 
Conclusion 
99mTc-AA5–based imaging of externalized PS in ischemic myocardium [rabbit] 
1 99mTc-AA5 At reperfusion 10 180 min Brief ischemia results in detectable PS 
exposure but no apoptosis or necrosis 
seen histopathologically 
2 99mTc-AA5 At reperfusion 40 180 min Prolonged ischemia results in 
detectable PS exposure, apoptosis, 
and necrosis 
Cardiomyocytes expose PS after brief ischemia [mouse]  
1 AA5 Before ischemia 5 90 min, 24 h Brief ischemia results in PS exposure 
but no TUNEL positivity 
2 AA5 Before ischemia 30 90 min, 24 h Prolonged ischemia results in PS 
exposure and TUNEL positivity 
PS and AA5 are internalized in cardiomyocytes [mouse]  
1 AA5 Oregon 
Green 
At reperfusion 5 90 min Brief ischemia results in PS exposure 
on cardiomyocytes 
 AA5 Alexa 
568 
30 min before 
sacrifice 
 
 
  that bind and internalize AA5 
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Exposure 
[model] 
AA5 
and tracer 
Time of  
injection 
Ischemia  
(min) 
Reperfusion  
(min) 
Conclusion 
Characterization of PS-dependent internalization [mouse] 
1 AA5 M23-
Alexa 568 
Before ischemia 5 90 min 2-dimensional crystallization of AA5 is 
mandatory for internalization 
2 AA5 M1234-
FITC 
Before ischemia 5 90 min PS binding of AA5 is mandatory for 
internalization 
Cardiomyocytes expose PS up to 6 h after brief ischemia [mouse] 
1 AA5-biotin 10 min before 
sacrifice 
5 90 min, 3 h, 6 h, 
24 h 
Brief ischemia results in caspase-
dependent PS exposure 
PS exposure is a transient process [mouse] 
1 AA5 Oregon 
Green 
At reperfusion 5 90 min, 6 h, 24 h Brief ischemia results in PS exposure 
that is transient and persists up to 6 h 
 AA5 Alexa 
568 
10 min before 
sacrifice 
   
PS = phosphatidylserine. 
M23 and M1234 are AA5 mutants. 
Surgical induction of brief ischemia in rabbits and mice 
Myocardial ischemia and reperfusion models were produced in rabbits and mice as re-
ported previously (13,14). In the New Zealand White rabbits, the heart was exposed by 
mid sternotomy. Brief myocardial ischemia was produced by ligation of the lateral 
branch of the left coronary artery for 10 min (I-10), followed by reperfusion for 180 min 
(R-180). The myocardial infarction model was created for comparison to brief ischemia 
by a 40-min occlusion of the coronary artery, followed by reperfusion for 180 min (I-
40/R-180) (positive control). In addition, sham-operated animals were used as negative 
controls for imaging experiments. 
 In the mouse model, the heart was exposed by left thoracotomy. The left coronary 
artery was ligated for 5 min (I-5) and reperfusion was established for 90 min (R-90), 3 h 
(R-180), 6 h (R-360), or 24 h (R-24 h) (Table 2). Ischemia and reperfusion were per-
formed once only for all experiments, and no preconditioning or recurrent ischemia 
experiments were undertaken. For positive control, infarction was produced by coronary 
arterial occlusion for 30 min with reperfusion times of 90 min and 24 h (I-30/R-90 or I-
30/R-24 h). In a subset of animals, pan-caspase inhibitor zVAD-fmk (3 mg/kg; BIOMOL) 
was injected through an intravenous line into the jugular vein 10 min before ischemia to 
assess whether the cascade of apoptosis could be aborted. 
 Imaging of Rabbit Myocardial Ischemia with 99mTc-AA5 and Pathologic Characteriza-
tion 
 To investigate the potential of imaging myocardial ischemia, 99mTc-labeled AA5 was 
intravenously administered to the rabbits subjected to brief myocardial ischemia (I-10/R-
180; n = 6). Concurrent studies were performed in the prolonged ischemia (I/R-40/180; n 
C H A P T E R  6  
 80 
= 6) model for positive controls and sham-operated (I-0/R-0; n = 4) hearts for negative 
controls. 99mTc-AA5 (30–40 μg of AA5/kg; 444 ± 37 MBq of 99mTc [12 ± 1 mCi]) was ad-
ministered at the time of reperfusion through the marginal vein of the ear. Animals were 
killed after 3 h with an overdose of pentobarbital, and explanted hearts were subjected 
to ex vivo planar imaging (X-SPECT; Gamma Medica, Inc.) for 15 min in a 128 × 128 ma-
trix using a 1-mm pinhole collimator. Quantitative uptake of 99mTc-AA5 was determined 
by well-type  γ-counter (PerkinElmerWallac Inc.) and reflected as percentage injected 
dose per gram (%ID/g). Tissue from the ischemic zone and remote myocardium were 
subjected to ultracentrifugal isolation of the cell membrane, cytoplasm, and other sub-
cellular organelles to localize the 99mTc-AA5 uptake, based on the methodology de-
scribed previously (14). In addition to subcellular analysis, myocardial tissue sections 
from the ischemic (or infarcted) and remote myocardial regions were stained by hema-
toxylin and eosin for standard histology. Tissue sections were also processed for the 
identification of apoptosis by terminal deoxynucleotidyl transferase-mediated dUTP 
nick-end labeling (TUNEL) (in situ cell death detection kit, POD; Roche) as described 
previously (15). 
 Targeting of Phosphatidylserine Exposure in Murine Models of Ischemia and Patho-
logic Characterization 
 For the characterization of surface phosphatidylserine exposure in response to is-
chemia, unlabeled recombinant human AA5 or fluorescent recombinant human AA5 was 
administered through a line inserted into the jugular vein of mice. The data were col-
lected for 3 mice in each experimental group. To confirm the phosphatidylserine exteri-
orization, AA5 was used in I-5/R-90 and I-5/R-24 h mouse models. To assess the length of 
time for which the phosphatidylserine was expressed, I-5/R-90, I-5/R-180, I-5/R-360, I-
5/R-24 h, I-30/R-90, and I-30/R-24 h models were studied with AA5–biotin injected at 
the onset of reperfusion. Conversely, to evaluate the fate of expressed phosphatidylser-
ine, AA5–Oregon Green (2.5 mg/kg) and AA5–Alexa 568 (2.5 mg/kg) were used at 2 
different time points after reperfusion, at the onset of reperfusion and 10 min before 
sacrifice. The hearts were removed and snap-frozen in liquid nitrogen for the histologic 
localization of exogenously administered AA5 and apoptosis. To study the internalization 
of AA5 occurring in vivo, a mutant of AA5 M23–Alexa 568, which binds to phosphatidyl-
serine but does not induce its internalization, was injected before reperfusion. To test 
whether the internalization of AA5 was phosphatidylserine-dependent, a mutant of AA5 
M1234–Oregon Green, which does not bind to phosphatidylserine, was injected before 
reperfusion. Both experiments with mutant AA5 were performed in the I-5/R-90 model 
(n = 3 each). 
 For the localization of the fluorescent AA5, frozen 7-μm tissue sections were ob-
tained, dried overnight, and mounted in 4,6-diamino-2-phenylindole–containing medi-
um (Vector Laboratories) and examined by fluorescence microscopy. Intravenously ad-
ministered human recombinant AA5 was tracked by immunohistochemical staining of 
frozen tissue sections. The tissue sections were dried overnight and fixed in dry acetone 
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for 10 min at room temperature. After the blocking of endogenous peroxidase, sections 
were stained with an antibody against AA5 (rabbit polyclonal antihuman AA5; Hyphen 
Biomed). AA5 was detected by polyclonal horseradish peroxidase–labeled goat anti-
rabbit antibody (Powervision peroxidase detection system; Immunovision Technologies). 
In contrast, biotin–AA5 was tracked by direct avidin/biotin conjugate peroxidase staining 
without the need for anti-AA5 antibody. Frozen tissue sections were also stained with 
hematoxylin and eosin for standard histology and stained by TUNEL (in situ cell death de-
tection kit, POD; Roche) for the identification of apoptosis, as described previously (15). 
RESULTS 
Radionuclide imaging of brief myocardial ischemia is feasible 
To explore whether phosphatidylserine exposure could be used potentially to detect 
recent ischemic events, 99mTc-AA5 was administered intravenously in the I-10/R-180 
rabbit model at the time of reperfusion, and imaging of the explanted hearts was per-
formed after 3 h (14). Significant radiolabeled 99mTc-AA5 uptake in the zone of initial 
ischemia was observed (Fig. 1A). 99mTc-AA5 uptake in the ischemic region was 9 ± 3-fold 
higher than in the normal myocardium (0.27 ± 0.16 %ID/g vs. 0.03 ± 0.01 %ID/g). Fur-
ther, at least 85% of the radioactivity was recovered from the ultracentrifugally isolated 
cytoplasmic and organelle compartment of the cells, suggesting that 99mTc-AA5 bound to 
phosphatidylserine was internalized. Although enhanced uptake of 99mTc-AA5 had oc-
curred in the ischemic regions, no histologic evidence of apoptosis or necrosis in the 
hearts was observed (Fig. 1B). Prolonged ischemia and reperfusion (I-40/R-180) was 
associated with prominent 99mTc-AA5 uptake (0.55 ± 0.3 %ID/g) (Fig. 1A), and apoptosis 
and necrosis (Fig. 1B). The 99mTc-AA5 uptake in the sham-operated animals (0.042 ± 
0.012 %ID/g) was similar to the uptake in the remote nonischemic myocardium. The 
data from the rabbit model indicated that the phosphatidylserine exposure occurred 
after a brief episode of ischemia and may serve as a marker of ischemic memory in the 
myocardium. Data also suggested that 99mTc-AA5 accumulated intracellularly in ischemic 
cells. These data confirmed our previous in vitro observations (16) that AA5 mediated 
internalization of phosphatidylserine-positive membrane patches. To characterize the 
phosphatidylserine exposure observed in the rabbit imaging experiments, multiple sets 
of mouse experiments were conducted. 
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FIGURE 1. 99mTc-AA5–based imaging of externalized phosphatidylserine in ischemic myocardium. (A, top) In I-
10/R-180 model in rabbit, radiolabeled AA5 clearly delineates ischemic zone with 9-fold higher uptake than in 
remote myocardium. Uptake is seen in γ-image of whole heart and slices. (B, top) On tissue sections, no necro-
sis (left) or apoptosis (right) was observed in ischemic zone. In prolonged ischemic model (I-40/R-180) (A, 
middle), intense 99mTc-AA5 uptake is seen; pathologic characterization reveals (B, bottom) extensive evidence 
of necrosis (left) and apoptosis (right). Necrosis is represented by contraction bands and apoptosis by TUNEL 
staining. No 99mTc-AA5 uptake is seen in sham-operated animals (A, bottom). This experiment provides prelimi-
nary data generating hypothesis that hot-spot imaging of ischemia by radiolabeled AA5 is feasible. 
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Phosphatidylserine exposure occurs after brief ischemia but not cell death 
To establish the phosphatidylserine exposure characteristics after brief episodes of is-
chemia observed in the rabbit model, a series of experiments was performed in mice. In 
the first set of experiments, I-5 hearts received human recombinant AA5 before coro-
nary occlusion, and its localization was traced by immunoperoxidase staining using anti-
human AA5 antibody in myocardial sections (13). AA5-positive cardiomyocytes were 
observed in the ischemic area of the hearts in I-5 animals that were subjected to reper-
fusion for 90 min and 24 h (Fig. 2). Cardiomyocytes of the nonischemic area and cardio-
myocytes from sham-operated animals did not bind AA5. The AA5 was localized to the 
intracellular compartment. On TUNEL staining, only rare apoptotic cells were observed 
in the ischemic area of I-5/R-90 animals (Fig. 2). These findings suggested that the apop-
tosis program was initiated, phosphatidylserine was exposed that was available for tar-
geting by AA5, and AA5 was internalized. However, because TUNEL-positive cells were 
not seen even after phosphatidylserine exposure had occurred, the apoptotic process 
was aborted on reperfusion after brief ischemia. As compared with the I-5/R-90 ischemia 
model, significantly more myocytes were AA5-positive in I-30/R-90 mice, and many AA5-
positive cardiomyocytes demonstrated TUNEL-positive nuclei. This set of experiments 
confirmed the data obtained in the rabbit model that the phosphatidylserine externaliza-
tion had occurred after brief episodes of ischemia and that AA5 ended up being internal-
ized. 
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FIGURE 2. Cardiomyocytes expose phosphatidylserine after brief ischemia. Immunostaining for AA5 (×400) 
(left) and apoptosis detection with TUNEL staining (×400) (right) was performed on frozen tissue sections of 
mouse hearts subjected to different ischemia/reperfusion (I/R) time points. Scale bars represent 25 μm. AA5 
was injected before coronary occlusion in I-5/R-90, I-5/R-24 h, I-30/R-90, and I-30/R-24 h mouse models. Note 
intracellular location of AA5, more so in prolonged ischemia. Rare apoptotic cells are seen in brief ischemia, 
unlike abundant apoptotic cells in infarcts. In I-5/R-90 model, preadministration of pan-caspase inhibitor zVAD-
fmk prevents phosphatidylserine exteriorization. Arrows (right panels) refer to TUNEL-positive nuclei. 
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Apoptosis assays in vitro have shown that phosphatidylserine exposure is downstream of 
critical events in the cell death program such as the release of cytochrome c from mito-
chondria and the activation of caspase-3 (17,18). To evaluate the relationship between 
brief ischemia and caspase activation, immunoblotting of caspase-3 was undertaken in I-
5/R-90 hearts. The presence of 12- and 17-kDa split active fragments of caspase-3 indi-
cated the activation of caspase-3; densitometric analysis confirmed a 4-fold increase in 
activation of caspase-3 (data not shown). Increased densitometric intensity of activated 
caspase-3 was seen after longer ischemia. 
 Phosphatidylserine Is Expressed After Brief Ischemia and Internalized After AA5 
Binding 
 From the rabbit heart ultracentrifugation data and the first sets of mouse experi-
ments, it was presumed that AA5 after targeting of the phosphatidylserine was internal-
ized by the ischemic cells. To evaluate the kinetics of the internalization process in vivo 
after ischemia or reperfusion injury, we performed the second set of experiments. For 
this purpose, we injected AA5–Oregon Green at the beginning of reperfusion in the I-
5/R-90 model. As expected, the green AA5 was localized intracellularly. In two separate 
groups of these I-5/R-90 animals that had already received AA5–Oregon Green at the 
start of reperfusion, AA5–Alexa 568 was injected either 10 or 30 min before the end of 
the reperfusion (or sacrificing the animal). AA5–Alexa 568 injected 10 min before sacri-
fice showed binding almost exclusively to the cardiomyocyte membrane; green AA5 was 
entirely intracellular (Fig. 3A). However, the injection of AA5–Alexa 568 30 min before 
sacrifice showed colocalization of AA5–Alexa 568 with AA5–Oregon Green within the 
cytoplasmic compartment of the cell (Fig. 3B), indicating that after AA5 targeting of the 
phosphatidylserine on the cell surface, the phosphatidylserine–AA5 complex was inter-
nalized between 10 and 30 min. These in vivo data confirmed our previously reported in 
vitro data that AA5 mediates the internalization of phosphatidylserine-positive mem-
brane patches as endocytic vesicles, which detach from the plasma membrane and fol-
low cytoskeleton-dependent trafficking into the cytosol (16). 
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FIGURE 3. Phosphatidylserine and AA5 are internalized in cardiomyocytes. (A) Tissue section (×400) of mouse 
hearts injected with AA5–Oregon Green at beginning of reperfusion and AA5–Alexa 568 10 min before end of 
reperfusion episode in I-5/R-90 model show surface binding and internalization of AA5–Oregon Green. In 
contrast, only surface binding but no internalization of AA5–Alexa 568 is seen. Parenthesis entry of 10 follow-
ing I-5/R-90 denotes time of AA5–Alexa 568 administration before the end of R-90 reperfusion period. (B) 
Injection of AA5–Alexa 568 30 min before completion of reperfusion showed colocalization of AA5–Alexa 568 
with AA5–Oregon Green within cytoplasmic compartment of cell. Scale bars represent 25 μm. (C) Ex vivo image 
(×160) of heart of mouse injected with M23–Alexa 568, before 5-min ischemia and 90-min reperfusion (I-5/R-
90), demonstrates binding to cell membrane but no internalization. (D) Ex vivo image (×160) of heart of mouse 
injected with M1234–FITC before I-5/R-90 shows neither binding nor internalization. Scale bars represent 25 
μm.
AA5 binding to phosphatidylserine is necessary for phosphatidylserine 
internalization 
To demonstrate that the AA5 targets phosphatidylserine and is subsequently internal-
ized, we conducted the third set of experiments with 2 fluorescently labeled mutant 
species of AA5. The AA5 mutant M23, by prediction from the available structural data 
(19), binds to phosphatidylserine but lacks the ability to crystallize on the phosphatidyl-
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serine-expressing membrane surface, the step necessary before internalization. M23–
Alexa 568 was injected before reperfusion in the I-5/R-90 model. The mutant M23 was 
observed targeting the cell membrane of the cardiomyocytes in the ischemic zone but 
was not seen intracellularly (Fig. 3C). Furthermore, to test the phosphatidylserine de-
pendence of the internalization process in vivo, we used yet another AA5 mutant M1234 
that lacked the ability to bind to phosphatidylserine. M1234–fluorescein isothiocyanate 
(FITC) was injected before reperfusion in the I-5/R-90 model. The mutant M1234 did not 
bind to the cardiomyocyte surface, nor was fluorescence observed intracellularly (Fig. 
3D). 
 Continuous Phosphatidylserine Externalization–Internalization Represents Ischemic 
Memory 
 The internalization experiments of the second and third sets raised another im-
portant possibility. If phosphatidylserine exposure occurred as early as 5 min after is-
chemia and internalized within 30 min after AA5 binding, then cell surface binding of 
AA5 injected at 80 min of reperfusion (10 min before the end of a 90-min reperfusion) 
would suggest an ongoing, continuous, and fresh expression of phosphatidylserine after 
a solitary initial episode of brief ischemia. To evaluate this possibility, a fourth and fifth 
sets of experiments were performed with AA5 administration at various time points 
after brief ischemia up to 24 h. 
 To demonstrate the length of phosphatidylserine exposure after brief ischemic in-
sult, in the fourth set of experiments, I-5 animals were reperfused for 90, 180, and 360 
min and 24 h. AA5–biotin was injected 10 min before sacrifice. Phosphatidylserine expo-
sure was detectable up to 6 h after the ischemic insult (Fig. 4). No AA5 uptake was ob-
served in the area at risk at 24 h of reperfusion. It seems that as long as apoptotic ma-
chinery remains active after the brief ischemic episode, phosphatidylserine continues 
being exposed and is amenable to removal from the cell surface, if AA5 is available. This 
concept was further substantiated by the pretreatment of animals with zVAD-fmk before 
the induction of brief ischemia (Fig. 4). In the pretreated I-5/R-90 mice, no AA5 binding 
was seen in these animals, suggesting that the inhibition of caspase successfully pre-
vented phosphatidylserine externalization in response to brief ischemic insult. All exper-
iments indicate that cardiomyocytes recovered and phosphatidylserine exposure re-
solved if reperfusion was restored in a timely manner or if caspase inhibition was ap-
plied. 
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FIGURE 4. Cardiomyocytes expose phosphatidylserine up to 6 h after brief ischemia. 
Mouse hearts subjected to 5 min of ischemia and 90, 180, and 360 min and 24 h of 
reperfusion received AA5–biotin injected 10 min before sacrifice (parentheses entry). 
Cardiomyocytes in ischemic zone demonstrate AA5 binding up to 6 h; cardiomyocytes in 
I-5/R-24 h do not bind AA5–biotin (25 mg/kg) when injected 10 min before sacrifice. 
zVAD (3 mg/kg) was injected intravenously before application of ischemia in I-5/R-90 
model. 
To further demonstrate whether phosphatidylserine exposure was a continuous process 
and the fresh phosphatidylserine was available until 6 h after the initial brief ischemic 
episode, we again subjected I-5 mice to R-90, R-360, and R-24 h reperfusion (Fig. 5). 
AA5–Oregon Green was administered at the onset of reperfusion; green fluorescence 
was exclusively localized intracellularly. The administration of AA5–Alexa 568 10 min 
before sacrifice revealed that 90 min and 6 h after the brief ischemic insult cardiomyo-
cytes with internalized AA5–Oregon Green still bound AA5–Alexa 568 on their cell sur-
face. When AA5–Alexa 568 was injected 24 h after brief ischemia, the cardiomyocytes 
with internalized AA5–Oregon Green did not bind AA5–Alexa 568, indicating that these 
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cardiomyocytes had already restored phosphatidylserine asymmetry. Although en-
hanced uptake of AA5 had occurred in the ischemic regions, no histologic evidence of 
apoptosis or necrosis in the hearts was observed. The data suggested that phosphatidyl-
serine exposure occurred continuously at least up to 6 h after the ischemic episode and 
was amenable to AA5 targeting. These sets of experiments further highlighted the possi-
bility of phosphatidylserine expression as a sign of ischemic memory. 
 
 
FIGURE 5. Phosphatidylserine exposure and internalization are transient processes. Tissue sections (×400) of 
I-5/R-90, R-360, and R-24 h mouse hearts, injected with AA5–Oregon Green at beginning of reperfusion, fol-
lowed by injection of AA5–Alexa 568 10 min before completion of reperfusion. There is binding of AA5–Alexa 
568 to plasma membrane of (internalization) AA5–Oregon Green–positive cells after 90 min and 6 h of reper-
fusion. After 24 h of reperfusion, AA5–Oregon Green–positive cells do not bind AA5–Alexa 568. This experi-
ment suggests that after brief episode of ischemia, phosphatidylserine exposure, although transient, is contin-
uously exposed for 6 h. Scale bars represent 25 μm. 
Discussion 
Our data show that brief episodes of ischemia result in phosphatidylserine exposure that 
normally lasts for at least 6 h after the ischemic insult and offers a target for 99mTc-AA5 
for after-the-fact imaging of ischemia (ischemic memory). Phosphatidylserine exposure 
occurs continuously for the duration because the AA5–phosphatidylserine complex is 
continuously removed from the cell surface by internalization and new phosphatidylser-
ine is exteriorized. Because the AA5–phosphatidylserine complex is internalized, the 
signal stays in situ after 99mTc-AA5 administration and may concentrate radiolabeled AA5 
in the ischemic cells. This explains the possibility of imaging even if phosphatidylserine 
exposure may not be extensive or intense after brief ischemia. These data deliver anoth-
er important message. Because phosphatidylserine exposure and caspase activation are 
the hallmarks of apoptosis (20), it appears that ischemia-induced apoptosis in cardiomy-
ocytes is interrupted by reperfusion such that the cardiomyocytes survive. An escape 
from activated apoptosis has been reported previously in Caenorhabditis elegans (2,3). 
During developmental apoptosis, engulfment genes act in concert with CED-3 in cells 
destined to die in the anterior pharynx. In the absence of activation of the engulfment 
machinery, such cells show all the features of apoptosis, but cell death does not occur; 
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these cells recover completely and remain viable thereafter. Our data confirm recovery 
from apoptosis in mammalian cells in vivo, despite activation of one of the key execu-
tioner caspases, caspase-3. Reversible phosphatidylserine exposure not associated with 
the execution of apoptosis has been observed in vitro with myocytic cell lines (21,22). 
Other examples include the activation of B-cell lymphoma cells, which in response to 
cross-linking of the membrane immunoglobulin receptor stained positive for AA5 but 
were able to restore their phospholipid asymmetry and resume growth on withdrawal of 
the stimulus (23). It seems that the phenomenon of recovery from apoptosis may be 
evolutionarily conserved. However, in contrast to C. elegans the absence of engulfment 
gene activity may not be critical in the recovery of cell death in the heart, because phag-
ocytes enter the ischemic zone only after 24 h. An interesting aspect of the binding of 
AA5 to externalized phosphatidylserine is that this may offer the cells protection from 
being recognized by “professional” phagocytes, because externalized phosphatidylserine 
is necessary for the engulfment of apoptotic cells and serves as an “eat me” signal (20). 
Clinical studies have shown that plasma AA5 levels are elevated in patients with acute 
myocardial infarction (24). These data suggest that AA5 may serve as an acute-phase 
reactant, which may save cells that are susceptible to engulfment. It is also justified to 
hypothesize that exogenously administered AA5 may accelerate the internalization of 
externalized phosphatidylserine. The data on the internalization of phosphatidylserine in 
the presence of AA5 indicate that internalization is not the result of the inhibition of 
scrambling of phosphatidylserine molecules but results from invagination and vesicle 
formation of the patches of plasma cell membrane that expose phosphatidylserine (16). 
Together, our data suggest a novel model of phosphatidylserine exposure and internali-
zation wherein phosphatidylserine exposure is continuously driven by caspase activation 
and phosphatidylserine internalization is mediated by AA5-aided formation of the endo-
cytic vesicle (16). Cytoplasmic uptake of exogenous AA5 has been previously reported in 
animal studies of apoptotic cell death during embryogenesis (25), tooth development 
(26), and stroke (27). The investigators in these studies concluded that the intracellular 
uptake of exogenous AA5 was due to the ingestion of apoptotic vesicles coated with AA5 
by neighboring cells. This mechanism in our model seems unlikely given the lack of apop-
totic or necrotic cells in the hearts of animals subjected to brief ischemia. Our un-
published in vitro data further indicate that the perinuclear vesicles in an increased hy-
percalcemic intracellular milieu may prevent cytochrome c release from mitochondria, 
supporting the antiapoptotic role of AA5 at least in ischemic heart muscle cells. The 
reversible phosphatidylserine exposure constitutes an attractive target for the noninva-
sive detection of myocardial ischemia as a hot-spot imaging agent in addition to tradi-
tional stress myocardial perfusion imaging. Furthermore, persistence of phosphatidylser-
ine externalization for at least 6 h after ischemic stress may allow retrospective diagnosis 
of cardiac chest pain and support the concept of ischemic memory. This concept would 
be somewhat similar to the metabolic stunning of myocytes after a myocardial ischemic 
episode, wherein fatty acid use is interrupted in favor of glucose use. These 2 metabolic 
A N N E X I N  A 5  U P T A K E  I N  I S C H E M I C  M Y O C A R D I U M  
 91 
alterations have been well characterized by the absence of 123I-BMIPP uptake (28) and 
enhanced18F-FDG uptake (29) in the ischemic myocardial territories. 
Conclusion 
Our data demonstrate that caspase-3 is activated and phosphatidylserine is externalized 
in mammalian cells in response to brief ischemia of the heart. Cardiomyocytes destined 
to die recover from the initiation of the cell death program on restoration of blood flow. 
The transient exposure of phosphatidylserine by cardiomyocytes recovering from apop-
tosis may be exploited for diagnostic imaging. Further, AA5 binding to phosphatidylser-
ine leads to the internalization of AA5 into vesicles. Although logically protective, the 
role of AA5–phosphatidylserine internalization remains to be understood. 
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Abstract 
 Objectives. Using molecular imaging techniques, we examined interstitial alterations 
during postmyocardial infarction (MI) remodeling and assessed the efficacy of antiangio-
tensin and antimineralocorticoid intervention, alone and in combination. 
Background. The antagonists of the renin-angiotensin-aldosterone axis restrict myocar-
dial fibrosis and cardiac remodeling after MI and contribute to improved survival. Radio-
nuclide imaging with technetium-99m–labeled Cy5.5 RGD imaging peptide (CRIP) targets 
myofibroblasts and indirectly allows monitoring of the extent of collagen deposition 
post-MI. 
 Methods. CRIP was intravenously administered for gamma imaging after 4 weeks of 
MI in 63 Swiss-Webster mice and in 6 unmanipulated mice. Of 63 animals, 50 were 
treated with captopril (C), losartan (L), spironolactone (S) alone, or in combination (CL, 
SC, SL, and SCL), 8 mice received no treatment. Echocardiography was performed for 
assessment of cardiac remodeling. Hearts were characterized histopathologically for the 
presence of myofibroblasts and thick and thin collagen fiber deposition. 
 Results. Acute MI size was similar in all groups. The quantitative CRIP percent inject-
ed dose per gram uptake was greatest in the infarct area of untreated control mice (2.30 
± 0.14%) and decreased significantly in animals treated with 1 agent (C, L, or S; 1.71 ± 
0.35%; p = 0.0002). The addition of 2 (CL, SC, or SL 1.31 ± 0.40%; p < 0.0001) or 3 agents 
(SCL; 1.16 ± 0.26%; p < 0.0001) demonstrated further reduction in tracer uptake. The 
decrease in echocardiographic left ventricular function, strain and rotation parameters, 
as well as histologically verified deposition of thin collagen fibers, was significantly re-
duced in treatment groups and correlated with CRIP uptake. 
 Conclusions. Radiolabeled CRIP allows for the evaluation of the efficacy of neurohu-
moral antagonists after MI and reconfirms superiority of combination therapy. If proven 
clinically, molecular imaging of the myocardial healing process may help plan an optimal 
treatment for patients susceptible to heart failure. 
 Key Words. Collagen; remodeling; radionuclide imaging; angiotensin receptors; an-
giotensin-converting enzyme; mineralocorticoids; heart failure 
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Up regulation of the renin-angiotensin-aldosterone axis after myocardial infarction (MI) 
contributes to the process of cardiac remodeling and hence the evolution of heart fail-
ure (1-4). Although this remodeling process is initiated by myocyte loss, interstitial and 
myocytic alterations continue to occur inexorably even after the initial injury has abated 
(5-7). Antiangiotensin (8-10) and antialdosterone (11) treatments effectively control this 
process and delay or prevent the development of heart failure (12-15). These therapeu-
tic interventions reduce the extent of interstitial collagen deposition, which is considered 
to be the basis of their efficacy (1 and 2). The combination of these agents has been 
shown to be more effective than the solitary agents (16,17). 
 The efficacy of pharmacologic intervention in a clinical milieu is variable, and it is 
desirable to define optimal use of antiremodeling agents for individual patients. Alt-
hough pharmacogenomics has been proposed as an important determinant of such a 
strategy (18,19), the role of phenotypic characterization by novel imaging methods is 
also being explored (4). It has recently been reported that the extent of new collagen 
deposition can be assessed by molecular imaging employing technetium-99m-labeled 
Cy5.5-RGD-imaging peptide (99mTc-CRIP) (20). Through Arg-Gly-Asp (RGD)-based target-
ing, 99mTc-CRIP binds to the myofibroblasts in the healing infarct and correlates with 
the extent of new collagen deposition after experimental MI (20). In our preliminary 
experiment we proposed that such imaging strategy may have a role in identifying the 
impact of a therapeutic intervention on collagen deposition and hence the efficacy of 
therapy. In the present study, we evaluated the effect of an angiotensin-converting 
enzyme inhibitor (ACE-I), an angiotensin receptor blocker (ARB), and a selective aldoste-
rone receptor antagonist (SARA), individually and in combination, on infarct healing by 
using 99mTc-CRIP imaging. 
Methods 
Study protocol 
The present study was performed in 69 Swiss-Webster mice. Of these, MI was produced 
in 63 mice by occlusion of the left coronary artery. Echocardiograms were obtained 
before and after coronary occlusion to demonstrate the basal left ventricular (LV) di-
mensions and function in addition to the infarct size. Of the 63 infarcted mice, 20 mice 
received a single agent intervention (1Rx); 8, 6, and 6 animals were started on spirono-
lactone (S), captopril (C), and losartan (L), respectively. A total of 22 of 63 animals re-
ceived dual therapy (2Rx); 6, 8, and 8 animals were started on a combination of captopril 
+ losartan (CL), spironolactone + captopril (SC), or spironolactone + losartan (SL), respec-
tively, and 8 of 63 post-MI animals received a combination of 3 neurohumoral antago-
nists (3Rx, spironolactone + captopril + losartan [SCL]) (Table 1). Eight post-MI animals 
did not receive any pharmacologic agent and served as treatment controls (No Rx), and 5 
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post-MI animals received a scrambled version of the imaging peptide (sCRIP) to serve as 
tracer controls. In addition to 63 infarcted mice, 6 unmanipulated animals were included 
in the imaging protocol as disease control animals. After 4 weeks, all animals again un-
derwent echocardiographic examination for the characterization of the remodeling 
process and received 99mTc-labeled CRIP intravenously. After 3.5 h of CRIP administra-
tion, hearts were explanted and ex vivo imaging was performed with a microSPECT cam-
era. The hearts were then sectioned into 3 cross-sectional bread-loaf slices to represent 
apical (predominantly infarct), middle, and the basal (predominantly remote) areas. All 
samples were gamma-counted for quantitative 99mTc-CRIP (and sCRIP) uptake. Subse-
quently, all myocardial specimens were processed for histopathological characterization, 
particularly the extent of myofibroblast proliferation and thick and thin collagen fiber 
deposition. 
 
Table 1. Various Treatment Groups, Dosage Schedules, and Quantitative CRIP Uptake 
Group Dose n Infarct Remote 
Spironolactone Captopril Losartan %ID/g p Value %ID/g p Value 
Control — — — 6 0.590 ± 0.19 † 0.677 ± 0.162 NS 
No Rx — — — 8 2.302 ± 0.136 □ 0.921 ± 0.218 NS 
S 20 mg/kg/day — — 8 1.798 ± 0.437 □† 0.903 ± 0.221 NS 
C — 60 mg/kg/day — 6 1.718 ± 0.296 □† 0.867 ± 0.234 NS 
L — — 20 mg/kg/day 6 1.576 ± 0.279 □† 0.752 ± 0.114 NS 
CL — 30 mg/kg/day 10 mg/kg/day 6 1.374 ± 0.549 □† 0.783 ± 0.272 NS 
SC 20 mg/kg/day 60 mg/kg/day — 8 1.280 ± 0.408 □† 0.786 ± 0.168 NS 
SL 20 mg/kg/day — 20 mg/kg/day 8 1.293 ± 0.316 □† 0.821 ± 0.364 NS 
SCL 20 mg/kg/day 60 mg/kg/day 20 mg/kg/day 8 1.157 ± 0.261 □† 0.796 ± 0.196 NS 
The quantitative CRIP uptake in control animals was obtained from the myocardial specimen corresponding to 
infarct and remote regions of post-MI animals. 99mTc-CRP = technetium-99m-labeled Cy5.5-RGD imaging 
peptide; MI = myocardial infarction; NS = nonsignificant. 
□ p < 0.05 to < 0.0001 compared with control animals. 
†p < 0.05 to < 0.0001 compared with No Rx-treated animals. 
Experimental MI in mice 
This experimental protocol was approved by the Institutional Animal Care and Use 
Committee of the University of California Irvine School of Medicine. In 63 adult Swiss 
Webster male mice (age, 3 months; body weight, ≈50 g), the lateral branch of the left 
coronary artery was ligated under pentobarbital (75 mg/kg intraperitoneally) and gas 
anesthesia (2.0 to 3.0% isoflurane) to induce MI, as per previous description (21). Suc-
cessful ligation was verified by visual inspection of myocardial blanching and akinesis or 
dyskinesis of the apical segment. The chest was closed, and animals were gradually 
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weaned from the respirator. Six of the 69 mice were left unmanipulated as disease con-
trol mice for comparison with the post-MI mice. 
Treatment protocols after MI in mice 
Captopril (Sigma, St. Louis, Missouri) and losartan (kind gift of Merck, Rahway, New Jer-
sey) were administered in the drinking water, 60 and 20 mg/kg/day, respectively. Spiro-
nolactone (Innovative Research of America, Sarasota, Florida) was administered via a 
subcutaneous pellet, releasing 1 mg/day, placed under the skin on the back immediately 
after MI surgery. The animals received the intervention for 4 weeks beginning immedi-
ately after surgery (Table 1). 
Echocardiography 
Echocardiographic studies were performed in all mice for the evaluation of left ventricu-
lar dimensions and function, as reported previously (20). All animals underwent 3 echo-
cardiographic studies; one performed at baseline level, one immediately after MI, and 
one 4 weeks after MI, just before CRIP imaging. Mice were anesthetized with 2% isoflu-
rane, and echocardiograms were made (Sequoia, Siemens, Mountain View, California) 
with a 14-MHz linear probe (15L8, Acuson). An advanced high frame rate imaging tech-
nique (Paragon, Siemens) was adopted to increase temporal resolution at a frame rate 
of 120 fps. B-mode images of LV parasternal long-axis, parasternal short-axis, and apical 
views were digitally acquired at 2 to 3 cardiac cycle lengths. Images of LV short-axis were 
standardized at 3 levels: base, mid, and apex. M-mode imaging was unified according to 
the American Society of Echocardiography guidelines for measurements of wall thickness, 
chamber dimensions, and functional parameters (22). Infarction area and LV area were 
measured by tracing relative endocardial borders respectively on the long-axis images. 
Myocardial infarction percentage was calculated as: infarction area/LV area × 100. Left 
ventricular cavity dimensions, ejection fraction, strain, and rotation were calculated (23). 
Radionuclide imaging with 99mTc-CRIP 
The technetium-99m-labeled Cy5.5-RGD imaging peptide (AH110863, kind gift of GE 
Healthcare, Oslo, Norway) is a 2.5-kDa peptide conjugated to both a fluorescent cyanine 
dye Cy5.5 and the chelating agent cPN216, which is linked for radiolabeling of the pep-
tide with 99mTc. The peptide comprises 10 amino acids, contains an RGD motif, and has 
a bicyclic structure formed by a disulfide and a thioether bridge. The dye moiety and the 
chelating agent are conjugated to the peptide by the side-chains of lysine residues at the 
N- and C-terminal ends, respectively. The technetium-99m–labeled Cy5.5-RGD imaging 
peptide, by RGD-based targeting, binds to myofibroblasts (20) and is labeled with 99mTc 
for radionuclide imaging. For radiolabeling, 50 μg of 99mTc-CRIP was dissolved in 50 μl 
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of methanol and then added to the freeze-dried kit. A total of 1.0 ml of 99mTcO4- was 
added to the compound and left at room temperature for 20 to 30 min. Instant thin-
layer chromatography confirmed radiopurity of more than 90%. Then, 3.7 ± 0.2 mCi (137 
± 7.4 MBq) of 99mTc-CRIP was injected intravenously through the tail vein. At 3.5 h after 
99mTc-CRIP administration, mice were sacrificed with an overdose of pentobarbital (150 
mg/kg intraperitoneally). Hearts were carefully dissected and planar images of ex vivo 
hearts were acquired for 15 min in 128 × 128 matrix with the use of a low-energy, high-
resolution pinhole collimator, mounted in a dual-head micro single-photon emission 
computed tomography gamma camera (X-SPECT, Gamma Medica, Inc., Northridge, Cali-
fornia). Thereafter, hearts were cut into apical, middle, and basal slices. The quantitative 
CRIP uptake was determined with a gamma scintillation counter (1480 Wizard 3″, Wal-
lace & Co., Monrovia, California). We also determined CRIP biodistribution and radiation 
burden to lung, liver, spleen, and kidney. 
Histological evaluation of myocardial specimens 
After completion of the nuclear studies, the 3 bread-loaf slices were washed in phos-
phate-buffered saline, fixed in 4% paraformaldehyde in phosphate-buffered saline for 24 
h, processed, and embedded in paraffin; then, 4-μm sections were prepared. After de-
paraffinization and rehydration, sections were stained with hematoxylin & eosin, Mas-
son’s trichrome, and picro-Sirius red, as reported previously (20). In picro-Sirius–stained 
sections, the relative collagen areas in the infarcted, and remote areas were determined 
under a microscope (×200) coupled to a computerized morphometry system (Quanti-
met, Leica, Cambridge, United Kingdom). The quality of collagen fibers was investigated 
with the use of Sirius red polarization microscopy, allowing quantitation of the thick, 
tightly packed, more mature orange/red fibers and the newly formed, thin, loosely as-
sembled yellow/green fibers (24 and 25). Approximately 4 to 5 fields per section were 
analyzed in the myocardium. Finally, alpha smooth muscle actin (ASMA) was used to 
determine myofibroblasts in the infarct area, as reported earlier (20). Alpha smooth 
muscle actin area was quantified by Quantimet analysis in 4 to 5 fields per section; AS-
MA uptake was only counted for myofibroblasts, and care was taken not to include AS-
MA uptake observed in vasculature. 
Statistical analysis 
Quantitative radiotracer uptake was calculated as percent total injected dose per gram 
(%ID/g) of the tissue. Radiotracer uptake and echocardiographic measurements were 
expressed as mean ± standard deviation. In our previous study (20), CRIP uptake was 
reduced by >25% in the captopril group compared with the untreated group and in 
combination treatment (losartan plus captopril) compared with single therapy (captopril 
alone) group; as such, we propose that having at least 6 mice per group is sufficient to 
P H A R M A C O L O G I C  I N T E R V E N T I O N  I N  M Y O C A R D I A L  R E M O D E L I N G  
 101 
detect, with at least 90% power and alpha = 0.01, reductions in the uptake of CRIP of at 
least 25% in treated compared with untreated animals, or 2 versus 1 agent groups. This 
calculation confirms that our current study is well-powered. To determine the statistical 
significance of differences among treatment groups, we used 1-way analysis of variance 
followed by post-hoc analysis for multiple comparisons. Because we had a limited num-
ber of pre-specified pairwise comparisons, namely comparison of control and untreated 
animals with uptake among 1, 2, or 3 Rx-treated animals, we used the Bonferroni’s 
method for post-hoc analysis. The correlation between the quantitative tracer uptake 
and echocardiographic parameters or histological characteristics was evaluated by linear 
regression analysis. p Values < 0.05 were considered as statistically significant. 
Results 
Uptake of 99mTc-CRIP and pharmacologic intervention 
Maximum CRIP uptake was observed in the infarct zone of the untreated post-MI mice; 
CRIP uptake was substantially reduced in the treated animals (Table 1, Fig. 1A); no CRIP 
uptake was observed in the unmanipulated hearts. Scrambled CRIP, which has a de-
ranged RGD sequence, did not show uptake in the infarcted myocardium and demon-
strated that CRIP uptake is RGD dependent and specific. 
 The quantitative CRIP uptake in the myocardial tissue specimens was calculated and 
represented as percent of injected CRIP dose per gram (%ID/g) of myocardial tissue. We 
observed CRIP uptake in the infarcted area to be the greatest in the untreated MI group 
(No Rx; 2.30 ± 0.14%). There was a significant reduction in CRIP uptake in the infarct area 
in all treated animals (1.46 ± 0.42%) compared with the untreated animals (p < 0.0001). 
The reduction of uptake was significant even when the animals were treated with a 
single neurohumoral antagonist (1Rx, 1.71 ± 0.35%, p = 0.0002) (Fig 1B). Each agent was 
independently effective; spironolactone (1.80 ± 0.44%; p = 0.0011), captopril (1.72 ± 
0.30%; p = 0.0059), and losartan (1.58 ± 0.28%; p < 0.0001) (Table 1). 
 The use of 2 neurohumoral antagonists (2Rx, 1.31 ± 0.40%) influenced the CRIP 
uptake to a greater extent than a single agent (1Rx, 1.71 ± 0.35%) treatment (p = 0.0005) 
(Fig 1B). Uptake with various combinations was as follows; CL (1.37 ± 0.55%; p < 0.0001), 
SC (1.28 ± 0.41%; p < 0.0001), and SL (1.29 ± 0.32%; p<0.0001) (Table 1). The combina-
tion of all 3 agents further reduced the CRIP uptake (3Rx, 1.16 ± 0.26%) in the infarct 
area (Fig. 1B). The decrease in CRIP uptake in triple-treated animals was significantly 
lower than 1-agent treatment (p = 0.0001) but was statistically insignificantly reduced 
compared with 2-agent therapy (p = 0.33) (Fig. 1). 
 We found that CRIP uptake in the remote myocardium tended to be increased, alt-
hough not statistically significant, in the untreated post-MI animals (0.92 ± 0.22) compared 
with the unmanipulated control animals with no infarcts (0.68 ± 0.16, p = 0.077) (Fig. 1B). 
C H A P T E R  7  
 102 
 
Figure 1. Radiolabeled CRIP Uptake After Neurohumoral Antagonist Treatment in Post-MI Animals 
(A) Disease control (unmanipulated) heart with RGD probe shows no radiotracer uptake in ex vivo image of the 
heart. However, intense 99mTc-CRIP uptake is found in 4-week untreated (no Rx) post-MI animals (upper panel, 
right). The uptake in the infarcted area is reduced after neurohumoral treatment with solitary agents and 
combination therapy (middle and lower panels). Losartan (L) images are displayed twice (middle panel) for the 
convenience of comparison. C = captopril; S = spironolactone. (B)Quantitative 99mTc-CRIP uptake in the infarct 
(apex, above) and remote (base, below) areas. The%ID/g uptake in the infarct area is greatest in untreated
mice, followed by treatment with 1 (1Rx), 2 (2Rx), and 3 (3Rx) agents, respectively. On the other hand, the 
uptake in the remote area shows no significant differences between treated and untreated animals. Quantita-
tive data confirmed the findings of ex vivo images. Data are presented as mean ± SEM. 99mTc-CRIP = techneti-
um-99m-labeled Cy5.5-RGD imaging peptide; MI = myocardial infarction;%ID/g = percent of injected CRIP dose 
per gram; RGD = Arg-Gly-Asp. 
 
P H A R M A C O L O G I C  I N T E R V E N T I O N  I N  M Y O C A R D I A L  R E M O D E L I N G  
 103 
Echocardiographic examination and remodeling characteristics 
As shown in Table 2, initial MI size was similar in all animal groups. During the 4-week 
follow-up period, there was a reduction in LV ejection fraction in untreated post-MI (30 
± 8%) animals compared with unmanipulated disease control animals (64 ± 4%, p < 
0.0001). Neurohumoral antagonists significantly prevented the functional loss (ejection 
fraction 44 ± 10%), compared with untreated animals (30 ± 8%; p = 0.0016). Similar to LV 
ejection fraction, there was a significant decrease in the myocardial strain development 
in untreated animals (−4.59 ± 1.85 U%) compared with unmanipulated (−12.00 ± 2.31 
U%) animals (p < 0.0001); loss of myocardial strain was significantly prevented by treat-
ment with neurohumoral agents (−8.04 ± 2.4 U%, p = 0.0005). The strain development in 
1Rx (−7.17 ± 2.28 U%, p = 0.0126), 2Rx (−8.28 ± 2.51 U%, p = 0.0011), and 3Rx (−9.33 ± 
1.7 U%, p < 0.0001) groups was better preserved compared with the untreated control 
group. However, the preservation of strain development did not reach statistical signifi-
cance on comparison of 1Rx versus 2Rx (p = 0.13) or 2Rx versus 3Rx (p = 0.25) agents; 
3Rx was statistically significantly better than the 1Rx intervention (p = 0.0168). The re-
sults of loss of apical rotation or counterclockwise twist of the LV were similar to the loss 
of strain development. The rotation in all (0.55 ± 0.18°, p < 0.0001), 1Rx (0.49 ± 0.17°, p 
= 0.0006), 2Rx (0.57 ± 0.19°, p < 0.0001), and 3Rx (0.63 ± 0.17°, p < 0.0001) groups was 
preserved compared with the untreated control group. However, once again, the pre-
vention of rotational loss did not reach statistical significance on comparison of 1Rx 
versus 2Rx (p = 0.17) or 2Rx versus 3Rx (p = 0.36) agents; 3Rx was statistically significant-
ly better than the 1Rx intervention (p = 0.048). The LV ejection fraction, strain develop-
ment, and rotation correlated with%ID/g CRIP uptake (r2 = 0.309, = 0.397, and = 0.469, 
and p <0.0001, <0.0001, and <0.0001, respectively) (Fig. 2). 
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Figure 2. Correlation of radiolabeled 99mTc-CRIP Uptake and 
echocardiographic parameters of remodeling an all animals 
A significant correlation between CRIP uptake and left ven-
tricular ejection fraction (A), myocardial strain (B), and apical 
counterclockwise rotation (C) is observed. Abbreviations as in 
Figure 1. 
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Histologic characterization of infarct and remote myocardium and correlation 
with 99mTc-CRIP uptake 
Masson’s trichrome and picro Sirius red staining (Fig. 3) of the myocardial slices allowed 
the assessment of total collagen content and the composition in thick and thin collagen 
fibers. The percent collagen content in the infarcted area in untreated animals was 79 ± 
4%, which reduced substantially in the treated animals (66 ± 8%, p < 0.0001) (Fig. 
4A,Table 3). The collagen content decreased in animals treated with 1Rx (71 ± 7%, p = 
0.006), 2Rx (64 ± 9%, p < 0.0001), or 3Rx (65 ± 4%, p = 0.0008) agents (Fig 4A). The re-
sults were similar for the yellow-green collagen fiber deposition in the infarcted myocar-
dium, suggesting a decrease in new or thin collagen fiber synthesis (Fig. 4C). The new, 
thin collagen fibers correlated with CRIP uptake in the infarct (r2 = 0.5475, p < 0.0001) 
(Fig. 4E). In the remote region, the overall collagen deposition was markedly lower com-
pared with the infarct region. The collagen content of the untreated remote myocardi-
um (No Rx, 2.1 ± 0.6%) was significantly greater than the unmanipulated hearts (0.73 ± 
0.2%, p < 0.0001) (Fig 4B). A marked decrease in collagen content and yellow-green 
collagen fiber deposition was observed in the remote region after treatment (Fig. 4D, 
Table 3); collagen content in treated animals was not different from unmanipulated 
animals. There was a direct correlation between tracer uptake and thin collagen fiber 
deposition in the remote region (r2 = 0.347; p < 0.0001) (Fig. 4F). 
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Figure 3. Histopathological Characterization of the Treated and Untreated Animals 
Masson’s trichrome staining was performed for infarct localization in control, untreated, 
and treated animals (A). In addition, histological staining was performed with picro Sirius 
red to demonstrate collagen deposition, which on polarized light allowed identification of 
the quality of collagen, in the infarct (B and C) and remote regions (D and E). The left 
column presents control animals, the middle column shows untreated animals (no Rx), 
and the right column shows animals treated with 3Rx neurohumoral antagonists (SCL). 
The remote region shows minimal fibrosis and collagen deposition (D). On the other hand, 
infarct region shows significant wall thinning (A) and fibrosis with evidence of substantial 
collagen deposition in untreated animals (B, No Rx). 3Rx-treated animals show reduced 
fibrosis (A, SCL) and collagen deposition (B, SCL) in the infarcted area. The Sirius staining 
under polarized light provides distinction of thick red-orange and thin yellow-green colla-
gen fibers in the infarct region (C). SCL = spironolactone, captopril, and losartan. 
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Figure 4. Collagen Fiber Deposition in Infarct and Remote Regions
The total collagen content decreases with treatment in the infarcted (A), as well as the remote (B) areas. 
Further characterization of the collagen fibers by polarization reveals that the thin or new yellow-green 
collagen fibers decreased both in the infarct (C) and remote (D) regions after treatment. This indicates 
cessation of new collagen production and maturation of the collagen fibers after treatment. The prevalence 
of new collagen fibers paralleled the CRIP uptake and demonstrated a significant direct correlation, both in 
infarct (E) and remote (F) regions. 
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Table 3. The Extent of Collagen Deposition and Myofibroblast Count in Various Animal Groups 
Group Infarct     Remote 
Collagen (%) YG (mm2) OR (mm2) ASMA (mm2)  Collagen (%) YG (mm2) OR (mm2) 
Control 0.90 ± 0.14† 221 ± 79† 2430 ± 402† 0† 0.73 ± 0.18† 170 ± 66† 2052 ± 670† 
No Rx 79.3 ± 4.0□ 2343 ± 564□ 190026 ± 47815□ 6.1 ± 5.2□ 2.11 ± 0.63□ 571 ± 235□ 5234 ± 1491□ 
S 70.9 ± 3.8□† 1452 ± 505 157337 ± 24731□ 4.0 ± 2.8 1.32 ± 0.78† 323 ± 268† 3181 ± 1948† 
C 71.3 ± 8.2□† 1591 ± 342□ 165676 ± 31450□ 6.1 ± 2.0□ 1.29 ± 0.47† 328 ± 111† 3139 ± 1489† 
L 70.1 ± 8.4□† 1849 ± 774□ 145112 ± 75498□ 4.5 ± 0.5 1.31 ± 0.29† 304 ± 108† 3155 ± 889† 
CL 68.2 ± 9.2□† 2304 ± 827□ 137198 ± 46884□† 4.2 ± 4.8 1.17 ± 1.04† 298 ± 248† 2950 ± 2678† 
SC 61.3 ± 8.5□† 1545 ± 1064□ 154679 ± 41481□ 1.3 ± 1.4 1.12 ± 0.43† 313 ± 133† 3197 ± 1575† 
SL 62.2 ± 7.3□† 1248 ± 937† 168002 ± 27358□ 0.7 ± 0.2† 1.32 ± 0.33† 342 ± 79† 3873 ± 1150† 
SCL 64.7 ± 3.8□† 689 ± 249† 159914 ± 49453□ 1.5 ± 0.9† 1.12 ± 0.41† 291 ± 160† 3321 ± 1499† 
ASMA = alpha smooth muscle cells; OR = orange-red, thick, crosslinked collagen fibers; YG = yellow-green, thin, 
new collagen fibers; other abbreviations as in Table 2. 
□ p < 0.05 compared with control animals. 
†p < 0.05 compared with No Rx-treated animals. 
 
We performed ASMA staining for quantitation of the myofibroblasts (Fig. 5A). The AS-
MA-positive area was substantially larger in the untreated animals (No Rx, 6.11 ± 
5.17μm2) compared with the unmanipulated animals (0.007 ± 0.01μm2, p = 0.013). 
Treatment with 1Rx (4.91 ± 2.12 μm2, p = 0.51), 2Rx (2.22 ± 3.30 μm2, p = 0.037), or 3Rx 
(1.54 ± 0.92 μm2, p = 0.039) interventions substantially restricted the myofibroblast 
prevalence (Fig. 5B, Table 3). There was a directly proportional relationship between 
CRIP uptake and ASMA-positive area (r2 = 0.582, p < 0.0001) (Fig. 5C). 
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Figure 5. Radiolabeled CRIP Uptake and the Prevalence of ASMA-Verified Myofibroblasts 
Immuohistochemical staining with ASMA antibody allowed quantitative assessment of myofibro-
blasts infiltration in the infarct and remote regions (A). The left column presents control animals, 
the middle column shows untreated animals (no Rx), and the right column shows 3Rx-animals 
(SCL). There is a marked decrease in number of myofibroblasts in the infarct region in 2Rx and 3Rx 
groups (B). There is a significant direct correlation between the extent of myofibroblasts and the 
CRIP uptake in infarct region (C). ASMA = alpha smooth muscle actin; other abbreviations as in 
Figure 1 and Figure 3. 
Discussion 
Molecular imaging in myocardial remodeling 
The present study used molecular imaging of myofibroblasts during infarct healing. The 
radiotracer, CRIP, contains an RGD sequence and binds to myofibroblasts through acti-
vated avB3/5 integrins with an affinity of 1 to 3 nmol/l (20); RGD is also known to com-
monly target the integrin expression associated with neoangiogenesis early after MI and 
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macrophage influx during infarct healing. We have observed that after 2 weeks of infarct 
healing, myofibroblasts comprise a predominant target for RGD probes (20). In addition, 
a specific noncovalent interaction of CRIP also was observed with custom-made DDX-
sequence contained within pro-collagen I. The previous study using 99mTc-CRIP had 
demonstrated the feasibility of noninvasively imaging the extent of myofibroblasts prev-
alence in a post-MI mouse model (20). The CRIP uptake receded over time in the infarct 
region with substantial resolution over the course of 3 months after the myocardial 
injury. This previous report also demonstrated that the uptake was significantly reduced 
at 4 weeks upon treatment with captopril alone or in combination with losartan and 
proposed that CRIP uptake could monitor the efficacy of neurohumoral antagonists and 
help identify the optimum level of therapeutic intervention (20). A simultaneously con-
ducted clinical study, using RGD-seeking peptide demonstrated the feasibility of molecu-
lar imaging early after MI (26). The radiotracer uptake after MI predicted the extent of 
eventual magnetic resonance imaging-verified fibrosis after 1 year. On the basis of these 
results, the present study investigated the effect of various neurohumoral antagonists, 
alone or in combination, on the extent of myocardial interstitial alterations in a 4-week 
post-MI mouse model. 
 This study confirmed the efficacy of antiangiotensin and antialdosterone interven-
tion on interstitial alterations and demonstrated that combination of 2 neurohumoral 
antagonists was superior to an individual agent; 3 agents decreased the radiotracer 
uptake further, albeit not significantly. The radiotracer uptake correlated closely with 
parameters of depressed myocardial mechanics, the quantitative prevalence of myofi-
broblasts, and thin fiber collagen deposition, suggesting that treatment with neurohu-
moral antagonists results in decreased new collagen production. The data obtained in 
the present study corroborate with information provided by the estimation of collagen 
synthesis and fragmentation markers in the serum (27- 29). Procollagen type III amino-
terminal peptide is decreased in chronic heart failure patients using antiangiotensin and 
anti-aldosterone treatment (30, 31). 
What is the optimum therapy? 
The clinical role of ACE-I, ARB, and SARA has been conclusively demonstrated in trials 
confirming the reduction in morbidity and mortality in patients with overt heart failure 
(8-11,17,32). These agents also decrease the likelihood of the development of heart 
failure in patients with asymptomatic decrease in LV ejection fraction (13,14), as well as 
those predisposed to development of heart failure but normal LV ejection fraction (12, 
33). It is also established that antiangiotensin agents in combination are superior to any 
agent used alone. The combination of ACE-I with ARB in the presence of beta-blockers ± 
aldosterone inhibitors reduces the combined end point of mortality (16) and hospitaliza-
tion for worsening of heart failure (17). The experimental data from the present study 
confirm the superior effect of combination of 2 agents. However, the addition of the 
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third agent did not decrease the uptake significantly. It is encouraging to observe the 
efficacy of an imaging agent to identify difference in infarct healing, which could be of 
translational clinical benefit. 
Is lack of collagen deposition favorable? 
The present study raises an important question about the relevance of decrease in colla-
gen deposition in the post-infarct patients. Total abolition of collagen deposition, which 
has been evaluated in clodronate liposome-treated animals (wherein infarct healing 
becomes defective with minimal collagen deposition and inefficient necrotic myocyte 
removal) (34), leads to greater tendency for aneurysmal formation and infarct rupture. 
On the other hand, direct myocardial injection of collagen in experimental infarcts leads 
to dense collagen deposition and prevents myocardial remodeling (35). Such experi-
ments suggest that the collagen deposition may not necessarily be harmful. However, 
the use of ACE-I or SARA allows the reduction of collagen deposition as demonstrated by 
circulating collagen degradation products (30). The present study demonstrated a de-
crease in collagen deposition with suppression of angiotensin-aldosterone axis. Because 
neurohumoral antagonists lead to favorable clinical outcomes, conceivably reduced 
collagen deposition should be of benefit. Although the present study is not capable of 
explaining these paradoxical observations, it is possible that predominant decrease of 
collagen content observed in the remote myocardium in the present study, and the 
collagen fiber maturation (to thick fibers) observed in the infarct region may contribute 
to a more balanced healing. 
Conclusions 
The present study demonstrates that 99mTc-CRIP imaging allows for the evaluation of 
the efficacy of antiremodeling therapy. It also reconfirms the superiority of combination 
therapy over a solitary use of neurohumoral antagonists. If proven clinically, molecular 
imaging of the remodeling processes could facilitate individualizing the treatment for 
patients susceptible to heart failure. 
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CHAPTER 8 
Noninvasive molecular imaging of cell 
death in myocardial infarction using 
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Acute insult to the myocardium is associated with substantial loss of cardiomyocytes 
during the process of myocardial infarction. In this setting, apoptosis (programmed cell 
death) and necrosis may operate on a continuum. Because the latter is characterized by 
the loss of sarcolemmal integrity, we propose that an appropriately labeled tracer di-
rected at a ubiquitously present intracellular moiety would allow non-invasive definition 
of cardiomyocyte necrosis. A trivalent arsenic peptide, GSAO (4-(N-(S-glutathionyl-
acetyl)amino)phenylarsonous acid), is capable of binding to intracellular dithiol mole-
cules such as HSP90 and filamin-A. Since GSAO is membrane impermeable and dithiol 
molecules abundantly present intracellularly, we propose that myocardial localization 
would represent sarcolemmal disruption or necrotic cell death. In rabbit and mouse 
models of myocardial infarction and post-infarct heart failure, we employed In-111-
labelled GSAO for noninvasive radionuclide molecular imaging. 111In-GSAO uptake was 
observed within the regions of apoptosis seeking agent- 99mTc-Annexin A5 uptake, sug-
gesting the colocalization of apoptotic and necrotic cell death processes. 
 Cell death plays a central role in various cardiovascular diseases. Two morphological-
ly distinct modes of cell death - apoptosis (a programmed process characterized by en-
zymatic degradation and clean removal of the cell) and necrosis (an uncontrolled pro-
cess characterized by cell swelling, membrane rupture and spill of its contents) have 
been reported to contribute to the myocardial tissue loss. It is being increasingly realized 
that apoptosis and necrosis, rather than being entirely independent, may operate on a 
continuum, at least in response to noxious stimuli.1-3 
 Numerous strategies have been proposed for the detection of cell death early after 
onset of ischemia within the time window amenable to intervention. Most experience 
for the recognition of apoptosis has been obtained with single photon emission comput-
ed tomography (SPECT) imaging using 99mTc-Annexin A5 (AA5). 99mTc-AA5 targets exter-
nalized phosphatidylserine (PS) on membranes of cells with active apoptotic signaling4 
and the clinical feasibility of 99mTc-AA5 imaging has been demonstrated in the setting of 
myocardial infarction5,6, transplant rejection7 and heart failure.8 On the other hand, 
several radiotracers targeting necrotic cells through membrane disruption have been 
developed.9-11 Notably, antimyosin antibody imaging has been successfully employed for 
the detection of myocardial necrosis associated with myocardial infarction9, myocardi-
tis9, heart failure12 and cardiac allograft rejection.12 However due to technical disad-
vantage of prolonged wait time for imaging, the necrosis-avid radiotracers have not 
become popular. 
 4-(N-(S-glutathionylacetyl)amino)phenylarsonous acid (GSAO) GSAO labeled with 
fluorophores and radionuclides has been used for targeting of cell death in culture, in 
tumor-bearing mice, and in mice with experimental brain trauma.13-15 The principle be-
hind GSAO cell death targeting is displayed in figure 1. GSAO is a tripeptide with a triva-
lent arsenic moiety. The arsenic group binds to dithiols, which are abundantly present in 
intracellular milieu and virtually absent from the extracellular space.16 GSAO cannot 
reach its intracellular target molecules in intact cells, because it is not able to negotiate 
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across the cell membrane.17 Cell membrane γ-glutamyl transferase (GGT) is upregulated 
during ischemic stress and other situations, splice off GSAO’s glutamyl residue and allow 
cellular entrance of GSAO’s metabolite GCAO (4-(N-(S-cysteinylglycylacetyl)amino) phe-
nylarsonous acid).17 However, when radioactive or fluorescent reporter molecules are 
attached to glutamyl residue of GSAO it is not able to bind to GGT, rendering the mole-
cule membrane impermeable.13 After the necrotic process sets in and the sarcolemmal 
integrity is lost; and GSAO gains free entry to the intracellular microenvironment. Of 
numerous dithiol-bearing intracellular targets including filamin A, eukaryotic translation 
elongation factor 2, and protein disulfide isomerase (PDI), HSP90 is most widely pre-
sent.13 HSP90 comprises approximately 2% of the intracellular protein content and in-
creases by two-threefold in response to acute stress including ischemia.18 
 
 
Figure 1. Targeting mechanism of GSAO. 
GSAO binds to dithiol molecules, which are abundant in the intracellular space and virtually absent in the 
extracellular space. When labelled with radioactive or fluorescent reporter molecules, GSAO cannot negotiate 
across the cell membrane of healthy cells (a) but gains free access through disrupted membranes of dying cells 
(b). Thus, GSAO accumulates in dying cells. 
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In this study we evaluated feasibility of cell death imaging using 111In-GSAO in mouse and 
rabbit models of acute MI and a mouse model of chronic MI. In addition, a subgroup of 
animals, serial SPECT/CT imaging using 99mTc-AA5 and 111In-GSAO was performed to 
determine the relationship between these two modes of cell death in the setting of 
myocardial ischemia and reperfusion. Fluorescent GSAO and AA5 were employed in 
another subgroup of animals for pathological characterization of the mode of cell death. 
In addition, 111In-GSCA (4-(N-(S-glutathionylacetyl)amino)benzoic acid), which is identical 
to 111In-GSAO except for replacement of the arsenic group with a carboxylic acid group, 
was used as a negative control compound in radionuclide experiments. 
Results 
Fluorescence microscopic characterization of GSAO uptake 
Uptake characteristics of GSAO were evaluated and compared with AA5 in mice with 
acute MI and sham-operated mice. Experimental acute MI was induced by 30-minute 
coronary ligation followed by 30 minutes of reperfusion. Sham procedure was identical, 
except that coronary ligation was not performed. Mice with acute MI (n=3) and sham-
operated mice (n=3) were injected Cy5.5-labelled GSAO and Oregon Green-labeled AA5. 
Qualitative fluorescent microscopic analysis of heart sections showed that cardiomyo-
cytes of sham-operated mice were positive neither for GSAO nor for AA5. In contrast, in 
ischemia/reperfusion-injured hearts, cardiomyocytes positive for GSAO and AA5 were 
observed (Fig. 2a-c). Interestingly, all GSAO-positive cardiomyocytes bound AA5 (Fig. 2a-
c), suggesting that necrosis in the reperfused myocardium coexists with apoptotic signal-
ing. Not all AA5 positive cardiomyocytes had taken up GSAO (Fig. 2c). 
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Figure 2. Characterization of target binding of GSAO. 
Tissue sections of acute MI mice, injected fluorescently labeled GSAO and AA5. (a,b) GSAO accumulation (red) 
was only observed in cells with AA5-positive cell membranes (green). (c) All cells AA5-positive cells were not 
GSAO positive. 
Radiolabelled GSAO imaging in acute myocardial infarction 
Acute MI was induced in rabbits and mice by coronary ligation for 40 and 30 minutes, 
respectively. Reperfusion was achieved by removal of the suture and 111In-GSAO was 
administered thirty minutes later. Three hours thereafter, in vivo micro-SPECT/micro-CT 
imaging was performed, animals were sacrificed and hearts were explanted. Next, ex 
vivo SPECT/CT and planar cardiac imaging were performed. Then, rabbit hearts were cut 
into ~32 small pieces and mice hearts were sectioned in three short axis slices: basal 
(remote area), middle (border zone) and apical (infarct). Radiotracer uptake was quanti-
fied by γ-counting, and myocardial pieces were histopathologically characterized. 
 In vivo SPECT/CT imaging in MI rabbits (n=10) revealed intense uptake of 111In-GSAO 
in the apical area (Fig. 3a). Ex vivo SPECT/CT and planar imaging (Fig 3b) of explanted 
hearts confirmed intense apical radiotracer uptake. γ-counting confirmed that the 111In-
GSAO uptake in the myocardial infarct was markedly higher than the 111In-GSAO uptake 
in the remote region (1.10±0.45%ID/g vs. 0.03±0.01%ID/g, P=0.005, Fig. 3c). 
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Figure 3. 111In-GSAO imaging, quantification and comparison with 99mTc-Annexin A5 and 99mTc-MIBI in rabbits 
with acute myocardial infarction. 
(a) In vivo SPECT (left panels), and fused SPECT/CT images (right panels) in acute MI rabbits revealed intense 
111In-GSAO uptake (top) and only modest uptake of radiotracer control compound 111In-GSCA (bottom). (b) Ex 
vivo planar images confirmed intense 111In-GSAO uptake (top) and modest 111In-GSCA (bottom) uptake. (c) γ-
counting of myocardial sections confirmed 111In-GSAO uptake in infarct was higher than in remote area and 
higher than 111In-GSCA uptake in infarct. Although low, 111In-GSCA uptake in infarct was higher than remote. 
Difference Between 111In-GSAO and 99mTc-AA5 uptake did not reach significant uptake. Black horizontal lines 
denote Kruskal-Wallis ANOVAs + Bonferroni correction, and red lines denote Wilcoxon signed rank tests + 
Bonferroni correction. (d) Serial imaging revealed that 111In-GSAO uptake (top) was predominantly localized in 
the region of the 99mTc-MIBI perfusion defect (bottom). (e) γ-counting of myocardial sections showed high 
111In-GSAO uptake in sections with low MIBI uptake and vice versa. (f) A significant inverse Spearman’s correla-
tion between uptake of 111In-GSAO and 99mTc-MIBI was observed. (g) Serial planar imaging in acute MI rabbit 
demonstrates similar uptake region and higher uptake of 111In-GSAO (top) when compared with 99mTc-AA5 
(bottom). (h) γ-counting of myocardial sections showed high 111In-GSAO uptake in sections with high 99mTc-AA5 
uptake and vice versa (i). A significant Spearman’s correlation between uptake of 111In-GSAO and 99mTc-AA5 
was observed. 
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To study the specificity of 111In-GSAO, the myocardial uptake of negative control com-
pound GSCA was evaluated in acute MI rabbits (n=5). In vivo (Fig. 3a) and ex vivo 
SPECT/CT imaging and planar imaging (Fig. 3b) revealed very low cardiac uptake of 
GSCA; only slightly increased infarct uptake was observed. This was confirmed by γ-
counting; when compared with 111In-GSAO, 111In-GSCA uptake in the infarct area was 
significantly lower (0.07±0.03%ID/g, P=0.002, Fig 3c). Although low, GSCA uptake in the 
infarct area was higher than in the remote area (0.03±0.01%ID/g, P=0.043). This demon-
strated that the trivalent arsenical group was necessary for targeting of dying cells. 
Moreover, myocardial 111In-GSAO uptake in an unmanipulated control animal was similar 
to 111In-GSAO uptake in the spared myocardium of the MI rabbits (0.01%ID/g vs. 0.03 ± 
0.01%ID/g), further supporting specificity of GSAO. 
 To evaluate localization of cardiac 111In-GSAO uptake, three of ten animals receiving 
111In-GSAO also received the myocardial perfusion tracer 99mTc-sestamibi (MIBI), imme-
diately after coronary ligation. Serial in vivo SPECT/CT imaging confirmed that 111In-GSAO 
uptake was localized in the infarct zone as identified by 99mTc-MIBI perfusion defect. 
Similarly, ex vivo serial SPECT/CT imaging and serial planar imaging (Fig. 3d) revealed 
uptake of 111In-GSAO in the infarct zone as shown by 99mTc-MIBI perfusion defect. In 
each animal, γ-Counting of 99mTc-MIBI and 111In-GSAO in myocardial sections confirmed 
increased uptake of 111In-GSAO in the perfusion defects as sections with low MIBI uptake 
showed increased 111In-GSAO uptake and vice versa (fig 3e). γ-counting of all myocardial 
sections from the animals receiving both 111In-GSAO and 99mTc-MIBI revealed an inverse 
correlation between 111In-GSAO uptake and 99mTc-MIBI uptake (ρ=-0.70, p<0.01, Fig 3f). 
 Of ten animals receiving 111In-GSAO, three also received 99mTc-AA5. Serial in vivo 
SPECT/CT imaging with 111In-GSAO and 99mTc-AA5 revealed similar area of increased 
uptake; 111In-GSAO uptake was more intense than 99mTc-AA5 uptake This was confirmed 
by ex vivo serial SPECT/CT imaging and ex vivo serial planar imaging (Fig. 3g). Quantita-
tive tracer uptake paralleled the imaging data. In each animal, in sections with increased 
99mTc-AA5 uptake, 111In-GSAO uptake was also increased (fig. 3h). Using all myocardial 
sections in all animals receiving 111In-GSAO and 99mTc-AA5, a strong correlation between 
uptake of the radiotracers was observed (ρ=0.82, p<0.01, Fig 3i). Like the fluorescence 
experiments, this supports that secondary necrosis after apoptotic signaling may be the 
dominant mode of cell death in myocardial infarction. The 111In-GSAO uptake in the 
infarct zone was higher than 99mTc-AA5 uptake, although the results did not reach statis-
tical significance, due to the small sample size (1.10±0.45%ID/g vs. 0.47±0.23%, P=0.47). 
Uptake in the remote area was low for both tracers (0.03±0.01%ID/g vs. 0.04±0.02% 
ID/g, P=NS). 
 After γ-counting myocardial pieces from infarct, border and remote zones were 
histologically characterized. Representative examples of the stainings are given in figure 
4a. H&E staining revealed hypereosinophilic change and contraction band necrosis in the 
myocardial sections from the infarct area; the morphological changes were less frequent 
in the border zone. The remote area was morphologically normal. The rate of apoptosis 
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as shown by terminal deoxyribonucleotide transferase TdT-mediated nick-end labeling 
(TUNEL) staining (%area positive, %AP) was higher in the infarct (2.83±1.42%AP) and 
border zone (2.55±1.84%AP) than in the remote zone (0.02±0.0%AP, P<0.001 for both). 
The %caspase positive area was higher in the infarct (1.04±0.48%AP) than in the remote 
zone (0.46±0.48%AP, P=0.054). 111In-GSAO uptake in the myocardial sections showed a 
direct correlation with TUNEL (ρ: 0.743, P<0.001, Fig. 4b) and Caspase-3 (ρ=0.533, 
P<0.001, Fig. 4c) stains, further supporting that necrosis as shown by GSAO is secondary 
after apoptotic signaling. 
 
 
Figure 4. Histopathological characterization of 111In-GSAO uptake in rabbit heart after experimental acute 
myocardial infarction. 
H&E staining demonstrates clear signs of tissue damage in infarct and border zone, whereas the remote zone 
is morphologically normal. TUNEL and Caspase-3 stains demonstrate substantial apoptosis in the infarct zone, 
whereas positive cells are rarely seen in the remote area. Significant Spearman’s Rank correlations between 
111In-GSAO uptake and apoptotic signaling as shown by TUNEL (b) and Caspase-3 (c) stains were observed. 
 
The non-target organ distribution of 111In-GSAO and 111In-GSCA demonstrated kidney to 
be the major organ of radiation burden and urine major route of excretion; all other 
organs revealed minimum burden for both radiotracers (Supplementary Fig.1a). Serial 
blood samples from six animals revealed bi-exponential blood clearance with an initial 
fast component T1/2α of 5.3min followed by a slower component T1/2β of 9.7 h; the plat-
eau phase was approached at 15 min (Supplementary Fig. 1b). 
 In vivo SPECT/CT imaging in mice after acute MI (n=6) demonstrated high 111In-GSAO 
uptake; the use of CT allowed precise localization of the radioactivity in the infarcted 
region of the heart (Fig. 5a,b). Specific apical uptake was confirmed by ex vivo SPECT/CT 
and planar imaging (Fig. 5c). Imaging experiments revealed absence of specific 111In-
GSAO uptake in control animals. 111In-GSAO uptake in the infarct area (2.56±2.75%ID/g) 
was markedly higher than in remote myocardium (0.48±0.22%ID/g, P=0.028) and 20-fold 
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higher than apical uptake in unmanipulated control animals (n=5, 0.13±0.02%ID/g; 
p=0.004, Fig. 5d). 
 
 
Figure 5. In vivo and ex vivo 111In-GSAO imaging and quantification in mice with acute 
myocardial infarction. 
In vivo SPECT (a), and fused SPECT/CT images (b) in acute MI rabbits revealed intense 
cardiac 111In-GSAO uptake. (c) Ex vivo planar images confirmed intense 111In-GSAO 
uptake. (d) γ-counting of myocardial sections confirmed 111In-GSAO uptake in infarct 
(apex) was higher than manyfold higher than in remote area and higher than apical 
111In-GSAO uptake in unmanipulated control animals. Black horizontal lines denote 
Mann-Whitney U tests and red lines denote Wilcoxon signed rank tests. 
 
Radionuclide imaging in a post-MI HF model 
111In-GSAO uptake was also evaluated in post-MI HF mouse model, in which the LCA 
territory was not reperfused. Subgroups underwent imaging experiments at different 
time points. Also, a disease control group consisting of animals that did not undergo 
infarction surgery before 111In-GSAO imaging, and a radiotracer control group consisting 
of animals receiving negative control compound 111In-GSCA imaging at 2 weeks post-MI 
were used. 
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 111In-GSAO uptake in the HF mice was markedly lower than in AMI mice, and could 
not be detected by in vivo SPECT/CT imaging. Quantification of radionuclide uptake in 
short axis slices confirmed that infarct uptake of 111In-GSAO in mice at 2 weeks post-MI 
(n=6) was higher than in the five disease control animals that did not undergo infarction 
surgery (0.42±0.17%ID/g vs. 0.13±0.02%ID/g, P=0.025, Fig 6); remote uptake was not 
statistically different (0.25±0.12%ID/g vs. 0.14±0.04%ID/g, P=1.0, Fig 6). Moreover, 111In-
GSAO uptake at 2w post-MI was significantly higher than uptake of the negative control 
compound 111In-GSCA in the infarct and remote area (0.04±0.02%ID/g, P<0.001 and 
0.04±0.03%ID/g, P=0.004, respectively) 
 Moreover, when compared with uptake at 2 weeks post-MI, 111In-GSAO uptake 
showed a trend of decline at 4 weeks (n=6, infarct 0.28±0.09%ID/g, P=1.0; remote 
0.22±0.04%ID/g, P=1.0, Fig 6) and 12 weeks (n=8, infarct: 0.19±0.07%ID/g, P=0.332; 
remote: 0.15%±0.1%ID/g, P=1.0, Fig 6) although differences were not statistically signifi-
cant. 
 
 
Figure 6. Quantification of 111In-GSAO uptake in mice with chronic myocardial infarction. 
Γ-counting revealed 111In-GSAO uptake in the infarct area at 2 weeks; uptake was significantly higher than 111In-
GSAO uptake in unmanipulated control animals and 111In-GSCA uptake at 2w post-MI in controls. A trend of 
declining 111In-GSAO uptake over time was observed, but did not reach statistical significance. 111In-GSAO 
uptake in remote area was higher than 111In-GSCA uptake at 2w post-MI. Results of Kruskal-Wallis ANOVAs + 
Bonferroni correction are shown. 
Discussion 
Here we demonstrate cell death imaging in acute myocardial infarction using 111In-GSAO. 
The specificity of the radiotracer was confirmed by the localization of 111In-GSAO in the 
infarct zone as shown by 99mTc-MIBI. This was further supported by the lack of uptake of 
fluorescently labeled GSAO in sham-operated animals outside of the regions directly 
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damaged by the suture. The lack of GSCA uptake in our radionuclide studies confirmed 
that the trivalent arsenic group on GSAO is responsible for its targeting characteris-
tics.15,29,30 The radiotracer showed favorable pharmacokinetic profile with rapid blood 
clearance and low background uptake in most organs. 
 In the 1990’s evidence of apoptotic signaling in myocardial infarction accumulated19-
22, sparking the discussion over the relative importance of the apoptotic and necrotic 
forms of cell death. In 2000, 99mTc-AA5 SPECT in patients with acute myocardial infarc-
tion revealed intense uptake in the entire region of the perfusion defect5. This observa-
tion was provocative as 99mTc-AA5 was believed to identify apoptotic cell death but the 
infarct area was traditionally expected to be necrotic. It was subsequently proposed that 
the ischemic insult may be initiated as apoptosis but conclude with secondary necrosis. 
Ischemic loss of ATP production during myocardial infarction would preclude completion 
of the energy-dependent apoptosis program.23 Restoration of blood flow by reperfusion 
may either interrupt the apoptotic process to allow cell salvage6,24 or resume the process 
of apoptosis in critically damaged cells.20,22 The latter may even be augmented further by 
production of radical oxygen species25, or intracellular calcium overload.26 These chang-
es may also contribute to secondary necrosis by opening of the mitochondrial permea-
bility transition pore.27-30 It is conceivable that the apoptotic process initiated by noxious 
stimuli may not follow classical picture of physiologic apoptosis observed during normal 
turnover of skin or mucosal cells. 
 The feasibility of cell death imaging using fluorescently labeled and radiolabelled 
GSAO has recently been demonstrated in tumor-bearing mice and mice with experi-
mental brain trauma.13-15 GSAO accumulation was characterized by fluorescent micros-
copy in various cell models of apoptotic and in explanted brains and tumors after in vivo 
GSAO administration. GSAO was observed intracellularly and colocalized with propidium 
iodide and Sytox blue, standard markers of membrane disruption, which supported 
GSAO uptake in secondarily necrotic cells. Similarly, our fluorescent experiments showed 
that GSAO accumulated intracellularly and only occurred in AA5+ cells, thereby support-
ed the notion that necrosis followed apoptotic signaling in the setting of acute myocar-
dial infarction. 
 In vivo and ex vivo 111In-GSAO imaging in rabbits and mice with acute myocardial 
infarction showed intense dual serial imaging with 99mTc-AA5 and 111In-GSAO in rabbits 
after acute myocardial ischemia and reperfusion revealed the same area of uptake. At a 
segment level, 111In-GSAO uptake showed the same pattern as 99mTc-AA5 and a strong 
correlation between uptakes of the two tracers was shown. In addition, 111In-GSAO cor-
related with presence of Caspase-3 and TUNEL staining, classic markers of apoptosis. 
This shows that not only does secondary necrosis after apoptotic signaling occur in myo-
cardial ischemia and reperfusion, it may play a dominant role. As in rabbits, high 111In-
GSAO uptake was seen in mice with acute myocardial infarction. However, 111In-GSAO 
uptake in post-myocardial infarction HF model in mice was too low to be detected by 
micro-SPECT/CT imaging. The most important explanation for this is the lower rate of 
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necrotic cell death in heart failure.31-33 It is tempting to speculate that the more benign 
circumstances such as lesser energy depletion and ROS cause lower transition from 
apoptosis to necrosis in this setting. In fact, the apoptotic process may remain suspend-
ed in chronic heart failure.34 
 A number of imaging tracers for myocardial necrosis have been clinically evaluated. 
Like 111In-GSAO, most tracers exploited membrane disruption, the hallmark of necrosis 
as a target. Tc-99 labelled antimyosin antibody was the most widely studied necrosis 
tracer. Antimyosin antibody imaging has been successfully employed for the detection of 
myocardial necrosis associated with myocardial infarction9, myocarditis9, heart failure12 
and cardiac allograft rejection.12 However, because of long circulation time of the radio-
labelled antibody, imaging was not feasible for up to 6-12 hours after administration of 
the agent. 99mTc-pyrophosphate on the other hand, showed maximal myocardial uptake 
at 24-72 hours after injection, although necrosis imaging at 3 hours post-administration 
was feasible, maximum myocardial uptake was at 24-72h. Also, this tracer required re-
sidual blood flow, which precluded uptake in the infarct center.35 99mTc-glucarate can be 
used to necrotic cells in myocardial infarction11,36, and has good imaging characteristics 
but in the setting of myocardial infarction, use is limited to a clinical window of >9 hours 
after onset as its target, histone bodies, quickly wash out of the tissue.11 Late gadolini-
um-enhanced MRI has also been used to assess cardiac cell death; the contrast medium 
accumulates in necrotic cells through the disrupted membranes. However, its specificity 
is limited, as in all instances of increased extracellular space such as cardiac edema, 
fibrosis, sarcoidosis and amyloidosis.37-39 111In-GSAO appears to have advantages over 
the previously evaluated cell death imaging techniques. First, 111In-GSAO requires mem-
brane disruption, the hallmark of necrotic or late-apoptotic cell death, for reaching its 
intracellular targets. Therefore it does not suffer from the lack of specificity of late-
gadolinium enhanced MRI. Moreover, its rapid blood clearance results in feasibility of 
early imaging of cell death using 111In-GSAO. This gives 111In-GSAO an advantage over 
99mTc-antimyosin and 99mTc-pyrophosphate. HSP90, the main target of GSAO, functions 
in complexes. This may allow for targeting over a longer time period, giving 111In-GSAO 
an edge over 99mTc-glucarate. However, this has to be evaluated in follow-up studies. 
 Micro-SPECT/CT imaging using 111In-GSAO can be used to visualize necrotic cell 
death in acute myocardial infarction. The uptake in the HF model was too low to allow 
imaging. Because the GSAO uptake reflects membrane permeabilization, and occurs 
predominantly in AA5 positive cells, we propose that secondary necrosis is a dominant 
mode of cell death in the setting of myocardial ischemia and reperfusion. 
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Methods 
Materials 
Cy5.5 GSAO and DTPA-GSAO were prescribed as described previously13 and were a kind 
gift of Covidien Imaging Solutions (Hazelwood, Missouri, United States). DTPA-GSAO and 
DTPA-GSCA were labeled with In-111 as described previously.13 The other used materials 
were of standard analytical grade. 
Ethical statement 
The experimental protocols followed the Guidelines for the Care and Use of Laboratory 
Animals established by the National Institutes of Health (NIH Publication No. 85-23, 
revised 1996) and was approved by the Institutional Laboratory Animal Care and Use 
Committees at the University of California, Irvine and University of Maastricht, Maas-
tricht, The Netherlands. 
Experimental myocardial infarction in mice 
For fluorescence experiments, C57Bl6/j (Age: 3 months, weight: ~50g, Jackson Laborato-
ries, Sacramento, CA) and for radionuclide studies Swiss-Webster mice (Age: 3 months, 
weight ~50g, Charles River, Wilmington, MA) were used. MI was induced under isoflu-
rane anesthesia (2-3%) using a stereomicroscope (Leica MZ FL III, Leica, Switzerland) as 
described previously.40 Animals were placed on a heating pad in the supine position, 
intubated under direct laryngoscopy, and mechanically ventilated using a small animal 
respirator (tidal volume, 1.0 ml; rate, 120 breaths/min, Harvard Apparatus, Holliston, 
MA). After a minimum thoracotomy, the anterior descending branch of the left coronary 
artery was ligated with a 6.0-silk suture 3 to 4 mm below the tip of the left atrium. Suc-
cessful ligation was verified by visual inspection of the LV apex for myocardial blanching, 
indicating interruption in coronary flow. For induction of acute MI experiments, the 
suture was removed after 30 minutes to induce reperfusion. The sham operation was 
identical, but the coronary artery was not ligated. Acute MI and sham animals remained 
under anesthesia for ensuing radionuclide imaging or fluorescence experiments. For 
induction of chronic MI, the ligation was not released. In these animals, the chest cavity 
was closed in layers with 6.0-silk and the skin was closed with 4.0-silk sutures. Thereaf-
ter, animals were gradually weaned from the respirator and put back into their cages 
until imaging procedure. 
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Experimental acute myocardial infarction in rabbits 
Acute experimental MI was induced by the occlusion of left anterior descending coro-
nary artery (LAD) in New Zealand White male rabbits (weight, 3.0-3.5kg) as described 
previously.24,41 All rabbits were anesthetized with a mixture of ketamine and xylazine 
(100 mg/ml, 10:1 vol/vol; 2.0 to 3.0 ml subcutaneously). Surgical tracheostomy was 
performed, and ventilation was maintained with a volume-cycled rodent respirator (Har-
vard Apparatus, Holliston, MA) provided positive pressure ventilation at 50 mL/cycle and 
a respiratory rate of 50 cycles/min. After surgical procedure, anesthesia was maintained 
on 3-4% isoflurane Briefly, the heart was exposed through parasternal thoracotomy, and 
the pericardium was fenestrated. The LAD was identified and a monofilament suture was 
placed at the site. The LAD was occluded by tightening the snare created by passing 
suture through a polyethylene tube. The snare was removed after 40 minutes of occlu-
sion to induce reperfusion. Lead II or III of the electrocardiogram was continuously moni-
tored during the experiments to confirm myocardial ischemia. Animals remained anes-
thetized for ensuing radionuclide imaging experiments. 
Fluorescence experiments in mice 
Acute MI mice and sham-operated mice were injected with Cy5.5-labelled GSAO at 5 
minutes before ischemia and 1 hour before sacrifice, respectively. All mice received 
Oregon Green-labeled AA5 10 minutes before sacrifice. Of each fluorescent probe a 
dosage of 2.5 mg/kg was used. Acute MI animals were sacrificed after 30m reperfusion, 
sham mice at 1 hour after sacrifice hearts were snap-frozen in liquid nitrogen, 7µm thick 
frozen sections were obtained, dried and mounted in 4,6-diamino-2-phenylindole (DAPI) 
containing medium and examined with a confocal scanning laser microscope (Bio-Rad) 
equipped with a krypton/argon mixed gas laser (Ion Laser Technology). 
In vivo and ex vivo imaging protocols mice and rabbits 
For mice and rabbits, the same imaging procedure was followed. In vivo SPECT imaging 
was performed at 3 hours after radiotracer administration using a dual-head micro-
SPECT γ-camera combined with micro-CT (X-SPECT, Gamma Medica, Inc., Northridge, 
CA) under isoflurane anesthesia. SPECT images of the heart were acquired in a 64 × 64 
matrix at 32 steps at 60 seconds per step with a 247 keV photo peak of 111In with 15% 
windows using a medium energy parallel-hole collimator. In the animals also undergoing 
99mTc-MIBI 99mTc-AA5, this was followed by imaging using the same protocol, at a 140 
keV photo peak of 99mTc with 15% windows using a low-energy, high-resolution parallel-
hole collimator. Gating was not performed. After SPECT imaging acquisition, a CT scan 
was acquired using an X-ray tube operating at 50 kVp and 0.6 mA. Images were acquired 
for 2.5 seconds per view for 256 views in 360° rotation. After transferring to 256 × 256 
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matrix, the SPECT images and CT studies were fused. After imaging, anesthetized ani-
mals were terminated by heart explantation and ex vivo SPECT/CT excised heart was 
performed using the same protocols but at 45 seconds per step for SPECT. Thereafter, 
planar 111In-GSAO imaging of the hearts was performed for 15 minutes, followed by 
99mTc-MIBI or 99mTc-AA5 planar imaging in GSAO-MIBI and GSAO-AA5 animals. After ex 
vivo imaging, rabbit hearts were cut into 4 short axis slices and further divided into 31-32 
pieces. Mice hearts were cut in 3 short-axis slices. All sections were weighed, and γ-
counted in an automatic well-type γ-counter (Perkin Elmer Wallac Inc., Gaithersburg, 
MD) for calculation of the percent total injected dose per tissue weight (%ID/g) uptake. 
Tissue samples of the main organs were used for calculation of the %ID/g uptake to 
evaluate the bio distribution. To correct for the radioactive decay and permit calculation 
of the concentration of radioactivity as a fraction of the administered dose, aliquots of 
the injected dose were counted simultaneously. For evaluation of infarct 111In-GSAO 
uptake in rabbits, the section with the highest 111In-GSAO uptake in the infarct area was 
used of each animal, and for evaluation of remote 111In-GSAO uptake, the section with 
the lowest 111In-GSAO uptake in the remote area was selected. In all mice, the apical 
slice was used for evaluation of infarct uptake, the middle slice for uptake in the border 
zone and the basal slice for remote uptake. 
Pharmacokinetic studies 
The pharmacokinetic parameters were derived using the KINFIT module of the 
MW/PHARM computer program package (Version 3.60, MediWare, Groningen, The 
Netherlands).42 The data, consisting of the blood concentration of 111In radioactivity or 
GSAO versus time, were analyzed by non-linear regression analysis using a least-squares 
weighted simplex algorithm, with data weighted with the reciprocal of the observed 
value. 
Histological, immunohistochemical evaluation 
After γ-counting of 111In-GSAO uptake, myocardial pieces of seven rabbits were pro-
cessed for histopathologic characterization. Of each animal, two pieces from each region 
(infarct, border zone, remote) were selected. 
 The myocardial pieces were fixed overnight 4% paraformaldehyde in PBS (pH 7.4 at 
4°C), and stored in PBS with 0.02% sodium azide at 4°C until used. The specimens were 
further processed by dehydration in a graded series of ethanol for paraffin-embedding. 
The blocks were cut in 5-μm thick sections, floated on a water bath containing deionized 
water (43°C), and transferred to vectabond (Vector Laboratories Burlingame, California) 
reagent-treated slides (Vector SP-1800, Vector Laboratories), dried overnight, and 
stored until ready for use. Sections were deparaffinised by heating (25 minutes at 56°C) 
and dehydration using xylene and graded series of ethanol. Tissue sections were stained 
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with standard haematoxylin & eosin and Masson’s trichrome staining. For immunohisto-
chemical characterization, adjacent sections were incubated with primary antibodies 
against Caspase-3. After washing with PBS, sections were incubated with a biotinylated 
secondary antibody. The presence of apoptotic cells was further evaluated using TUNEL 
staining as described previously. Briefly: exposed DNA fragments were labeled with bio-
tinylated nucleotides (dNTPs) and TdT for 1h at 37°C after blocking of endogenous pero-
sidase activity using 0.3%hydrogen peroxide and incubation with proteinase K.41 For 
color reactions, sections were incubated with diaminobenzidine. For the assessment of 
the immunopositive area, stained tissue sections were observed under appropriate 
magnification (Carl Zeiss, Thornwood, New York), and the images were captured with a 
high-resolution digital camera (Axiocam, 1,300 × 1,030 pixels, Carl Zeiss) using Axiovision 
3.1 software. Digital images were analyzed using Image-Pro Plus 5.0 (Media Cybernetics, 
Bethesda, Maryland). 
Statistical analysis 
All results are presented as the mean ± SD. In most cases, the data did not meet the 
assumptions of parametric tests. For consistency, non-parametric tests were used for all 
comparisons. Related samples were compared using Wilcoxon Signed Rank test (two 
groups) or Friedman’s Two Way ANOVA followed by post-hoc Wilcoxon Signed-Rank 
tests and Bonferroni correction for pair-wise significance (more than two groups). Unre-
lated samples were compared using Mann Whitney U tests (two groups) or Kruskal-
Wallis ANOVA followed by Mann-Whitney U tests and Bonferroni Correction for pair-
wise significance (more than two groups). When the Kruskal-Wallis test revealed no 
significant differences among groups, no post-hoc tests were performed and P=NS was 
reported. Bonferroni correction was also applied to results of multiple Wilcoxon signed 
rank tests regarding the uptake of radiotracers in infarct vs. remote areas in rabbits (fig 
3c). To assess the correlation between 111In-GSAO uptake and 99mTc-AA5 uptake, 99mTc-
MIBI uptake and histologic findings (caspase-3 and TUNEL), Spearman’s ρs were calcu-
lated. P values of <0.05 were considered statistically significant. 
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Myocardial infarction (MI) remains a leading cause of morbidity and mortality world-
wide. Myocardial infarction occurs when myocardial ischemia, a diminished blood supply 
to the heart, exceeds a critical threshold and overwhelms myocardial cellular repair 
mechanisms designed to maintain normal operating function and homeostasis. Ischemia 
at this critical threshold level for an extended period results in irreversible myocardial 
cell damage or death (1). 
 Cell death is often divided into two distinctive processes, apoptosis and necrosis; 
however, there is increasing evidence for additional pathways such as autophagy, mitot-
ic catastrophe, and senescence. Apoptosis is characterized by classical morphology 
changes such as cytoplasm shrinkage, cell detachment, chromatin condensation, nuclear 
fragmentation and the formation of apoptotic bodies. In contrast, necrotic cells exhibit 
increased cytoplasmic vacuolation, organelle degeneration, condensation of chromatin 
into irregular patches, and an increase in cell volume that results in irreversible rupture 
of the plasma membrane. 
 The myocardium reacts to an ischemic challenge with a complex series of changes in 
cellular and extracellular components, characterized at the tissue level by altered wall 
structure, chamber geometry, and pump function, a process termed left ventricular 
remodelling (2–4). Furthermore, the lack of oxygen supply induces necrosis in the cardi-
ac myocytes, which stimulates the complement cascade and initiates an inflammatory 
response (5). The inflammatory component is primarily composed of neutrophil and 
macrophage infiltration. In particular, the macrophage is a primary responder cell type 
that is involved in the regulation of post-MI wound healing at multiple levels. Indeed, 
following MI circulating blood monocytes respond to chemotactic factors, migrate into 
the infarcted myocardium, and differentiate into macrophages. At the injury site, mac-
rophages remove necrotic cardiac myocytes and apoptotic neutrophils; secrete cyto-
kines, chemokines, and growth factors (6) and modulate phases of the angiogenic re-
sponse (7). Moreover, the timing and rate of macrophage infiltration is regulated by a 
wide range of cytokines and chemokines (8) and plasminogen activation appears to be a 
clinical link between the activation of macrophages and collagen production in the heart 
in response to injury (9). In addition, as demonstrated in animal models, mono-
cytes/macrophages dominate the cellular infiltrate for the first 2 weeks after MI and 
participate in infarct wound healing (10-14). According to recent studies, different sub-
sets of macrophages are responsible for these different activities; during the early in-
flammatory phase (phase 1), proinflammatory macrophages dominate the injury site and 
phagocytose apoptotic/necrotic myocytes and other debris, whereas during inflamma-
tion resolution (phase 2), the dominant subsets are the reparative macrophages, which 
propagate infarct repair (15, 16). The duration and extent of the early inflammatory 
phase have major implications on infarct size and ventricle remodelling (17). Finally, 
impaired monocyte/macrophage function appears to be an unrecognized new patho-
physiological mechanism for left ventricular thrombus development after MI (18). 
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A significant number of MI patients (3–40%, depending on the study) will undergo ad-
verse remodeling of the left ventricle (LV), leading to LV dilation and compromised LV 
function that drives the constellation of signs and symptoms indicative of congestive 
heart failure (CHF)(19). Hence MI predisposes patients to CHF, a significant long-term 
complication and leading cause of mortality in post-MI patients (3). Identifying vulnera-
ble patients early in the pathogenesis, therefore, will allow better risk stratification post-
MI (20–22). Since the macrophage regulates multiple aspects of the post-MI wound 
healing response, it represents a likely candidate for investigation and intervention. 
Nonetheless, while many studies correlate macrophage infiltration with changes in LV 
remodeling parameters, direct causal links between macrophages and many of the 
above-mentioned processes remains to be experimentally established and the effect of 
monocyte/macrophage recruitment after MI remains not fully defined. 
 Therefore one of the main aim of our research was to study the role of macrophages 
during MI and to establish the correlation between this role and the complex processes 
leading to collagen deposition, fibrosis, remodeling which end with ireeversible cardiac 
failure. 
 Molecular imaging is a highly active research discipline that has seen tremendous 
growth over the past decade. It has broadened our understanding of oncologic, neuro-
logic, and cardiovascular diseases by providing new insights into the in vivo biology of 
disease progression and therapeutic interventions. As it allows for the longitudinal eval-
uation of biological processes, it is ideally suited for monitoring treatment response. In 
MI and heart failure three biological features represents attractive targets for molecular 
imaging: 1) apoptosis, a form of programmed cell death which has been shown to play a 
key role in the process of gradual loss of pump function in heart failure, 2) The renin-
angiotensin pathway which plays a pivotal role in the development of post-MI heart 
failure and 3) The biological processes of angiogenesis and fibrogenesis which are con-
sidered key processes in myocardial scar formation and post-MI ventricular remodeling. 
Main findings 
New insights into the role of macrophages after myocardial infarction 
Despite previous demonstration that macrophages may contribute to myocardial dys-
function by producing inflammatory and profibrotic mediators (23) our experience sug-
gests that the depletion of macrophages results in accelerated development of end-
stage cardiomyopathy and CHF. In addition, our research poses an important question 
on the effective role of the inflammation on the entire process. In fact, while the im-
portance of the collagen framework in healing from myocardial injury has been widely 
demonstrated (24), and reduction of collagen deposition by neurohumoral antagonists is 
a well known mechanism to prevent ventricular remodelling (25), on the other hand it is 
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undoubtedly clear from our findings that lack of collagen deposit in the infarct zone 
allows accelerated ventricular remodeling. Indeed, we observed that after depletion of 
macrophages, the complete abolition of the fibrotic process including fibroblast and 
collagen deposition was observed. Therefore, it is reasonable to think that the complete 
abolition of fibrosis in absence of macrophages is a negative factor leading to CHF. This is 
in accordance with previous reports (26) and confirms the findings of published studies 
showing prevention of LV remodelling following intra-myocardial injection of collagen 
(27). 
 Macrophages can directly influence disease progression by altering the balance 
between matrix synthesis and degradation through protease and cytokine secretion 
(28,29). Duffield et al. (30) demonstrated in transgenic mice, in which macrophage de-
pletion is temporally regulated, that macrophage depletion during active remodelling 
reduced matrix deposition, whereas their removal during resolution phase exacerbated 
matrix deposition. However, in cardiac disease models, reduced monocyte/macrophage 
infiltration is accompanied by a substantial reduction in fibrosis (31). Interaction be-
tween mineralcorticoid receptors (MR) signalling and macrophages appear to be im-
portant in inflammatory conditions in the heart although the role of macrophage MR 
signalling in mediating these responses is unknown. Rickard et al. (31) demonstrated 
that selective deletion of MR from macrophages protected against mineralocorticoid-
mediated cardiac fibrosis, despite normal macrophage recruitment. In the macrophage 
MR-null mice, the reduced cardiac damage appears to be due to altered macrophage 
function following loss of MR signalling from these cells. In contrast, the sustained mac-
rophage recruitment is thought to be consequence of MR signalling in other cell types in 
the cardiovascular system following mineralocorticoid/salt treatment. This is not in con-
trast with our findings since we can postulate that the development of cardiomyopaty 
secondary to macrophage depletion can be due to over expression of MR on the surface 
of these cells. However, this aspect was not explored and deserves further investigation. 
It will be object of ongoing studies. 
 A variety of cytokines have been implicated in cardiac remodeling as well as in heal-
ing such as interleukin (IL)-1β and tumor necrosis factor alpha (TNF-α). The expression of 
TNF can have multiple effects yet extracellular matrix remodeling and it seems to be of 
major importance (32). Moreover, mice with over expression of TNF develop LV dilata-
tion and changes in collagen content prevented by a matrix metalloproteinase (MMP) 
inhibitor (33), further highlighting a potential importance of excessive activation of pro-
inflammatory cytokines on matrix remodeling and wound healing in the heart. Nonethe-
less, Bilate and co-workers (34) showed that TNF α /LT-alpha blockade with etanercept 
enhances left ventricular dysfunction in trypanosoma cruzi-induced chronic cardiomyo-
pathy. This is in accordance with our findings since TNF-α is produced primarily by mac-
rophages and TNF-α signaling may be cardioprotective, preventing cardiomyocite apop-
tosis after myocardial infarction (35). Interestingly, macrophage-deleted hearts showed 
abundant compensatory T-lymphocyte infiltration, mainly composed by Th1 and Th17. 
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We can hypotize that deleterious effects of CD4 T-cell infiltration plays an important role 
and contributes to deterioration of cardiac function after sustained depletion of macro-
phages. 
 Another interesting finding of our research is that functional deterioration of the 
heart was more pronounced when macrophages were present in the initial two weeks 
after MI whereas an improvement was observed if they were depleted early suggesting 
that a reduction in macrophage infiltration early after MI might be beneficial. It is pre-
sumable that, although macrophages are necessary to scavenge the necrotic debris from 
the infarct size (36), the accompanying cytokine activity may delay the healing process 
(37). 
 We also explored the transdifferentiation from macrophage to fibroblast during MI. 
We demonstrated that macrophages derived from CD14+ human monocytes gradually 
transformed into cells of fibroblast-like phenotype. These cell expressed all fibroblast 
markers most of which increased during the conversion process. Furthermore, and more 
importantly, these cells were able to secrete collagen I into the culture medium. This 
was confirmed by our experimental model of MI in transgenic mice marked with yellow 
florescent protein (YFP): YFP-expressing-macrophages were easily identified in the tissue 
sections and showed fibroblast markers indicating a transaction from macrophage to 
fibroblast-like cell. 
 We believe that a pro-fibrotic environment might induce this transdifferentiation 
that results in fibroblasts which, differently from “normal fibroblasts” have less “compe-
tence” in maintaining the collagen homeostasis, resulting in uncontrolled collagen and 
extracellular matrix deposition responsible of disease progression. Mechanical tension, 
TGF-β1 and fibronectin induce cardiac fibroblasts trans-differentiate into myofibroblasts, 
predominant cell types that synthesize the extracellular matrix (38,39). Furthermore, 
cathepsins (Cat K-L-S) are potent proteases which are able to degrade collagen and fi-
bronectin (40) and, in a recent study Chen et al (41) demonstrated that cathepsin S regu-
lates myofibroblast trans-differentiation and myocardium extracellular matrix protein 
differentiation. Interestingly, proinflammatory macrophages and T-cells express high 
levels of cathepsins (42,43) therefore cathepsins apart from mediating extracellular 
matrix degradation and participating importantly in post-MI left ventricular remodeling, 
might also have a role in transdifferentiation from macrophage to fibroblast during MI. 
This finding might have important repercussions on new anti remodeling therapies with 
cathepsin-inhibitors. However, macrophage to fibroblast transdifferentiation is a major 
new frontier in cardiovascular biology. Successful manipulation of this pathway is likely 
to have a positive impact on myocardial fibrosis, adverse myocardial remodeling and 
heart failure. 
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From cellular biology to molecular imaging 
The balance between proliferation and programmed cell death-apoptosis-is essential for 
multicellular organisms which use apoptosis to regulate and maintain the number and 
type of their cells during embryogenesis, growth and homeostasis (44). Increased cell 
proliferation or enhanced cell loss can be caused by dysregulated apoptosis and are 
observed in various diseases such as myocardial infarction. Therefore, non-invasive im-
aging of apoptosis is of great clinical interest as patients would clearly benefit from the 
diagnosis of cell loss post infarction. Several biochemical transformations occur in apop-
totic cells offering different biological targets for the development of specific molecular 
biomarkers of apoptosis. Key steps that occur during apoptosis have already been evalu-
ated; among these are the externalisation of phospholipid phosphatidylserine to the 
outer leaflet of the cell membrane, which can be visualized by labeled annexin-A5 (AA5) 
and the activation of caspases, especially effector caspase-3, which can be addressed by 
labeled enzyme substrates or synthetic caspase inhibitors. 
 We demonstrated that ischemia-induced apoptosis in cardiomyocytes is interrupted 
by reperfusion such that cardiomyocytes survive. Therefore, our data confirm recovery 
from apoptosis in vivo, despite activation of caspase 3. Reversible phosphatidylserine 
exposure not associated with the execution of apoptosis was previously demonstrated in 
myocitic cell lines and B-cell lymphoma cells (45-47). 
 Another interesting finding of our research is that the binding of AA5 to externalized 
phosphatidylserine has a “protective” function avoiding the complex being recognized 
by phagocytes which distinguish the externalized phosphatidylserine as signal for the 
engulfment of apoptotic cells (48). Hence, AA5 my serve as an acute-phase reactant 
which may save cells susceptible to engulfment and we can assume that exogenously 
administered AA5 may accelerate the internalization of externalized phosphatidylserine. 
Therefore, our data suggest a novel model of phosphatidylserine exposure and internali-
zation in which the exposure is continuously driven by caspase activation whereas inter-
nalization is mediated by AA5-aided formation of the endocytic vesicle (49). The reversi-
ble phosphatidylserine exposure confirmed to be an attractive target for molecular im-
aging. The administration of radiolabel AA5 allows to get images even after brief ische-
mia and with a no extensive phosphatidylserine exposure since the complex AA5 phos-
phatidylserine is internalized and may concentrate radiolabeled AA5 in the ischemic 
cells. The transient exposure of phosphatidylserine and the persistence of phosphatidyl-
serine exposure at least 6 hours after ischemic stress may be exploited in the clinical 
practice, for instance for retrospective diagnosis of cardiac chest pain. 
 Heat shock protein 90 (HSP90) is an ATP-dependent molecular chaperone responsi-
ble for protein quality control in cells. HSP90 has been shown to be overexpressed for 
instance in many human cancers. This has prompted extensive research on HSP90 inhibi-
tors as novel anticancer agents and, more recently, the development of molecular 
probes for imaging HSP90 expression in vivo (50). In addition, the HSP90 is a cytoprotec-
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tive protein chaperone that participates in mitochondrial import of a number of proteins 
and it has been demonstrated that HSP90-mediated mitochondrial import of Protein 
kinase C epsilon (PKCε) plays an important role in the protection of the myocardium from 
ischemia-reperfusion injury in an animal model of heart ischemia since pharmacological 
inhibition of HSP90 prevented ischemia-reperfusion -induced interaction between PKCε 
and the translocase of the outer membrane (Tom20), reduced mitochondrial import of 
PKCε, and increased necrotic cell death by ≈70% (51 ). Moreover, inducible nitric oxide 
synthase (iNOS) is an important key in the process of myocardial infarction, heart failure, 
and cardiac preconditioning (52). The expression of iNOS is mainly induced by inflamma-
tory substances such as endotoxins and cytokines. Previous studies showed that HSP90 
associates with iNOS and this association enhances iNOS activity. HSP90 is required for 
iNOS gene transactivation and intervening on it may represent a novel approach to 
modulate iNOS expression in myocardial infarction and cardiac preconditioning (53). 
 We exploited the capacity of radiolabeled trivalent arsenical peptide, 4-(N-(S-
glutathionylacetyl) amino) phenylarsonous acid (GSAO) to target intracellular dithiol 
molecules like HSP90. This has been already employed for non-invasive identification of 
tumor cell death (54). HSP90 contains a pair of highly conserved cysteines (Cys719 and 
Cys720) that can be selectively cross-linked by the GSAO probe. The high abundance of 
HSP90 makes it an attractive target for sensitive molecular imaging; however, it appears 
that the cell membrane must be partially compromised for GSAO entry. It is not precisely 
known when, and by how much, plasma membrane permeability changes as a cell pro-
gresses from early to late stage apoptosis. The plasma membrane of an apoptotic cell 
has high integrity and is permeable to only a select group of small molecules, including 
nucleotides and cyanine dyes (due in part to caspase-mediated activation of the mem-
brane channel protein, pannexin (55). In contrast, the plasma membrane of a necrotic 
cell is completely disrupted with free access of small and large molecules to the cell 
interior (56,57). We demonstrated the feasibility of cell death imaging in AMI using 
GSAO and the specificity of the radiotracer was confirmed by the localization of GSAO in 
the infracted zone. Our fluorescent experiments showed that GSAO accumulated intra-
cellularly and this only occurred in AA5 positive cells supporting the notion that necrosis 
followed apoptotic signalling in the setting of acute myocardial infarction and it may play 
a dominant role. 
 This confirms also that often there is a crosstalk between multiple death processes 
that are occurring simultaneously and it must be considered that in cell death different 
death processes can induce the same change in one biomarkers. For example, phospha-
tidylserine exposure, reactive oxygen species (ROS) generation, and lysosomal mem-
brane permeabilization (LMP) are biomarkers associated with both apoptosis and necro-
sis (58-60). 
 It is well known that upregulation of the renin-angiotensin system (RAS) after myo-
cardial infarction contributes to the process of the cardiac remodeling and hence the 
evolution of heart failure (61-64). Using ligands for the primary RAS mediator in myocar-
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dium, the angiotensin II type 1 receptor (AT1R), studies showed that regional AT1R up-
regulation can be visualized non-invasively in rodents after myocardial infarction (65,66). 
But interspecies differences of RAS have been reported (67,68), and the usefulness of 
cardiac AT1R imaging in large mammals and humans remains to be demonstrated alt-
hough recent data confirm that targeted molecular imaging of cardiac AT1R expression 
is feasible using clinical PET/CT technology and that, in the future, this technique may 
provide unique insights into regional myocardial RAS activation in cardiac disease (69). 
Furthermore, it has been recently reported that studies on the use of a novel arginine-
glutamate-aspartate (RGD) peptide, technetium-99m-labeled Cy5.5-RGD-imaging pep-
tide (CRIP) can be used for molecular imaging and to evaluate changes in collagen syn-
thesis in mice that were treated with angiotensin and/or aldosterone antagonists, either 
alone and in combination. CRIP is a cyclic peptide that was originally developed to image 
integrins such as avB3/5, which are up regulated during angiogenesis (70). Subsequently, 
CRIP was shown to bind to integrins expressed in activated myofibroblasts as well as to 
correlate with new collagen synthesis within the infarct zone (71). We evaluated the 
effect of an angiotensin-converting enzyme inhibitor (ACE-I), an angiotensin receptor 
blocker (ARB), and a selective aldosterone receptor antagonist (SARA), individually and in 
combination, on infarct healing by using 99mTc-CRIP imaging. The quantitative CRIP 
percent injected dose per gram uptake was greatest in the infarct area of untreated 
control mice and decreased significantly in animals treated with 1 or 2 agents. The addi-
tion of 3 agents demonstrated a further, although not statistically significant, reduction 
in tracer uptake. Moreover, the decrease in echocardiographic left ventricular function, 
strain and rotation parameters, as well as histologically verified deposition of thin colla-
gen fibers, was significantly reduced in treatment groups and correlated with CRIP up-
take. This demonstrates the efficacy of antiangiotensin and antialdosterone intervention 
on interstitial alterations and that the radiotracer uptake correlated closely with param-
eters of depressed myocardial mechanics, the quantitative prevalence of myofibroblasts, 
and thin fiber collagen deposition, suggesting that combined treatment with neurohu-
moral antagonists results in decreased new collagen production. Data obtained are in 
accordance with information provided by the estimation of collagen synthesis and frag-
mentation markers in the serum (72-74). 
 However, there are 2 potential limitations of this novel imaging approach that war-
rant further discussion. First, the in vivo data suggest that CRIP binds predominately to 
avB3/5 integrins on activated myofibroblasts. It bears emphasis that avB3/5 integrins are 
expressed on a variety of cell types, including macrophages, intimal and medial smooth 
cells, endothelial cells of microvessels, and platelets. Although CRIP binding was largely 
confined to the infarct zone this finding may have occurred because there was a pre-
dominance of myofibroblasts at the time radiolabeled CRIP was administered. Thus, the 
signal-to-noise ratio of this novel molecular imaging agent may become problematic in 
the clinical setting, wherein the timing of infarction is not as well known and/or patients 
are being administered anti-inflammatory agents (e.g., aspirin and statins) that decrease 
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inflammatory signaling, which might decrease the conversion of fibroblasts to myofibro-
blasts. Second, it is unclear from studies in the literature in which the authors used acute 
coronary artery occlusions whether the signal from radiolabeled CRIP is sufficient to 
image myocardial fibrosis in smaller infarcts (e.g., non–ST-segment infarcts) and/or myo-
cardial fibrosis after reperfusion injury, wherein there is an influx of inflammatory cells 
that express avB3/5 integrins. Notwithstanding these potential therapeutic limitations, 
the initial use of CRIP appears promising and offers a potentially exciting new “looking 
glass” for monitoring the development and progression of myocardial fibrosis during 
cardiac remodeling. 
Conclusions 
Following MI, circulating blood monocytes respond to chemotactic factors, migrate into 
the infarcted myocardium, and differentiate into macrophages. At the injury site, mac-
rophages remove necrotic cardiac myocytes and apoptotic neutrophils; secrete cyto-
kines, chemokines, and growth factors; and modulate phases of the angiogenic re-
sponse. As such, the macrophage is a primary responder cell type that is involved in the 
regulation of post-MI wound healing at multiple levels. Our studies correlated macro-
phage infiltration with changes in LV remodeling parameters, confirming the exciting 
results already seen in the macrophage biology arena revealing avenues for basic science 
research, in regards to macrophage function in the post-MI setting specifically and the 
wound-healing environment. Inhibition studies using anti-inflammatory strategies have 
taught us the importance of discerning beneficial and detrimental roles for the macro-
phage post-MI. The ability to isolate these opposing functions could potentially be used 
to derive novel therapeutic strategies. 
 In addition, the ongoing efforts of a large international group of biomedical re-
searchers are greatly expanding the collective understanding of cell death and its role in 
a range of diseases and therapeutic treatments. Recent research advances have greatly 
increased our molecular understanding of cell death and its role in a range of diseases 
and therapeutic treatments. Central to these ongoing research and clinical efforts is the 
need for imaging technologies that can locate and identify cell death in a wide array of in 
vitro and in vivo biomedical samples with varied spatiotemporal requirements. Useful 
biomarkers for dead and dying cells have been identified to develop molecular probes 
that target these biomarkers for optical, radionuclear, or magnetic resonance imaging. 
Our experiences confirm that high contrast image can be achieved within a specific win-
dow in time that will depend on the specifics of the cell death phenomenon under study. 
Our findings require further larger studies to be confirmed. 
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Summary 
Myocardial infarction remains a leading cause of morbidity and mortality worldwide.  
 The myocardium reacts to an ischemic challenge with a complex series of changes in 
cellular and extracellular components. The inflammatory component is primarily com-
posed of neutrophil and macrophage infiltration. In particular, the macrophage is a pri-
mary responder cell type that is involved in the regulation of post-MI wound healing at 
multiple levels. According to recent studies, different subsets of macrophages are re-
sponsible for these different activities; during the early inflammatory phase (phase 1), 
proinflammatory macrophages dominate the injury site and phagocytose apoptot-
ic/necrotic myocytes and other debris, whereas during inflammation resolution (phase 
2), the dominant subsets are the reparative macrophages, which propagate infarct re-
pair.  
 The first main goal of our research was to study the role of macrophages during 
myocardial infarction and to establish the correlation between this role and the complex 
processes leading to collagen deposition, fibrosis, remodeling which may end with irre-
versible cardiac failure.  
 Molecular imaging is a highly active research discipline that has seen tremendous 
growth over the past decade. As it allows for the longitudinal evaluation of biological 
processes, it is ideally suited for monitoring treatment response. In myocardial infarction 
and heart failure three biological features represents attractive targets for molecular 
imaging: 1) apoptosis, a form of programmed cell death which has been shown to play a 
key role in the process of gradual loss of pump function in heart failure, 2) the renin-
angiotensin pathway which plays a pivotal role in the development of post-MI heart 
failure and 3) the biological processes of angiogenesis and fibrogenesis which are con-
sidered key processes in myocardial scar formation and post-MI ventricular remodeling.  
 The second aim of the thesis was to use molecular imaging techniques to gain in-
sight in the (patho)physiological processes following ischemia; focusing on cell death and 
fibrosis.  
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In Chapter 2 we reviewed and discussed the recent progresses made in molecular cardi-
ac imaging, focusing mainly on the achievements made in the integrin alpha v beta 3 
(avB3) imaging, apoptosis imaging, and imaging of the activation of the renin-angio-
tensin system. 
 From this overview preclinical and clinical data obtained in molecular imaging of 
adverse left ventricular remodeling, the current outlook for the development of such an 
imaging technology is promising. For both the imaging of avB3 integrin and imaging of 
phosphatidylserine expression as a reflection of caspase-3 activation, the preliminary 
data provide a sufficient basis for the design and execution of novel studies. For imaging 
of the components of the renin–angiotensin system, the extent of uptake may be insuf-
ficient to form a basis for clinical applications. However, before one of these technolo-
gies could be adopted as diagnostic tests for routine clinical use, large clinical studies 
need to be conducted to address key questions. For instance, it is still unknown whether 
the uptake of avB3 targeting tracers is robust enough to uncover patients that are at the 
brink of developing adverse remodeling post myocardial infarction. In addition, it re-
mains to be seen whether the extent of the uptake of the tracer can be modulated by 
treatment with different regimes of cardiac failure treating compounds. 
 For imaging phosphatidyl serine exposure in the heart using annexin-A5, as a reflec-
tion of caspase-3 activation, the outlook depends largely on the availability of clinically 
graded annexin-A5 imaging diagnostic kits. With the availability of clinical annexin-A5 
imaging kits, studies could be designed to further explore the predictive value of annex-
in-A5 in patients with failing hearts and to study the effect of therapeutic interventions. 
 
In Chapter 3 we explored the inflammation contributes to the process of ventricular 
remodeling after acute myocardial injury. To investigate the role of macrophages in the 
chronic process of cardiac remodeling, they were selectively depleted by intravenous 
administration of liposomal clodronate in heart failure–prone hypertensive Ren-2 rats 
from the age of 7 until 13 weeks. Plain liposomes were used for comparison. 
 Liposomal clodronate treatment reduced the number of blood monocytes and de-
creased the number of macrophages in the myocardium. Compared to plain liposomes, 
liposomal clodronate treatment rapidly worsened left ventricular ejection function in 
hypertensive rats. Liposomal clodronate treated Ren-2 rat hearts showed areas of myo-
cyte loss with abundant inflammatory cell infiltration, predominantly comprising CD4 
positive T lymphocytes. Our study showed that lack of macrophages was associated with 
earlier development of myocardial dysfunction in hypertensive rats. Therefore, macro-
phages might have a potentially important role in ventricular remodelling in hyperten-
sion. Macrophage activation may be important in repair processes and debris clearance 
and hence depletion of macrophages may not necessarily be an effective strategy in 
prevention of heart failure. 
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In Chapter 4 we used clodronate liposome administration to selectively deplete macro-
phages early and late after infarction and evaluate the impact on the evolution of left 
ventricular function. 
 In clodronate liposome treatment experiments, the functional deterioration was 
more pronounced when macrophages were present in the initial two weeks after infarc-
tion and demonstrated improvement if they were depleted early. The results are intri-
guing, and it is reasonable to suggest that a reduction in macrophage infiltration early 
after myocardial infarction may be of some benefit. Although macrophages are neces-
sary for the scavenger function, accompanying cytokine activity may delay the healing 
process. 
 
In Chapter 5 left ventricular volumes and ejection fraction were quantified based on 7.0 
Tesla cine-magnetic resonance imaging in twelve wild-type mice, twelve adipose triglyc-
eride lipase knockout (ATGL-/-) mice (model of impaired cardiac function), and 11 rats in 
which we induced cardiac ischemia. The left ventricular volumes and function were ei-
ther assessed with parallel short-axis slices covering the full volume of the left ventricle 
(gold standard procedure) or with various geometrical models (modified Simpson rule, 
biplane ellipsoid, hemisphere cylinder, single-plane ellipsoid, and modified Teichholz 
Formula). Reproducibility of the different models was tested and results were correlated 
with the gold standard (FV). All models and the FV data set provided reproducible results 
for the left ventricular volumes and ejection fraction, with interclass correlation coeffi-
cients ≥0.87. All models significantly over- or underestimated EF, except for Simpson 
rule. Good correlation was found for all volumes and ejection fraction for the Simpson 
rule model compared with the full volume data set. The biplane ellipsoid and hemi-
sphere cylinder models also predicted EF well although proved to be less useful for 
quantitative analysis. The single-plane ellipsoid and modified Teichholz Formula models 
correlated poorly with the full volume data set. 
 For the reduction in acquisition and post-processing time, only the Simpson rule 
model proved to be a valuable method for calculating left ventricular volumes, stroke 
volume, and ejection fraction. 
 
In Chapter 6 we tested the hypothesis that that radiolabeled annexin-A5 could be able to 
identify the regions of myocardial ischemia since apoptotic cell death is characterized by 
phosphatidylserine externalization on cellmembrane and annexin-A5 avidly binds to 
phosphatidylserine. 
 Murine experiments demonstrated that the cardiomyocytes expressed phosphati-
dylserine on their cell surface after an ischemic insult of 5 min. Phosphatidylserine expo-
sure occurred continuously for at least 6 h after solitary ischemic insult. Annexin-A5 
targeted the exposed phosphatidylserine on cardiomyocytes and it was internalized into 
cytoplasmic vesicles within 10-30 min. Twenty-four hours after ischemia, cardiomyo-
cytes with internalized annexin-A5 had restored phosphatidylserine asymmetry of the 
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sarcolemma, and no detectable phosphatidylserine remained on the cell surface. The 
pre-administration of a pan-caspase inhibitor prevented phosphatidylserine exposure 
after ischemia.  
 Our study demonstrated that after a single episode of ischemia, cardiomyocytes 
express phosphatidylserine, which is amenable to targeting by annexin-A5 for at least 6 
h. Phosphatidylserine exposure is transient and internalized in cytoplasmic vesicles after 
annexin-A5 binding, indicating the reversibility of the apoptotic process. 
 
In Chapter 7 we examined interstitial alterations during postmyocardial infarction re-
modeling and assessed the efficacy of antiangiotensin and antimineralocorticoid inter-
vention, alone and in combination by using molecular imaging techniques.  
 Technetium-99m–labeled Cy5.5 RGD imaging peptide was intravenously adminis-
tered for gamma imaging after 4 weeks of myocardial infarction in 63 Swiss-Webster 
mice and in 6 unmanipulated mice. Of 63 animals, 50 were treated with captopril, losar-
tan, spironolactone alone, or in combination, 8 mice received no treatment. 
 Our findings showed that the quantitative Technetium-99m–labeled Cy5.5 RGD 
imaging peptide percent injected dose per gram uptake was greatest in the infarct area 
of untreated control mice and decreased significantly in animals treated with 1 agent. 
The addition of 2 or 3 agents demonstrated further reduction in tracer uptake propor-
tional to the number of agents employed. The decrease in echocardiographic left ven-
tricular function, strain and rotation parameters, as well as histologically verified deposi-
tion of thin collagen fibers, was significantly reduced in treatment groups and correlated 
with Technetium-99m–labeled Cy5.5 RGD imaging peptide uptake. 
 Therefore, in our experience, radiolabeled Technetium-99m–labeled Cy5.5 RGD 
imaging peptide allowed for the evaluation of the efficacy of neurohumoral antagonists 
after myocardial infarction and reconfirmed the superiority of combination therapy. If 
proven clinically, molecular imaging of the myocardial healing process may help plan an 
optimal treatment for patients susceptible to heart failure.  
 
In Chapter 8 we demonstrated the effectiveness of cell death imaging in acute myocardi-
al infarction using a trivalent arsenic peptide, 4-(N-(S-glutathionylacetyl)amino) phe-
nylarsonous acid [GSAO]), which is capable of binding to intracellular dithiol molecules 
such as HSP90 and filamin-A. Since this peptide is membrane impermeable and dithiol 
molecules abundantly present intracellularly, we propose that myocardial localization 
would represent sarcolemmal disruption or necrotic cell death. 
 In this study we evaluated feasibility of cell death imaging using 111In-GSAO in 
mouse and rabbit models of acute myocardial infarction and a mouse model of chronic 
myocardial infarction. In addition, a subgroup of animals, serial SPECT/CT imaging using 
99mTc- annexin-A5 and 111In-GSAO was performed to determine the relationship be-
tween these two modes of cell death in the setting of myocardial ischemia and reperfu-
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sion. Fluorescent GSAO and annexin-A5 were employed in another subgroup of animals 
for pathological characterization of the mode of cell death. 
 This study confirmed that the trivalent arsenic group on GSAO is responsible for its 
targeting characteristics. Our fluorescent experiments showed that GSAO accumulated 
intracellularly and only occurred in annexin-A5 + cells, thereby supported the notion that 
necrosis followed apoptotic signalling in the setting of acute myocardial infarction. 
Hence we can postulate that secondary necrosis is a dominant mode of cell death in the 
setting of myocardial ischemia and reperfusion. 
 In our experience, micro-SPECT/CT imaging using 111In-GSAO can be used to visual-
ize necrotic cell death in acute myocardial infarction whereas the uptake in the heart 
failure model was too low to allow imaging. 
 
Our studies correlated macrophage infiltration with changes in left ventricular remodel-
ing parameters, confirming the exciting results already seen in the macrophage biology 
arena revealing avenues for basic science research, in regards to macrophage function in 
the post-infarction setting specifically and the wound-healing environment. Inhibition 
studies using anti-inflammatory strategies have taught us the importance of discerning 
beneficial and detrimental roles for the macrophage post-infarction. The ability to isolate 
these opposing functions could potentially be used to derive novel therapeutic strate-
gies. Our experiences confirm that high contrast image can be achieved within a specific 
window in time that will depend on the specifics of the cell death phenomenon under 
study. Our findings require further larger studies to be confirmed.
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Samenvatting (Summary in Dutch) 
Het myocard infarct (MI) is de belangrijkste doodsoorzaak wereldwijd. Na ischemie doen 
zich verscheidene veranderingen op cellulair en extracellulair niveau voor. In reactie op 
de cardiale schade treedt een immuunrespons op; macrofagen en neutrofielen infiltre-
ren het aangedane gebied. De macrofaag speelt een centrale rol in de regulatie van de 
wondheling na MI. Recente studies hebben aangetoond dat in de verschillende fases van 
het herstelproces, verschillende subgroepen van macrofagen actief zijn. Tijdens de vroe-
ge inflammatie fase (fase 1) zijn pro-inflammatoire macrofagen aanwezig in het bescha-
digde myocard die apoptotische/necrotische myocyten en overig debris phagocyteren. 
In de tweede fase zijn met name reparatieve macrofagen die bijdragen aan reparatie van 
het infarctgebied dominant.  
 Een van doelstellingen van dit onderzoek was het bestuderen van de rol van macro-
fagen tijdens en na MI. Hierbij lag de focus op de rol van macrofagen in collageendeposi-
tie, fibrose en remodeling; factoren die kunnen bijdragen aan de ontwikkeling van hart-
falen.  
 Moleculaire beeldvorming is een diagnostische techniek die de afgelopen jaren sterk 
is ontwikkeld. Met moleculaire beeldvorming kunnen biologische processen op molecu-
lair en cellulair geëvalueerd worden. Bij MI en hartfalen zijn er drie biologische proces-
sen die middels moleculaire imaging kunnen worden geëvalueerd. 1) apoptose, een 
vorm van geprogrammeerde celdood die een belangrijke rol vervult in het proces van 
verlies van pompfunctie bij hartfalen, 2) activatie van het renine-angiotensine systeem 
dat een belangrijke rol speelt in remodeling en de ontwikkeling van hartfalen na MI en 3) 
fibrose. 
 Een tweede doelstelling van dit proefschrift is het toepassen van moleculaire beeld-
vorming om beter inzicht te krijgen in de (patho)fysiologische processen na het myo-
cardinfarct. De focus lag hierbij op celdood en fibrose. 
 
In hoofdstuk 2 gaven we een overzicht van de recente ontwikkelingen in moleculaire 
cardiale imaging, waarbij we ons met name richtten op de ontwikkelingen op het vlak 
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van moleculaire beeldvorming van integrine alpha v beta 3 (avB3), apoptose en van de 
activatie van het renine-angiotensine systeem. 
 Uit onze evaluatie van zowel preklinische als klinische data bleek dat de ontwikkeling 
van deze beeldvormingstechnologie veelbelovend is. Voor zowel avB3 integrine imaging 
als imaging van fosfatidylserine expressie ten gevolge van caspase-3 activatie, bleken 
beschikbare studies reden te geven voor het opzetten van grotere studies. Het is bij-
voorbeeld nog onduidelijk of de opname van avB3-gerichte markers voldoende is om 
patiënten met een hoog risico op het ontwikkelen van remodeling en hartfalen te identi-
ficeren. Daarnaast moet nog worden onderzocht of de mate van radiotracer opname 
gerelateerd kan worden aan de verschillende aspecten in de behandeling van hartfalen. 
De haalbaarheid van toepassing van annexine-A5 voor beeldvorming van fosfatidylserine 
expressie (een gevolg van caspase-3 activatie) is met name afhankelijk van de beschik-
baarheid van klinische annexine-A5 diagnostische sets. Met behulp van deze klinische 
annexine-A5 kits zouden studies kunnen worden opgezet waarbij de voorspellende 
waarde van annexine-A5 in patiënten met hartfalen verder kan worden geëxploreerd 
alsmede het effect van therapeutische interventie. Voor wat betreft moleculaire beeld-
vorming van componenten van het renine-angiotensine systeem, blijkt de radiotracer 
opname voorlopig nog te laag voor het vormen van een basis voor klinische toepassin-
gen.  
 
In Hoofdstuk 3 werd het inflammatieproces dat bijdraagt aan het ontstaan van ventricu-
laire remodeling na acuut MI onderzocht. Om de rol van macrofagen in het chronische 
proces van ventriculaire remodeling te kunnen onderzoeken, werden deze selectief 
uitgeschakeld door intraveneuze toediening van liposomaal Clodronate (LC) in hyperten-
sieve Ren-2 ratten tussen de 7 en 13 weken oud. Lege liposomen werden als controle 
behandeling toegepast. In de hypertensieve ratten behandeld met LC ging de linkerka-
merfunctie aanmerkelijk achteruit. Daarnaast lieten de harten van de met LC behandel-
de ratten gebieden met afname van myocyten en progressieve infiltratie van met name 
CD4 positieve T lymfocyten zien. Deze studie toonde aan dat een gebrek aan macrofa-
gen gerelateerd was aan vroegere ontwikkeling van myocardiale dysfunctie in hyperten-
sieve ratten; macrofagen spelen dus mogelijk een belangrijke rol in ventriculaire remo-
deling bij hypertensie. Macrofagen activatie kan van belang zijn voor het herstelproces 
en het phagocyteren van debris, echter, uitschakeling van macrofagen hoeft niet per 
definitie een effectieve strategie te zijn in de behandeling van hartfalen.  
 
In hoofdstuk 4 hebben we de rol van macrofagen in de vroege en late fase na het MI 
onderzocht door macrofaaginfiltratie selectief uit te schakelen middels LC.  
 Uitschakeling van de macrofaaginfiltratie vanaf de vroege fase na het MI zorgde 
ervoor dat de linkerkamerfunctie deels behouden bleef.   
 Deze resultaten zijn fascinerend, en het is reëel om aan te nemen dat een verminde-
ring van macrofagen vroeg na MI een voordeel kan zijn. Echter, zoals we in hoofdstuk 3 
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hebben laten zien, hebben macrofagen ook gunstige cardiale effecten. Verdere studies 
zijn daarom nodig om uit te sluiten dat complete uitschakeling van macrofagen na het 
infarct negatieve gevolgen heeft.  
 
In hoofdstuk 5 werden met behulp van 7.0 Tesla cine-magnetische resonantie imaging 
(MRI) de linker ventrikel volumes en ejectiefractie bepaald in 12 wild-type muizen, 12 
adipeuze triglyceride lipase knock-out (ATGL-/-) muizen (een model met verminderde 
cardiale functie) en 11 ratten waarbij cardiale ischemie werd geïnduceerd. De linker 
ventrikelvolumes en -functies werden gemeten met parallelle korte-as opnamen, waarbij 
het volledige volume van de linker ventrikel werd geëvalueerd (‘gold standard’ procedu-
re) of middels verschillende geometrische modellen (gemodificeerde ‘Simpson rule,’ 
‘biplane ellipsoid,’ ‘hemisphere cylinder,’ ‘monoplane ellipsoid’ en gemodificeerde 
Teichholz formule).  De reproduceerbaarheid van de verschillende modellen werd getest 
en de resultaten werden gecorreleerd met de gold standard (VV). Alle modellen en de 
FV data set toonden reproduceerbare resultaten voor de linker ventrikel volumes en 
ejectiefractie met correlatie coëfficiënten van ≥0.87. Alle modellen over- of onderschat-
ten de EF significant, met uitzondering van de Simpson rule. Adequate correlatie werd 
gevonden voor alle volumes en ejectiefractie voor de Simpson rule vergeleken met de 
volledige volume data set. De biplane ellipsoid en hemisfeer cylinder modellen voorspel-
den ook een adequate ejectiefractie hoewel deze methode minder bruikbaar bleek voor 
kwantitatieve analyse. De monoplane ellipsoid en gemodificeerde Teichholz formule 
modellen correleerden nauwelijks met de volledige volume dataset. Alleen het Simpson 
rule model bleek een bruikbare methode voor het berekenen van linker ventrikel volu-
me, slagvolume en ejectiefractie met betrekking tot de procestijd.   
 
In hoofdstuk 6 testten we de hypothese dat gelabeld annexine-A5 de myocardiale ische-
mische gebieden kon identificeren daar 1) apoptotische cellen phosphatidylserine pre-
senteren op de celmembraan en 2) annexine-A5 eenvoudig bindt aan phosphatidylseri-
ne. In een muizenmodel werd aangetoond dat cardiomyocyten phosphatidylserine laten 
zien op het celoppervlak na een ischemieduur van 5 minuten. Phosphatidylserine bleef 
continu aanwezig op het celoppervlak voor tenminste 6 uur na ischemie. Annexine-A5 
bond zich aan het geëxposeerde phosphatidylserine op cardiomyocyten en werd vervol-
gens opgenomen in het cytoplasma binnen 10-30 minuten.  
 Vierentwintig uur na ischemie hadden de cellen de phosphatidylserine asymmetrie 
hersteld. Er werd geen phosphatidylserine meer aangetroffen op de celmembraan; alle 
phosphatidylserine was geherinternaliseerd.  
 De studie toonde aan dat phosphatidylserine wordt gepresenteerd op de celmem-
braan in cardiomyocyten na een episode van ischemie, en daarmee toegankelijk is voor 
annexine-A5 tot tenminste 6 uur na ischemie. Phosphatidylserine expressie is tijdelijk en 
wordt uiteindelijk weer opgenomen in het cytoplasma na binding aan annexine-A5, wat 
aangeeft dat apoptose reversibiliteit is. 
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In Hoofdstuk 7 werd de mate van fibrose na MI en het effect van anti-angiotensine en 
anti-aldosteron therapie middels moleculaire beeldvorming onderzocht. Voor deze stu-
die is het myocardinfarct geïnduceerd in 63 muizen; zes ongemanipuleerde muizen wer-
den gebruikt als controles. Van de 63 MI-muizen werden er 50 behandeld met captopril, 
losartan en spironolacton, solitair of in combinatie; 8 muizen werden niet behandeld. 4 
weken na het MI werd de mate van fibrose geëvalueerd door gamma beeldvorming met 
technetium-99m–gelabeld Cy5.5 RGD imaging peptide. De radiotracer opname was het 
meest uitgesproken in het infarctgebied van onbehandelde controle muizen en signifi-
cant verminderd in de behandelde muizen. Een combinatie van middelen bleek hierbij 
effectiever dan enkelvoudige therapie. De afname van middels echocardiografie aange-
toonde linkerventrikelfunctie en de histologisch geobjectiveerde mate van fibrose, was 
significant verminderd in de behandelde groepen en correleerden met de opname van 
de Technetium-99m–gelabelde Cy5.5 RGD imaging peptide. Deze studie bevestigt de 
superioriteit van combinatietherapie en laat zien dat de effecten van therapieën geëva-
lueerd kan worden middels technetium-99m–gelabeld Cy5.5 RGD imaging. Indien kli-
nisch bewezen, kan moleculaire beeldvorming van het myocardiale herstelproces helpen 
een optimaal behandelingstraject voor patiënten met hartfalen samen te stellen.  
 
In hoofdstuk 8 hebben we in diermodellen van MI onderzocht of celdood in beeld ge-
bracht kan worden met Technetium-99m-4-(N-(S-glutathionylacetyl)amino) phenylar-
sonous acid (GSAO). GSAO is een peptide met een trivalente arseengroep dat specifiek 
bindt aan dithiol moleculen zoals HSP90 en filamine-A. Omdat 1) dithiolmoleculen vrij-
wel alleen intracellulair voorkomen, 2) deze radiotracer niet getransporteerd wordt over 
intacte celmembranen, 3) bij necrotische celdood disruptie van de celwand optreedt, 
was onze hypothese dat deze tracer specifiek zou worden opgenomen in dode cellen 
met een necrotisch fenotype  
 In deze studie werd 111In-GSAO beeldvorming onderzocht in een muis- en konijn-
modellen van het acute MI aangetoond. Vervolgens werd in een subgroep dieren mid-
dels SPECT/CT imaging met zowel 99mTc-annexine-A5 en 111In-GSAO de relatie tussen 
apoptose en necrose in het acute MI aangetoond. Fluorescent gelabeld GSAO en an-
nexine-A5 werden in een andere subgroep toegepast voor immunofluorescent-
microscopische ondersteuning van deze bevindingen. The fluorescentie experimenten 
lieten zien dat GSAO in de intracellulaire ruimte van cellen wordt opgenomen; dit werd 
alleen geobserveerd in annexine-A5+ cellen. Dit bevestigt dat necrotische celdood in het 
acute myocardinfarct volgt op apoptotische celdood; wij postuleren dat deze vorm van 
secondaire necrose een dominante vorm van celdood is in het acute myocardinfarct. 
Deze studie bevestigde dat de trivalente arseengroep van GSAO verantwoordelijk is voor 
de binding aan dode cellen.  
 Op basis van deze resultaten kan worden geconcludeerd dat 111In-GSAO micro-
SPECT/CT gebruikt kan worden om necrotische celdood in beeld te brengen in acuut MI; 
de opname in het hartfalenmodel was te laag was om in beeld gebracht te worden.  
S A M E N V A T T I N G  
 159 
We hebben de relatie tussen macrofaaginfiltratie en markers van linker ventrikel remo-
deling onderzocht. Hierbij werden de baanbrekende resultaten van eerder macrofaag-
biologisch onderzoek, die implicaties hadden voor verder fundamenteel onderzoek naar 
de rol van macrofagen in infarctgenezing bevestigd. Studies waarbij de macrofaaginfil-
tratie werd geblokkeerd hebben aangetoond dat het belangrijk is de gunstige en ongun-
stige rollen van macrofagen evalueren. Verdere kennis over deze tegengestelde rollen 
kan gebruikt worden voor de ontwikkeling van nieuwe therapieën. Onze resultaten laten 
zien dat hoogcontrast beelden na het infarct gemaakt kunnen worden en dat het tijds-
bestek waarbinnen dit mogelijk is afhankelijk is van het type celdood dat in beeld wordt 
gebracht.  
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Valorisatie 
Sociale relevantie 
Myocardinfarct (MI) is de belangrijkste doodsoorzaak wereldwijd. Daarnaast ontwikkelt 
40-60% van de patienten na MI hartfalen. De gevolgen van hartfalen kunnen van grote 
impact zijn voor de patient en resulteren in hoge kosten binnen de gezondheidszorg. In 
dit proefschrift worden belangrijke processen, zoals bijvoorbeeld celdood en remode-
ling, alsmede de componenten welke cruciaal zijn in de ontwikkeling van hartfalen on-
derzocht.  
 Naast onderzoek op cellulair niveau naar collageendepositie en fibrose resulterend 
in remodeling hebben we middels moleculaire imaging getracht beter inzicht te krijgen 
in de (patho)fysiologische processen na een MI. Hierbij hebben we gebruik gemaakt van 
verscheidene biomarkers gericht op celdood.  
  
Doelgroepen 
De onderzoeksresultaten van dit proefschrift zijn naast behandelaars, zoals cardiologen 
en radiologen, ook van betekenis voor (cardiologische) patienten met hartfalen en/of 
een myocardinfarct. Voor wat betreft de behandelaars kunnen de uitkomsten van dit 
proefschrift van groot belang zijn met betrekking tot de gepersonaliseerde behandeling 
voor de patient. Middels de verkregen resultaten kunnen immers de gevolgen van be-
handeling op een unieke manier voor iedere patient persoonlijk in kaart worden ge-
bracht. De patient heeft op zijn/haar beurt baat bij een adequate en gerichte strategie 
en behandeling. 
  
Activiteiten en producten 
Verscheidene moleculaire imaging tools, waarvan enkele beschreven in dit proefschrift, 
kunnen gebruikt worden in de diagnostiek naar het vroegtijdig detecteren van hartfalen 
en als leidraad dienen voor het behandelingstraject.  
 Welk moleculair proces het meest geschikt is voor beeldvorming van deze vroege 
veranderingen hangt af van factoren als beschikbaarheid van het target, gevoeligheid 
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van de probe maar ook klinische toepasbaarheid en uiteindelijk beschikbaarheid in de 
kliniek. Hierbij speelt uiteraard de medische industrie een essentiele rol.  
  
Innovatie, planning, realisatie 
De potentie van moleculaire imaging blijkt uit dit proefschrift zeer waardevol. Immers, 
de detectie van hartfalen op cellulair niveau alvorens het ziektebeeld door symptomen 
of anatomische veranderingen tot uiting komt, is essentieel. De diagnostische alsmede 
de prognostische waarde om de ziekte in de vroege fase te detecteren, kan dankzij het 
preventieve karakter van moleculaire imaging op zowel maatschappelijk als economisch 
niveau van ongekende waarde zijn. Daarnaast biedt het de mogelijkheid de therapeu-
tische behandeling te evalueren. Een belangrijke beperkende factor is in dit geval de 
kosten voor het detecteren van de juiste biomarkers alsmede de aanvullende diag-
nostiek/beeldvorming welke ervoor noodzakelijk is. Dit proefschrift heeft onder andere 
de toepasbaarheid van moleculaire imaging aangetoond om een beter beeld te vormen 
van de verschillende processen welke optreden na MI.  
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